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General Introduction 
Prologue
Nuclear hormone receptors are an important model system for studying the process leading 
to productive transcription. Aim of this thesis was to investigate the transcriptional 
mechanism of the nuclear receptor RORß. This subject is interesting because RORß 
belongs to a subgroup of nuclear receptors that differ in some characteristics from 
‘classical’ nuclear receptors: RORß is an orphan receptor which means that no specific 
ligand has been identified yet. In addition, RORß binds to DNA as a monomer, while 
‘classical’ nuclear receptors bind DNA mainly as dimers. Furthermore, the functional 
properties of RORß are interesting since expression of this receptor is highly restricted to 
the central nervous system and initial studies suggest a cell-type specific potential of its 
ligand-binding domain to regulate transcription.
Since the work described in this thesis deals with the mechanism of transcription in general 
as well as with specific aspects of the nuclear receptor RORß, two introductory chapters 
are preceding the experimental work: Chapter 1 gives an overview of the process of 
transcription regulation. In Chapter 2, the properties of nuclear receptors are reviewed, in 
particular with respect to their involvement in transcriptional processes. Finally a brief 
outline of the experimental part of the thesis is provided at the end of Chapter 2.

Chapter 1
Introduction to the mechanism of transcription
10
Chapter 1 Mechanisms o f transcription
1.1. Introduction........................................................................................................... 11
1.2. The general transcription machinery................................................................... 12
1.2.1. The general transcription factors..........................................................12
1.2.2. The TAFII components of the TFIID complex....................................17
1.2.3. Multiple forms of TFIID and other TAFII containing complexes...... 18
1.3. Cofactors present in the USA fraction................................................................ 22
1.4. Mediator complexes..............................................................................................23
1.5. Acetylation and transcription...............................................................................28
1.5.1. Coactivators with histone acetyltransferase activity........................... 29
1.5.2. HDAC-containing corepressor complexes..........................................32
1.6. ATP-dependent chromatin remodeling machines.............................................. 35
1.7. Cell-type-specific transcription............................................................................36
1.8. Summary .............................................................................................................. 37
Chapter 1 11
1. MECHANISMS OF TRANSCRIPTION
1.1. Introduction
Gene expression is the key event in nuclear pathways underlying differentiation, 
morphogenesis and proliferation. It is the endpoint in pathways that continually reshape the 
cell in response to metabolic needs and environmental signals. In short, it touches upon 
almost everything in eukaryotic biology.
In the beginning of the 1980s, the first regulatory transcription factors were genetically iso­
lated from the budding yeast Saccharomyces cerevisiae. A short while later, the Ptashne 
(Keegan et al., 1986) and Struhl (Hope and Struhl, 1986; Hope et al., 1988) laboratories 
demonstrated that transcription factors consist of at least two independent domains: a DNA- 
binding (DBD) and a transcriptional activation domain (AD). This bipartite structure of 
transcription factors suggested a transcription regulation model in which transcription factors 
bind to DNA, and recruit and position the general transcription machinery to the promoter 
(Figure 1).
activation model: recruitment of the general transcription machinery
Figure 1: Recruitment model. Transcription factors consisting of a DNA-binding domain (DBD) and an acti­
vation domain (AD) recruit the general transcription machinery to the promoter by direct protein-protein inter­
action. RNAP: RNA polymerase II.
Further studies uncovered that transcriptional regulation mechanisms are more complex than 
this first model suggested. The discovery of distinct factors that are required to mediate 
activated transcription in vitro revealed the highly sophisticated nature of the 'general' tran­
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scription machinery (Chapter 1.2), which seems to be assembled in a transcription-factor-, 
promoter- and cell-type-specific manner. In addition, various cofactors and cofactor com­
plexes (Chapters 1.3; 1.4; 1.5) that function as a bridge between transcription factors and the 
general transcription machinery were isolated. Several of these cofactors or cofactor com­
plexes contain intrinsic histone acetyltransferase (HAT) or deacetylase activity (Chapter 1.5). 
The degree of acetylation of chromatin was linked to transcriptional regulation. Hence, the 
discovery of cofactors with HAT activity suggested that transcription factors regulate 
transcription also by remodeling the chromatin structure at the promoter region. This view 
was strengthened by the isolation of ATP-dependent chromatin remodeling machines 
(Chapter 1.6) that could rearrange chromatin structures in a transcription-factor- and 
promoter-specific manner.
This chapter gives an overview about the various transcriptional complexes participating in 
activator-dependent transcription. The focus has been set on mammalian transcription. Since 
transcription mechanisms are highly conserved from yeast to man, several findings from 
Drosophila and yeast are discussed with respect to the mammalian systems.
1.2 The general transcription m achinery
1.2.1 The general transcription factors 
Isolation o f general transcription factors
In an effort to isolate the general transcription machinery, nuclear extracts from HeLa cells 
were fractionated over a phosphocellulose column and tested in in-vitro transcription assays 
for their ability to mediate basal (in the absence of an activator) and activated (in the presence 
of an activator) transcription (Weil et al., 1979; Matsui et al., 1980; Davison et al., 1983). 
Several fractions were identified to be required for efficient transcription in vitro. The cloning 
of the corresponding proteins (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH) turned out to be 
difficult, since most of these general transcription factors (GTFs) are large complexes with 
multiple subunits (see Table 1). The isolated genes revealed that the GTFs are highly con­
served from yeast to man (Orphanides et al., 1996).
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Table 1: the general transcription factors isolated from human HeLa cells.
General transcription Subunits Function refs.
factor (human) [kDa]
TFIIA a  [35], ß [19], y [12] - stabilizing TFIID DNA binding
- anti-repression function
TFIIB [35] - RNAP and TFIIF recruitment
- involved in start site selection (with RNAP)
- TAF contact
TFIID TBP [38], TAFs [12­
250]
- core promoter (TATA box) recognition
- TFIIB, TFIIA recruitment
- contacts TFIIF
- for specific TAF function see Table 2
TFIIE a  [34], ß [57] - TFIIH recruitment
- modulation of TFIIH helicase, ATPase and kinase 
activity
- direct enhancement of promoter melting
1,2
TFIIF a  (RAP 74) [74], 
ß (RAP 30) [34]
- promoter targeting of RNAP
- destabilization of non-specific RNAP-DNA inter­
actions
- inhibition of RNAP pausing
- interaction with TAFII250
3,4
TFIIH 9 [35 - 89] - promoter melting (helicase)
- promoter clearance by RNAP CTD phosphoryla­
tion (kinase)
- stabilization of TFIIE binding
- involved in nucleotide-excision repair
2,5
RNA polymerase II 12 [12 - 220] - catalytic unit for RNA synthesis (elongation)
(RNAP) - recruitment of TFIIE
- involved in start site selection (with TFIIB)
- promoter clearance
The table is based on tables published in Roeder, 1996; Ranish and Hahn, 1996. Further references are: 1, Oh- 
kuma et al., 1995; 2, Yamamoto et al., 2001; 3,Ruppert and Tjian, 1995; 4, Wei et al., 2001; 5, Svejstrup et al., 
1996.
Function o f the general transcription factors in the transcriptional process 
In-vitro assembling reactions with purified GTFs, coupled with the identification and 
characterization of stable intermediates, led to the so called 'stepwise assembly model' 
explaining DNA binding and complex formation of the general transcription machinery on the 
transcriptional start site (Roeder, 1996): In the first step, the TBP unit of TFIID recognizes the 
TATA box of the promoter and induces a bend of the promoter DNA. Association of TFIIA 
and TFIIB stabilizes TFIID binding to DNA (Buratowski et al., 1989; Ozer et al., 1994; 
Zawel et al., 1995; Medvedev et al., 1997). The association between TBP and TFIIA is 
strengthens by phosphorylation of TFIIA (Solow et al., 2001). In addition, TFIIA has an anti­
repression function (Ma et al., 1996; Ozer et al., 1998). Transcription factors, such as ZEBRA 
or VP16, have been shown to stabilize the DNA binding of the TFIIA-TFIID-TFIIB complex 
(Figure 2) or to isomerize the TFIIA-TFIID complex (Choy and Green, 1993; Chi and Carey, 
1996; Sandaltzopoulos and Becker 1998), an event that creates a surface for further 
assembling of the general transcription machinery.
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In cell-free systems and in the absence of nucleotides, GTFs and RNA polymerase II (RNAP) 
assemble further to the so-called ^reinitiation complex (PIC) (Figure 2). Initiation of the PIC 
starts by addition of nucleotides and includes several steps such as: (i) ATP- or dATP- 
dependent unwinding of an approximately 10bp region of the promoter just upstream of the 
transcription start site, driven by the TFIIH helicase activity in assistance with TFIIE, (ii) 
formation of the first phosphodiester bond, and (iii) downstream extension of the melted pro­
moter region (Holstege et al., 1996; Jiang et al., 1996; Holstege et al., 1997). At this stage of 
the transcriptional process, the promoter is still occupied and the general transcription 
machinery produces short abortive transcripts (Jiang et al., 1995). The clearance of the 
promoter depends on ATP and TFIIH and is thought to involve phosphorylation of the 
Carboxy terminal domain (CTD) of the largest subunit of RNAP (Jiang et al., 1996; Dvir et 
al., 1997; Yamamoto et al., 2001).
On several promoters, TFIID, eventually associated with factors such as TFIIA, TFIIB, 
TFIIH, TFIIE and Mediator (Chapter 1.4) was observed to remain bound to the promoter after 
the promoter has been cleared (Ranish and Hahn, 1996; Roeder, 1996, Hahn, 1998, 
Yudkovsky et al., 2000). TFIIE dissociates from the traveling elongation complex at position 
+10, TFIIH at position +30 to +68, TFIIF remains associated with the elongating RNAP. The 
moving of RNAP elongation complexes down the templates requires TFIIF and the 
association of elongation factors such as SII (also called TFIIS) and Elongin, otherwise the 
RNAP-elongation complexes pause or arrest on specific DNA-sequences (Reines et al.,
1996). Termination of transcription is driven by capping enzymes and 3' end processing 
factors that interact with the phosphorylated CTD, and, along with other events, leads to 
dephosphorylation of the CTD (Reines et al., 1996; Roeder, 1996).
It is important to note that this model derived from experiments carried out in highly purified 
in-vitro systems under very defined conditions. Naturally, the mechanism will differ in a 
cellular environment: In an in-vitro system purified from yeast cells, it was shown that several 
general transcription factors are recruited to the promoter in one big holoenzyme complex 
(Chapter 1.4) (Gaudreau et al., 1998). Furthermore, the organization of in-vitro transcription 
templates in a chromatin structure affects among other things transcriptional initiation (Kraus 
and Kadonaga, 1998) and might have an impact on preinitiation complex formation.
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Figure 2: Simplified model of an in vitro transcription reaction with naked templates. In a first step, the 
transcription factor (TF) recruits the TFIID complex together with TFIIA and TFIIB. In a second step, the 
preinitiation complex (PIC) is recruited to the promoter in the absence of nucleotides. Addition of nucleotides 
results in the initiation of the PIC and transcriptional elongation.
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Reinitiation o f transcription
A very important event for the net production of RNA transcripts is the reinitiation of 
transcription. It has been shown that, in vitro, reinitiation of transcription can be a rapid pro­
cess compared with the first round of transcription (reviewed in Hahn, 1998). This finding 
suggests a reinitiation mechanism that is different from the one employed in the first round of 
transcription, but little is know about this mechanism.
The complex of TFIID and other factors that remain at the promoter after initial RNAP 
escape, might allow a faster reassembly of new preinitiation complexes. This simple model 
predicts that the sequence of the TATA box is of great importance for the reinitiation process, 
a hypothesis which was underscored by a study of Yean and Gralla (1997). In their approach, 
Yean and Gralla measured the levels of active PIC formation and the rate of continuous RNA 
production in cell-free transcription assays using a series of promoters that contained 
mutations in either the activator-binding site, the TATA box or the initiator element. They 
found that mutations in the TATA-box have the most striking effects on multiple cycles of 
initiation in vitro. The rate of reinitiation may also be influenced by promoter clearance or 
enhanced elongation during the transcription reaction. A recent study revealed, for instance, 
the existence of a factor that increases the number of elongation complexes during an in-vitro 
transcription reaction (Woodard et al., 2001).
Transcription factors seem to influence the reinitiation of transcription on some promoters. 
This is illustrated in a study (Ho et al., 1996) that investigated the influence of the activation 
domain on on-going transcription in vivo. In these experiments the activation domain and the 
DNA-binding domain of a protein were reversibly linked to each other. When the two 
domains were dislinked by a competitor molecule, gene expression decreased markedly with 
initial kinetics being consistent with the expected dissociation of the two domains. Thus, the 
activation domain was necessary for on-going transcription. However, in these experiments, 
the authors could not distinguish whether the multiple cycles of transcription resulted from a 
facilitated reinitiation or a 'normal' initiation pathway. In vitro, the results of studies on the 
effect of activators on reinitiation are conflicting: In some experiments, reinitiation depends 
on the continued presence of the transcription factor GAL-VP16 (White et al., 1992). On the 
other hand, transcription factors such as the heat shock factor dissociate faster from DNA than 
the committed complex (Sandaltzopoulos and Becker, 1998), arguing against a requirement of 
transcription factors for reinitiation. These conflicting observations might be caused by the 
use of different promoters, since recently it was shown that in yeast two types of promoters
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exist: some that bind TFIID (Chapter 1.2.2) and others bind TBP (Kuras et al., 2000; Li X.-Y. 
et al., 2000). A recent in-vitro study demonstrates that the influence of transcriptional 
activators on PIC assembly differs for the two kinds of promoters (Wu and Chiang, 2001). On 
TBP-dependent promoters, transcriptional activators such as GAL-VP16 and human 
papillomavirus E2 mainly functioned by facilitating RNAP entry to the promoter region, 
whereas on TFIID-dependent promoters, promoter recognition by TFIID appeared to be the 
rate limiting step. Therefore, an activator may be required to promote facilitated reinitiation 
by stabilizing a committed complex after the first promoter clearance on TFIID-dependent, 
but not on TBP-dependent promoters.
An important factor influencing transcription reinitiation is the chromatin environment. In 
vitro, reinitiation of transcription is much more effective on chromatinized than on naked 
templates (Kraus and Kadonaga, 1998; Sandaltzopoulos and Becker, 1998; Dilworth et al.,
1999). The mechanism of this observation is not yet understood but possibly the chromatin 
structure is altered after the first round, allowing faster re-entry of the transcription machinery 
to the promoter region. Taken together, although several aspects of the process of 
transcriptional reinitiation have been studied the mechanism of reinitiation is still poorly 
understood.
1.2.2 The TAFII components of the TFIID  complex
The cloning of the TATA box-binding protein (TBP) suspected to correspond to the TFIID 
fraction led to surprising findings: In reconstituted cell-free systems, purified TBP activated 
only basal transcription, but, in contrast to the TFIID fraction, failed to mediate transcriptional 
activation by transcription factors (Meisterernst et al., 1990; Tanese et al., 1991; Dynlacht et 
al., 1991). In addition, the cloned TBP and the biochemically isolated TFIID complexes from 
Drosophila (d), yeast (y) and human (h) differ significantly in size, suggesting the existence 
of tightly bound TBP-associated factors (TAFIIs) that are required for mediating activated 
transcription (Horikoshi et al., 1989; Eisenmann et al., 1989; Hernandez, 1993; Burley and 
Roeder, 1996). These observations resulted in extensive biochemical studies and the cloning 
of a number of genes encoding TAFIIs (Table 2).
The TFIID complex containing TBP and 10-13 TAFIIs has a central role in transcriptional 
activation. While TBP recognizes the TATA box and is therefore involved in promoter recog­
nition and PIC recruitment, TAFIIs participate in promoter recognition, chromatin remodeling, 
activator-dependent PIC recruitment and PIC stabilization (Table 2).
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The requirement of TAFs for activated transcription, in addition to many other findings 
(reviewed in Bell and Tora, 1999), led to the idea that TAFIIs are an essential part of the 
bridge between the preinitiation complex and transcription factors. Direct contact between 
transcription factors and TAFIIs was detected for the Glutamine-rich activators SP1 or Bicoid 
and dTAFII110 (homologue of hTAFII135); the acidic activators VP16 or p53 and 
dTAFII40/TAFII60 (homologues of hTAFII31/hTAFII80), and the nuclear estrogen receptor 
and hTAFII30 (Jacq et al., 1994). However, several studies question the absolute requirement 
of TAFIIs in activated transcription by demonstrating that in vivo (yeast) (Moqtaderi et al., 
1996; Walker et al., 1996) and in vitro (Oelgeschläger et al., 1998), transcriptional activation 
can occur in the absence of TAFIIs. The latter study even demonstrates that the presence of 
TAFIIs decreases VP 16-dependent transcription levels in a promoter-dependent manner by 
impairing PIC assembly. This is in line with the observation that the same point mutation in 
TBP abolishes the binding of VP16 and dTAF230 (Nishikawa et al., 1997) suggesting that 
both proteins compete for binding to TBP. The recent finding that some promoters in yeast 
are dependent on TFIID, while others depend on TBP (Kuras et al., 2000; Li X.-Y. et al.,
2000) might explain these conflicting data.
1.2.3 M ultiple forms of TFIID and other TAFII containing complexes 
Multiple TFIID complexes within a cell
Immunoprecipitation with antibodies against TBP and distinct TAFIIs revealed the existence 
of several different TFIID complexes which consist of core TAFIIs, present in all TFIID com­
plexes, and specific TAFIIs, present only in a subpopulation of them (Brou et al., 1993). In 
addition, another form of TFIID complex, termed B-TFIID, that contains apart of TBP only a 
single TAFII170 was isolated (Timmers et al., 1992). B-TFIID supports transcription in vitro. 
These different TFIID complexes coexist in a cell, suggesting that distinct TFIID complexes 
have specific roles in promoter recognition, interaction with other GTFs and its response to 
transcriptional regulators.
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Table 2: The human TAFs (TBP associated factors).
TAF
(human)
present in properties & function 
complex*
refs.
TAFs with kinase and histone acetylase activities
250
histone like
TFIID -
TAFs
bipartite protein kinase, phosphorylates for instance RAP74
(TFIIF) and TFIIA
acetylates histones H3, H4 in vitro
contains bromodomains and HMG boxes
contacts DNA
associates with TBP
cell cycle; progression through the G1/S boundary 
repression of apoptosis
interaction with c-Jun which results in derepression of txn
1, 2, 3, 4, 5, 
6, 7,8, 9
140 TFIID - histone fold motif
contains a plant homeodomain finger
10
80 (70) TFIID, hTFTC, - 
ySAGA -
histone fold motif (H4)
contacts TFIIEa, RAP74 (TFIIF) and TBP
11, 12
31 (32) TFIID, hTFTC, - 
ySAGA, hPCAF -
histone fold motif (H3)
contacts DNA, TFIIB, acidic activators (VP16, p53) 
recognition motif for acidic activators
11, 12, 13
28 TFIID - histone like 
contacts VP16, TFIIB
14
20, 15 TFIID, hTFTC, - 
ySAGA, hPCAF -
histone fold motif (H2B)
required for the HAT activity of the SAGA complex 
(yTAF68)
12, 15,16
18
Others
TFIID - histone fold motif (H4)
150 TFIID - downstream promoter contact (specific) 
contacts TBP
17, 18
135 (130) TFIID, TFTC - Q-rich
contacts DNA (hTAF135), TFIIA, SP1, NFATp
12, 19, 20
95 (100) TFIID, TFTC, - WD 40 repeats 12, 21, 22,
ySAGA - contacts DNA and TFIIF (RAP30)
strong interaction with histone H4 and H3 like TAFs
promoter specific and complex stabilization function
23
68 TFIID - RNA or ssDNA-binding domain 
contacts hRNAP
might have a role in driving the PIC in an open conforma­
tion and in RNA chain initiation.
55
43
TFIID, TFTC - 
TFIID
contacts DNA (hTAF55) and many activators 12
30 TFIID, hTFTC, - 
ySAGA -
contacts the estrogen receptor 
progression through the G1/S boundary 
repression of apoptosis
12, 24, 25
170 B-TFIID - ATP-dependent inhibitor of TBP-mediated transcription 
specifically found in B-TFIID
26, 27
105 - related to hTAF135
specific for differentiated B-cells
28
Data were taken from the following sources: Burley and Roeder, 1996; Bell and Tora, 1999; 1, Hisatake et al., 
1993; 2, Weinzierl et al., 1993; 3, Ruppert and Tjian, 1995; 4, Dikstein et al., 1996a; 5, Mizzen et al., 1996; 6, 
Wang E.H. et al., 1997; 7, O'Brien and Tjian, 1998; 8, Lively et al., 2001; 9, Solow et al., 2001; 10, Gangloff et 
al., 2001; 11, Xie et al., 1996; 12, Wieczorek et al., 1998; 13, Uesugi et al., 1997; 14, Goodrich et al., 1993; 15, 
Hoffmann et al., 1996; 16, Grant et al., 1998a; 17, Verrijzer et al., 1994; 18, Verrijzer et al., 1995; 19, Mengus et 
al., 1997; 20, Kim et al., 2001; 21, Hisatake et al.,1995; 22, Dubrovskaya et al., 1996; 23, Tao et al., 1997; 24, 
Metzger et al., 1999; 25, Georgieva et al., 2000; 26, van der Knaap, 1997; 27, Chicca et al., 1998; 28, Dikstein et 
al., 1996b. The list of complexes containing the single TAFs might be incomplete since the presence of each 
TAF has not been determined for all complexes.
* The yeast complex, ySAGA, contains the yeast homologues of the cognate human TAFIIs.
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Cell-specific TBP or TBP-homologue containing complexes
The picture is getting even more complex by the isolation of other, cell-type-specific, TFIID 
complexes. A neuronal-specific TBP homologue, termed TRF, which is associated with 
neuronal TAFIIs has been described in Drosophila (Hansen et al., 1997; Hori and Carey, 
1998). In transient transfection assays TRF increases transcription levels in an activator- 
specific manner. Similar TRF homologues (TRF1, TRF2) were found also in higher eu­
karyotes (Teichmann et al., 1999). They differ from Drosophila TRF in their ubiquitous ex­
pression pattern. In addition, they were not able to functionally replace TBP or TFIID in basal 
or activated transcription. Recently a TBP-TFIIA-containing complex (TAC) was identified 
that is present in embryonal carcinoma (EC) cells but not in differentiated cells (Mitsiou and 
Stunnenberg, 2000). TAC contains TBP, TFIIAy and interestingly the unprocessed form of 
TFIIAaß. Classical TAFIIs could not be detected in the TAC complex. Although TAC- 
dependent promoters are not known at present, indirect analyses suggest that the TAC 
complex can mediate transcription in EC-cells.
TAFII-containing complexes without TBP
According to their definition as TBP-associated factors, TAFIIs were thought to exist in a cell 
solely in association with TBP. Therefore, the discovery of TAFIIs in complexes lacking TBP 
was very exciting. Several TBP-free, but TAFII-containing, complexes (Table 3) have been 
isolated from yeast (ySAGA) and human (hSTAGA, hGCN5/hsPCAF, hTFTC) (Martinez et 
al., 1998; Ogryzko et al., 1998; Wieczorek et al., 1998). All of these complexes contain 
TAFIIs and a protein with HAT activity either yeast or human Gcn5 (ySAGA, hTFTC, 
hSTAGA) (Grant et al., 1998a; Brand et al., 1999b) or the highly homologous PCAF 
(hPCAF) (Ogryzko et al., 1998). In addition, the ySAGA and hPCAF complexes contain 
various Ada and Spt proteins. The PCAF complex does not contain TAFII100 or TAFII80 but 
instead the closely related proteins PAF65a and PAF65ß which have not been described in 
other complexes. Several proteins in the complexes still need to be identified.
Although the TFTC, SAGA and PCAF complexes and their components were shown to be 
critical for activated transcription in vivo and in vitro (Grant et al., 1998a; Wieczorek et al., 
1998), little is known about the mechanism of their action. At least two functions of these 
complexes might contribute to transcriptional activation. Firstly, the TAFII-containing TBP- 
free complexes might increase the acetylation state of chromatin by their intrinsic HAT 
activities (Chapter 1.5). Secondly, the complexes might contact TBP or other GTFs to form
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Table 3: TBP-free, TAFn-containing complexes.
YSAGA hPCAF HTFTC hSTAGA Present in other 
complexes
functions
T A F iis TAFII90, (PAF65ß, PAF 65ß 31 TFIID - histone like
68/61, 60, PAF65a), TAFII150, TAFIIs form
25/23, 20/17 TAFII31, 30, 
20, 15
135,100, 
80, 55, 31, 
30, 20,15
octamer structures
HAT activity Gcn5 PCAF GCN5 GCN5 CBP-cofactor
complexes
- acetylation of 
histones in a free 
and nucleosomal 
context
TRRAP/Tra1 Tra1 PAF400 TRRAP - cofactor for 
oncogenic txn 
factor pathways
- interacts directly 
with acidic acti­
vators
Ada proteins ADA1, 2, 3 ADA2, 3 ADA3 - adapter
Spt proteins SPT3, 7, 8, 20 SPT3 SPT3 SPT3 - core promoter 
selective recogni­
tion
references 1, 2, 8 3, 4 5, 6 7
The data in the table were taken from the listed references: 1, Grant et al., 1998a; 2, Grant et al., 1998b; 3, 
Ogryzko et al., 1998; 4, Vassilev et al., 1998; 5, Wieczorek et al., 1998; 6, Brand et al., 1999b; 7, Martinez et 
al., 1998 ; 8, Brown et al., 2001. The proteins are either from yeast (ySAGA) or from human (hPCAF, hTFTC, 
hSAGA) systems.
the preinitiation complex. For the SAGA complex it was shown that the recruitment of this 
complex to the promoter by the acidic activator GAL4p seems to be essential for preinitiation 
complex formation (Bhaumik and Green, 2001). The recruitment is probably triggered by the 
subunit Tra1 of the SAGA complex which is a functional-interaction unit for acidic activators 
(Brown et al., 2001). In addition, the SAGA complex is necessary and sufficient to 
hyperacetylate the PHO8 promoter in an activator-dependent manner (Reinke et al., 2001), an 
event that might result in chromatin remodeling (Chapter 1.5)
Several observations argue that the TFTC, SAGA and PCAF complexes might have similar, 
and possibly redundant functions to TFIID. All of these complexes contain TAFIIs and a HAT 
activity (Table 3, Table 2). In addition, TFTC is structurally related to TFIID (Brand et al., 
1999a). Furthermore TFTC is able to replace TFIID on TATA-containing and TATA-less 
promoters in highly purified in-vitro transcription systems (Wieczorek et al., 1998). 
Moreover, the histone-acetylase components of the yeast TFIID and SAGA complex 
(yTAFII145 and Gcn5) seem to be functionally redundant (Lee T.I. et al., 2000).
Genome-wide expression analysis in yeast revealed that although inactivating shared subunits 
of the TFIID and the SAGA complex affect the transcription of ~ 70 % of the genome, 
distinct sets of genes were influenced by components of the RNAP holoenzyme, the general
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transcription factor TFIID and the SAGA complex. (Lee T.I. et al., 2000; Holstege et al., 
1998). These observations argue that although the complexes might functionally replace 
themselves on some promoters, they seem to have roles in the expression of distinct sets of 
genes.
1.3 Cofactors present in the USA fraction
Biochemical fractionation of HeLa nuclear extracts resulted in the identification of a fraction 
that was in conjunction with TFIID generally stimulating activator-dependent transcription in 
reconstituted cell-free systems (Meisterernst et al., 1991). Further biochemical fractionation 
and characterization of the so called USA (for upstream stimulatory activity) fraction revealed 
the existence of several positive (termed PC1, PC2, PC3, PC4, PC5, PC6 and AcF, CofA, 
HMG2) and negative (termed NC1, NC2, etc) general cofactors (reviewed in Kaiser and 
Meisterernst, 1996).
The cofactors PC4 (Ge and Roeder, 1994) and PC2 can fully reconstitute the USA coactivator 
activity (Guermah et al., 1998) and potentate synergistically the transcription levels of 
activators in highly purified cell-free systems (Ge and Roeder, 1994; Guermah et al., 1998; 
Luo et al., 1998; Fondell et al., 1999). The overall transcriptional stimulation in vitro 
mediated by PC4 and PC2 is the result of repression of basal transcription levels in the 
absence and an increase of transcription levels in the presence of transcriptional activators 
(Guermah et al., 1998; Wu and Chiang, 1998). PC2 and PC4 belong to different groups of 
cofactor complexes. While PC2 has recently been characterized as a Mediator-like complex 
(see Chapter 1.4), PC4 is a single protein and interacts with TFIID supporting activator- 
dependent stabilization of the TFIID/TFIIA complex (Ge and Roeder, 1994; Kaiser et al., 
1995). Whether TAFIIs are required for this interaction has been discussed controversially. 
One in-vitro study shows that the PC4 stimulating effect depends on TAFIIs and TFIIH (Malik 
et al., 1998), another study demonstrates activator-mediated in-vitro transcription dependent 
on PC4 and TFIIH but independent of TAFIIs (Wu et al., 1998).
Since the type of promoter and the transcription conditions influences the requirement of 
TAFIIs for transcriptional activation (Kuras et al., 2000; Li X.-Y. et al., 2000), these 
controversial observations might be explained by the use of different templates and 
transcription factors in the two studies. Alternatively, it is conceivable that the coactivation 
function of PC4 is not simply a matter of recruitment. PC4 can be phosphorylated when it is
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associated with the PIC (Malik et al., 1998). Such a modification could bypass the 
requirement for TAFs.
An important negative cofactor present in the USA fraction is NC-2, a cofactor consisting of 
two subunits (Goppelt et al., 1996; Mermelstein et al., 1996). The functional domains of both 
subunits are histone fold motifs of the H2A-H2B type. In vitro, the hNC-2a/ hNC-2ß 
heterodimer represses transcription by its interaction with TBP, preventing or inhibiting 
functional interactions between TBP and TFIIA or TFIIB (Goppelt et al., 1996). The crystal 
structure of a NC-2/TBP/TATA complex reveals that the significant contacts between NC-2 
and TBP appear to preclude recruitment of both TFIIB and TFIIA (Kamada et al., 2001). 
Several transcriptional repressors such as the homeodomain transcription factor AREB6 
(Ikeda et al., 1998) use NC-2-dependent repression mechanisms in cell-free transcription 
systems.
1.4 M ediator complexes
The yeast Mediator/ RNA polymerase II holoenzyme
Searching for factors that mimic the in-vivo effects of activators in vitro, Kornberg and co­
workers uncovered a complex in yeast, termed Mediator, which is required for the stimulation 
of transcription by transcription factors in highly purified systems (Flanagan et al., 1991; 
Kelleher et al., 1990). Subsequently the Mediator complex was found to be associated with 
the 12-subunit core complex of RNA polymerase II (RNAP) and called the RNAP 
holoenzyme (Myer and Young, 1998; Kim et al., 1994; Thompson, 1993; reviewed in 
Björklund and Kim, 1996).
Analysis of the protein composition of the RNAP holoenzyme revealed that the Mediator 
complex consists of several Srb proteins, which were initially identified as suppressors of 
RNAP-CTD truncations (Nonet and Young, 1989), other genetically identified proteins (such 
as GAL11, RGR1, SIN4, NUT1 and NUT2) (Carlson, 1997) and novel Mediator polypeptides 
(MEDs). In addition, some of the isolated RNAP holoenzymes contain a subset of GTFs as 
integral components of the complex (Koleske and Young, 1994).
The yeast Mediator complex exist in solution in RNAP-dependent and RNAP-independent 
forms (Myers et al., 1998; Liu et al., 2001). The relatively weak association between RNAP 
and the Mediator complex was also detected in a study in which the treatment with an anti- 
CTD antibody resulted in the release of the Mediator from the RNAP holoenzyme complex
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(Kim et al., 1994). Both, the RNAP-dependent and -independent forms are able to activate 
transcription in cell-free transcription assays (Kim et al., 1994; Liu et al., 2001).
Functional relevance of the yeast RNAP holoenzyme
In yeast, the RNAP holoenzyme triggers transcriptional activation by transcription factors 
(Koleske and Young, 1994; Flanagan et al., 1991) most probably by being directly recruited 
to the promoter (Figure 3A). This hypothesis was supported by studies of gene expression in a 
yeast strain that carried a point mutation in the RNAP holoenzyme component GAL11 (the 
mutant is named GAL11P). In yeast cells containing the mutant GAL11P, an artificial 
derivative of the transcription factor GAL4 that lacks any classical activation domain turned 
into a strong transcriptional activator in vivo and in vitro (Gaudreau et al., 1998; Farrell et al., 
1996; Barberis 1995). This activation mediated by an otherwise silent transcription factor was 
the result of an artificially created interaction domain between GAL11P and the GAL4 
derivative. The most likely explanation for this observation is that the interaction between 
GAL11P and GAL4 results in the recruitment of the RNAP holoenzyme to the promoter and 
implies that tethering the RNAP holoenzyme to the promoter is sufficient for transcriptional 
activation in yeast cells. Gain-of-function mutations in SRB2, SRB4, SRB5 and SRB6 
suggested that the Srb proteins are the targets of activators. Direct protein-protein contact was 
detected between the GAL4 activator and SRB4 (Koh et al., 1998). In addition, the yeast 
transcription factors GAL4 and VP16 can contact general transcription factors, in particular 
TFIIB and TFIID (Wu et al., 1996; Melcher and Johnston, 1995; Roberts et al., 1993; 
Goodrich et al., 1993; Lin et al., 1991; Stringer et al., 1990).
Whether activator-dependent recruitment of TFIID and RNAP holoenzyme are influenced by 
each other is still a matter of discussion. On the one hand, it has been demonstrated that, in 
vivo, the recruitment of TBP to the promoter depends on the SRB4 component of the RNAP 
holoenzyme (Kuras and Struhl, 1999). On the other hand, mutations in components of the 
holoenzyme have been shown to disrupt the recruitment of the RNAP holoenzyme, but not 
the one of TFIID (Ranish et al., 1999), arguing for two independent recruitment steps. The 
mutual dependence of the recruitment of TFIID-TFIIA and the RNAP holoenzyme might be 
due to the transcription factor, since GAL-VP16 enhances both the recruitment of the TFIID- 
TFIIA complex and the RNAP holoenzyme (Ranish et al., 1999), while GAL-AH is only 
stimulating TFIID-TFIIA recruitment.
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Yeast cells lacking subunits of the Mediator complex reveal particular defects not only in 
activation of transcription but also in repression (Balciunas et al., 1999). Several scenarios 
can be envisioned how the RNAP holoenzyme regulates transcriptional repression: (i) One 
hypothesis is that a cofactor contacts the RNAP holoenzyme and prevents it from binding to 
transcription factors (Figure 3B). This has been shown for the yeast corepressor Cyc8-Tup1 
which contacts the Mediator subunit Hrs1/Med3 (Papamichos-Chronakis et al., 2000). (ii) 
Another possible scenario is that DNA-bound transcriptional repressors contact the RNAP 
holoenzyme and keep it locked in an inactive conformation (Figure 3C).
The yeast RNAP holoenzyme contains histone-acetyltransferase activity (Lorch et al., 2000) 
and associates with enzymatic activities, such as cyclin-dependent protein kinases 
(SRB10/CDK8) (Hirst et al., 1999). Consequently, it had been demonstrated that protein 
phosphorylation (Hirst et al., 1999) and chromatin remodeling (Gaudreau et al., 1997) can be 
triggered by RNAP holoenzymes.
Metazoan Mediator complexes
After the discovery of RNAP holoenzymes in yeast, several RNAP holoenzymes have been 
described for metazoans (reviewed in Parvin and Young, 1998). The metazoan RNAP 
holoenzymes contain homologues of the yeast SRB/Mediator proteins and several general 
transcription factors. In some cases, the RNAP holoenzyme is found to be associated with 
cofactors such as CBP/p300 (Neish et al., 1998) and proteins involved in DNA repair 
(Maldonato et al., 1996).
Whether the metazoan Mediator functions as a coactivator complex analogous to its role in 
yeast, remained inconclusive from these initial studies (Jiang et al., 1998). Recently this 
question was solved by different sets of experiments. Several groups attempted to isolate 
cofactor complexes with modified classical biochemical approaches. Roeders group 
developed a screen in which they stably transfected HeLa cells with a flag-tagged thyroid 
hormone receptor. The cells were grown either in the presence or absence of ligand. 
Immunopurification of the protein extracts over a flag antibody column led to the isolation of 
a multicomponent complex (termed TRAP) from HeLa cells that had been treated with ligand 
(Fondell et al., 1996). The TRAP complex enhances TR-dependent transcription in a ligand- 
dependent fashion in vitro. The same complex - here named SMCC- was isolated in an 
approach to identify SrB interacting proteins (Gu et al., 1999). In addition, the groups of 
Freedman and Tijan identified two identical complexes - named DRIP (Rachez et al., 1999;
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recruitment and function of the RNAP holoenzyme
C
RNAP holoenzyme involved in repression
Figure 3: Model of the functional relevance of the yeast RNAP holoenzyme. (A) Transcription factors (TF) 
activate transcription by recruiting the RNA polymerase II (RNAP) holoenzyme to the promoter. RNAP 
holoenzyme might be in some cases cooperatively recruited with the TFIID complex. The RNAP holoenzyme is 
able to mediate transcription by modifying transcription factors and remodeling the chromatin structure. (B) 
Transcription mediated by the RNAP holoenzyme can be inhibited by corepressors (CR) that bind to the RNAP 
holoenzyme and prevents the interaction with the transcripion factor. (C) Transcriptional repression might be 
also triggered by promoter-tethered corepressors that keep the RNAP holoenzyme in an inactive conformation.
Rachez et al., 1998) and ARC (Näär et al., 1999) - which interact with different transcription 
factors such as the nuclear receptor VDR and the transcription factors SREBP-la and NF-kB.
These coactivator complexes contain human homologues of the yeast Srb proteins SRB 10, 
SRB11, SRB7, MED6, MED7, NUT2 and RGR1 in addition to novel proteins. Furthermore, 
the modular structure of the coactivator complexes strongly resemble that of the yeast
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Mediator, indicating that the TRAP/SMCC and DRIP/ARC complex are mammalian 
Mediator-like complexes.
Several smaller Mediator-like complexes that share a subset of the TRAP/DRIP subunits have 
since been described. The CRSP complex (Ryu et al., 1999) activates transcription, the NAT 
complex (Sun et al., 1998) represses transcription. PC-2, a coactivator activity present in the 
USA fraction (Chapter 1.3) appears to be also a Mediator-like complex (Malik et al., 2000). 
Regarding the similar subunit composition of the mammalian-Mediator-like complexes, it is 
apparent that they represent the same or highly similar complexes or derivatives thereof. A 
recent study tackled the question whether distinct Mediator complexes indeed exist or 
whether the slightly different protein composition of the complexes result from different 
purification procedures (Wang G et al., 2001). In this study, several high-molecular-mass 
complexes containing mammalian Mediator subunits were detected when HeLa nuclear 
extracts were fractionated over a Superose gel filtration column. However, no smaller 
complexes such as CRSP, could be found. This finding indicates that either the smaller 
complexes reported are much less abundant than the high molecular mass complexes or the 
subcomplexes are the result of a dissociation during the purification procedures.
The metazoan Mediator complexes in transcriptional regulation
Similar to the situation in yeast, the metazoan Mediators have been proposed to function as a 
bridging factor between transcription factors and the general transcription machinery 
(reviewed in Rachez and Freedman, 2001). This model was supported by a study in which the 
association of the DRIP complex and the RNAP holoenzyme was tested in cell extracts 
(Chiba et al., 2000). Immunoprecipitations did not reveal association of the DRIP complex 
with the RNAP holoenzyme in solution but the interaction between these complexes could be 
induced in the presence of a nuclear receptor and its ligand.
Highly purified in-vitro systems revealed that the metazoan Mediator complexes act in 
concert with the general coactivator PC4 (Fondell et al., 1999; Gu et al., 1999). TAFns are not 
required for transactivation mediated by the TRAP complex at least not for activation induced 
by the nuclear receptor TR (Fondell et al., 1999). In contrast, the subcomplex CRSP requires 
TAFns for SP1-dependent transactivation in vitro (Ryu et al., 1999). It is possible that distinct 
activators use different activation mechanisms at different promoters or that the subunits that 
can substitute for TAFns in TRAP-mediated transcription are lacking in the CRSP complex. It 
is still under discussion whether the function of these complexes is affected in vitro by a 
chromatin environment of the templates, since DRIP/ARC-mediated transcription is de­
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pendent on chromatinized templates (Rachez et al., 1999), while TRAP/SMCC-mediated 
transcription is not (Fondell et al., 1999; Näär et al., 1999). In this respect it is important to 
note that the yeast Mediator contains histone acetyltransferase activity and contacts 
nucleosomes (Lorch et al., 2000). It is therefore plausible that transactivation triggered by 
Mediator-like complexes includes several steps; some require chromatin (for instance binding 
to nucleosomes and modulating the chromatin structure), others are chromatin independent 
(such as the recruitment of the Mediator to the promoter by a transcription factor). The 
relative significance of these steps might vary dependent on the transcription factor, the 
promoter and the particular complex composition. Therefore chromatinized templates might 
be required for transcriptional activation in some experimental systems, but not in others.
1.5 Acetylation and transcription
In vivo, DNA is wrapped around histone octamers to form nucleosomes which in turn are 
packed into higher order chromatin structures. The chromatin structure was initially thought 
to be required to pack and organize the large amount of DNA into the relative small nucleus 
of a cell. Several studies, however, linked the structure of chromatin to its ability to control 
transcription. Of significant importance in this respect is the acetylation state of the histone 
components of chromatin. Nucleosomal DNA in its hypo-acetylated state generally correlates 
with repression of transcription, whereas acetylation of histones is associated with 
transcriptional activation. Other covalent histone modifications that seem to regulate gene 
expression are phosphorylation and methylation (reviewed in Rice and Allis, 2001; Strahl and 
Allis, 2001). The mechanisms by which the covalent modifications of histones are affecting 
transcriptional regulation are not yet clear. Initial models suggested that histone modifications 
may alter chromatin structures by influencing histone-DNA and hi stone-hi stone contacts 
(reviewed in Wolffe and Pruss, 1996; Struhl, 1998). However, in histone-DNA cross-linking 
studies, no significant change in histone-DNA interaction could be observed as a consequence 
of histone acetylation in vitro (Mutskov et al., 1998). Other hypotheses about how the 
acetylation state of chromatin can influence transcriptional regulation have been proposed 
(reviewed in Nakatani, 2001; Chen H. et al., 2001): The pattern of acetylated histone tails in 
chromatin appear to serve as a marker to prepare the chromatin for recognition by molecules 
such as the SWI/SNIF remodeling machine (Reinke et al., 2001, Hassan et al., 2001). In 
addition, acetylation of histones seems to facilitate TFIID binding to a chromatinized 
promoter (Sewack et al., 2001). All these observations point towards the hypothesis that
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covalent histone modifications function sequentially or in combination to form a ‘histone 
code’ that is recognized by other proteins and protein complexes which in turn trigger distinct 
downstream events (Strahl and Allis, 2001).
For a long time the enzymes that add or remove acetyl groups of histones were unknown 
(Pennisi, 1997). The discovery that the yeast transcriptional adapter protein Gcn5 and its 
human counterpart PCAF (Brownell et al., 1996) possess histone acetyltransferase (HATs) 
activities, revolutionized the picture of transcriptional regulation. It suggested a new 
transcriptional activation model in which transcription factors modulate the chromatin struc­
ture by recruiting cofactors with acetyltransferase or deacetylase activities (Figure 4). Subse­
quently, several other transcriptional cofactors with histone acetyltransferase activity were 
identified (Chapter 1.5.1). In addition, corepressor complexes with histone deacetylase 
activities have been isolated (Chapter 1.5.2).
1.5.1 Coactivators w ith histone acetyltransferase activity
Several histone acetyltransferases have been isolated notably the TBP-associated factor 
TAFn250 (see Chapter 1.2.2) (Mizzen et al., 1996), the enzymatic activity of the SAGA 
complex, Gcn5, (see Chapter 1.2.3) and several transcriptional cofactors such as CBP/p300 
(Bannister and Kouzarides, 1996; Ogryzko et al., 1996), or SRC-1-like proteins (Chapter 
2.2.2) (reviewed in Sterner and Berger, 2000).
The best-characterized HAT to date is the yeast Gcn5. Using truncation mutants, it were 
shown that the HAT domain of Gcn5 is required for transcriptional activation in vivo (Candau 
et al., 1997). In addition, conserved residues critical to HAT activity were identified by per­
forming an alanine scan mutagenesis. It was shown that the Gcn5 HAT function correlates 
directly with cell growth, transcription, and histone acetylation at the Gcn5-dependent HIS3 
promoter in vivo (Kuo et al., 1998; Wang et al., 1998).
Recombinant yeast Gcn5 strongly acetylates histone H3 and weakly histone H4 in a free 
histone mixture (Kuo et al., 1996). Interestingly recombinant Gcn5 is unable to acetylate 
nucleosomal histones (Grant et al., 1997). Only in the context of multicomponent complexes 
such as SAGA (see Chapter 1.2.3), Gcn5 acetylates nucleosomes efficiently, indicating that 
other proteins might affect the Gcn5 HAT activity.
In mammals (human and mice), two closely related homologues of the yeast Gcn5 protein 
were found: hGCN5 and the p300/CBP-associated factor PCAF. These proteins share highly
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homologous amino acid sequences (about 70% identity) and an additional approximately 400- 
residue amino-terminal region which is not present in the yeast protein (Xu et al., 1998). The 
HAT activities of the mammalian GCN5 and PCAF proteins are functional in vitro (Yang X.J. 
et al., 1996). In addition, they can functionally replace the HAT activity of the yeast Gcn5 
protein in vivo (Wang L. et al., 1997), indicating a high degree of conservation of the HAT 
function throughout evolution. The requirement of PCAF as a histone acetyltransferase and 
transcriptional coactivator has been described, among other processes, for myogenesis (Puri et 
al., 1997), growth factor signalling pathways (Xu et al., 1998) and nuclear receptor mediated 
transcription (Blanco et al., 1998; Korzus et al., 1998).
The ability of PCAF to acetylate proteins is not restricted to histones. PCAF can also acetylate 
other proteins such as the chromatin proteins HMG17 (Herrera et al., 1999) and HMG I(Y) 
(Munshi et al., 2001), transcriptional activators such as p53 (Liu et al., 1999) and MyoD 
(Sartorelli et al., 1999) and the general transcription factors TFIIE and TFIIF (Imhof et al.,
1997).
p300 and CBP are highly homologous and are therefore often referred to as a unit 
(CBP/p300). CBP was originally identified as a coactivator for the transcription factor CREB 
and it was, as p300, later shown to posses intrinsic HAT activity. CBP/p300 are ubiquitously 
expressed and have critical roles in many cellular processes such as cell cycle control, 
differentiation and apoptosis (Giordano and Avantaggiati, 1999; Shikama et al., 1999). 
Mutations in CBP and p300 are associated with certain cancers and other human diseases 
(Giles et al., 1998). CBP/p300 can act as a coactivator for a wide variety of transcription 
factors including nuclear receptors and other activators such as c-Fos, c-Jun and c-Myb and 
might therefore be a point of intersection between different signaling pathways.
In vitro, recombinant CBP and p300 can acetylate all four histones in solution as well as 
within nucleosomes. Several experiments linked the HAT activity of CBP/p300 to their 
ability to increase transcriptional activation: A GAL4-fusion protein containing only the HAT 
activity of CBP/p300 is able to activate transcription, suggesting that the HAT domain of 
CBP is necessary for transcriptional activation (Martinez-Balbas et al., 1998). In addition, 
mutating amino acids critical for histone acetylation in vitro, abolish transcription in vivo 
(Martinez-Balbas et al., 1998). These experiments argue for a causal link between the 
transcriptional coactivator function of CBP and its HAT activity.
CBP/p300 might also influence transcription regulation by its ability to acetylate factors in­
volved in transcriptional processes such as HMG I(Y), the activators p53 (Gu et al., 1997; Liu
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L et al., 1999), GATA (Boyes et al., 1998; Hung et al., 1999) and YY1 (Yao et al., 2001), the 
erythroid Krüppel-like factor (EKLF), Drosophila T-cell factor (dTCF) (Waltzer and Bienz, 
1998), the HIV Tat protein, the nuclear receptor coactivators SRC-1, ACTR and TIF2 and the 
general transcription factors TFIIE and TFIIF.
In addition, single round in-vitro transcription studies have demonstrated that p300 is 
increasing the formation of a preinitiation complex on chromatin templates dependent on the 
nuclear estrogen receptor (ER) (Kraus and Kadonaga, 1998; Kraus et al., 1999). This finding 
argues that CBP/p300 might function also by stabilizing the promoter binding of the general 
transcription machinery by direct protein-protein contact. This hypothesis is supported by 
studies that show physical interactions between CBP/p300 and components of the general 
transcription machinery, such as TFIIB (Kwok et al., 1994), TBP and the non-phosphorylated 
form of RNAP (Cho et al., 1998). These interactions do not necessarily imply a bridging 
function of CBP/p300 between a transcription factor and the general transcription machinery. 
Instead, binding of CBP/p300 to components of the general transcription machinery might be 
necessary for bringing an enzyme (HAT) into close vicinity of its target (general transcription 
factor).
CBP, PCAF and proteins of another HAT superfamily (the nuclear receptor coactivators 
SRC-1 and SRC-1-like proteins (Chapter 2.2.2)) can bind simultaneously to a given 
transcription factor, forming an activation complex with several HAT-activities. The required 
components and their arrangement within this complex appear to be distinct for different 
classes of transcription factors (Kurokawa et al., 1998; reviewed Torchia et al., 1998). This 
could be demonstrated, for instance, by a study that used an assay in which the histone 
acetyltransferases PCAF and CBP were first blocked by the injection of highly specific anti­
bodies and then replaced by mutant proteins in which the HAT activity was destroyed. The 
experiments demonstrated that nuclear receptors require the HAT activity of PCAF but not 
the one of CBP for transactivation (Korzus et al., 1998). In contrast, transcriptional activation 
by the transcription factor CREB is dependent on the HAT activity of CBP and only to a 
lesser extend on that of PCAF (Korzus et al., 1998). The HAT activities of the different 
coactivators seem to influence each others activity and target specificity. For instance, the 
histone acetyltransferase pCIP (a SRC-1-like protein) inhibits specifically the acetylation of 
histones H3 and H4 by CBP, but enhances CBP-dependent acetylation of other substrates 
such as Pit-1 (Perissi et al., 1999a). The histone acetyltransferse activity of CBP appears to be
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affected also by transcription factors such as the b-zip proteins Zta, NF-E2 and C/EBPa 
(Chen C.J. et al, 2001).
Figure 4: Transcriptional activation by coactivators containing HAT activities. Transcription factors (TF) 
activate transcription by recruiting a coactivator complex with several factors that have HAT activities (e.g. 
CBP/p300; p160 proteins and PCAF). These complexes act by acetylating histone tails, transcription factors and 
other proteins such as general transcription factors. In addition, they might stabilize PIC formation by direct 
protein-protein interaction.
1.5.2 HDAC-containing corepressor complexes
Although transcription regulation is an equilibrium between transcriptional activation and 
repression, for years research focused on activation mechanisms. This changed a few years 
ago when cofactor complexes were identified that possess histone deacetylase activity 
(HDAC).
Different HDAC-containing complexes have been identified in mammalian cells such as Sin3 
corepressor complexes (Hassig et al., 1997; Laherty et al., 1997; Zhang et al., 1997), NuRD- 
Mi2 complexes (Tong et al., 1998; Xue et al., 1998; Zhang Y. et al., 1998), CoREST 
complexes (You et al., 2001; Humphrey et al., 2001) and the complexes containing nuclear 
receptor corepressors N-CoR and SMRT (Chapter 2.2.4) (Guenther et al., 2000; Li J. et al., 
2000b).
The catalytic subunits of all of these complexes are histone deacetylases HDAC1 (the human 
homologue of yeast Rpd3), HDAC2 (also referred to as mRPD3) or HDAC3 (Alland et al., 
1997; Heinzel et al., 1997; Laherty et al., 1998; Li J. et al., 2000b; Underhill et al., 2000). 
HDACs can deacetylate core histones or a histone H4 peptide in vivo and in vitro (Rundlett et
Chapter 1 33
al., 1996; Taunton et al., 1996). Several observations suggest that the deacetylase activity of 
HDACs is responsible for the transcriptional repression: A series of experiments with single 
amino acid substitutions in the presumptive catalytic core of the two HDACs, RPD3 and 
HDAC1, demonstrated a direct correlation between the enzymatic activity of HDACs and 
their ability to repress transcription (Hassig et al., 1998; Kadosh and Struhl, 1998). In 
addition, nuclear-receptor-dependent repression can be inhibited by the deacetylase inhibitor 
trichostatin A (Alland et al., 1997; Heinzel et al., 1997, Nagy et al., 1997, Ciana et al., 1998).
In addition to the histone deacetylases HDAC1 and HDAC2, the Sin3 histone-deacetylase 
complex contains two histone-binding proteins RbAp46 and RbAp48 and the proteins Sin3, 
SAP18 and SAP30 (Nomura et al., 1999) (see Table 4). The functions of the later proteins are 
not clear, but Sin3 has been proposed to act as a scaffold for the complex. In addition, Sin3 
and SAP30 might couple the complex to particular repressors since Sin3B has been shown to 
directly interact with members of the Mad/Mxi family of repressors (Spronk et al., 2000) and 
SAP30 interacts with Sin3A and the nuclear receptor corepressor N-CoR (Laherty et al.,
1998). The Sin3 corepressor complex interacts with many different repressors such as the 
methylated-DNA-binding protein MeCP2, proteins of the Mad family, the yeast protein 
Ume6, the POU domain containing protein Pit1, the homeodomain containing protein Rpx, 
and unliganded nuclear receptors (reviewed in Ayer, 1999). The Sin3 complex has been 
proposed to mediate repression of transcription by deacetylating histones (see Figure 5) since 
the recruitment of the Sin3 histone deacetylase complex to DNA results in a hypo-acetylated 
form of chromatin.
The basic structure of the Sin3 complex consisting of the four proteins HDAC1, HDAC2, 
RbAp46 and RbAp48 was also found in a complex called NuRD (nucleosome remodeling 
histone deacetylase) complex. In mammalian cells, the NuRD-Mi2 complex comprised at 
least seven polypeptides (see Table 4). In addition to the histone acetyltransferase activities, 
the NuRD complex contains proteins of the Mi-2/CHD family. These proteins have a 
chromodomain, a DNA helicase/ATPase domain of the SWI/SNF type, and PHD fingers, 
suggesting that the NuRD complex is involved in ATP-dependent chromatin remodeling. Like 
the Sin3-HDAC complex, the NuRD complex appears to be recruited to DNA via DNA- 
binding factors. For example, Ikaros and Aiolos, which are involved in the determination of 
the lymphoid lineage, associate with the NuRD complex in T-cells (Kim J. et al., 1999).
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Table 4: Biochemical functions of NuRD and SIN3 complex members.
Component SIN3 NuRD Function
HDAC1, HDAC2 + + Histone deacetylases
RbAp46, RbAp48 + + Histone-binding proteins
Sin3 + - Scaffold?
SAP18 + - Unknown
SAP30 + - Targeting SIN3 complex to N-CoR associated 
repressors?
M i-2a (CHD3),Mi-2ß (CHD4) - + ATP dependent nucleosome remodeling
MTA1, MTA2 - + Unknown
MBD3 - + Scaffold?
P66 - + Unknown
This table is based on information published in Ahringer, 2000.
A third type of corepressor complexes contain N-CoR and SMRT. Recently, at least three 
distinct N-CoR complexes from HeLa cells were purified (Underhill et al., 2000; Guenther et 
al.,2000; Li J. et al., 2000b). One complex contains HDAC1 and HDAC2 and several other 
components found in the Sin3A-HDAC complex. The second complex contains several 
additional components, including KAP-1, a corepressor that has been linked to 
heterochromatin silencing. The third complex contains HDAC3 and transducin ß-like protein 
1 (TBL-1), a protein with structural and functional similarities to the WD40-containing Tup1 
and Groucho corepressors. A specific conserved corepressor domain of N-CoR and SMRT 
were also shown to interact with HDAC4 and HDAC5 (Huang et al., 2000).
N-CoR and SMRT can interact with nuclear receptors and has been implicated in the 
repression mechanisms by many other transcription factors such as SRF, AP-1 and NF-kB, 
which are all transcription factors involved in stimulation of cell proliferation (Lee S.K. et al.,
2000). N-CoR and SMRT have both been implicated in repression of transcription by the 
POU homeodomain factors Pit-1 (Xu et al., 1998) by the bHLH proteins MAD (Heinzel et al.,
1997) and others.
It is likely that the N-CoR repression complexes function as pointed out before by 
deacetylating histones. In addition, these complexes might also repress transcription by 
inhibiting the formation of active preinitiation complexes either by complete prevention or by 
locking central components into an inactive complex (Figure 5). This model is based on the 
observation that N-CoR and SMRT can directly interact with the preinitiation complex 
components TFIIB, TAFII32 and TAFII70 (Wong and Privalsky, 1998; Muscat et al., 1998). 
Furthermore the unliganded thyroid hormone receptor inhibits transcription at an early step 
during preinitiation complex formation (Fondell et al., 1993; Malik et al., 1998).
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Figure 5: Transcriptional repression by the HDAC corepressor complex. Transcription factors repress 
transcription by recruiting cofactor complexes that contain histone deacetylase activities. The cofactor 
complexes act by deacetylating histones and by preventing functional PIC formation.
1.6 A TP-dependent chrom atin remodeling machines
The state of chromatin is not only modulated by enzymes with histone acetyltransferase or 
deacetylase activity, but also by chromatin remodeling machines such as the yeast SWI/SNIF, 
RSF, the fly CHRAC, ACF, NURF, BRM and the vertebrate hSWI, NuRD and RSF com­
plexes (reviewed in Kornberg and Lorch, 1999, Havas et al., 2001). All of these complexes 
contain a DNA-dependent ATPase subunit, which is either a Swi2/Snf2 homolog, the more 
distantly related ISWI protein or a CHD (chromodomain-helicase-DNA-binding domain) 
protein (Delmas et al., 1993).
In cell-free transcription assays with chromatinized templates, these remodeling machines 
(e.g. SWI/SNIF and NURF) support the activity of transcription factors (Mizuguchi et al., 
1997; Wallberg et al., 2000a). It is thought that SWI/SNIF machines catalyze ATP-dependent 
chromatin rearrangement by perturbing the chromatin structure, forming an activated or 
altered chromatin structure with diminished histone-DNA interactions, detectable by an 
increased sensitivity to DNA nucleases. Rearranged chromatin structures can influence the 
transcription efficiency by changing the three dimensional structure of the promoter, altering 
the direct neighborhood of transcription factors and cofactor complexes. It is also possible 
that positioned nucleosomes are 'blocking' the access of factors or the general transcription 
machinery to the promoter.
The isolation of related chromatin remodeling machines such as NRD (Tong et al., 1998) and 
NuRD (Xue et al., 1998) that in addition to the ATPase remodeling activity contain 
deacetylase activity suggest a coexistence of divers chromatin modifying mechanisms.
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A lot of questions about the precise mechanism of transcriptional regulation by these com­
plexes remain open. It is not clear yet, whether chromatin remodeling is an equilibrium be­
tween two different stages or whether it requires an activated intermediate state. In addition, 
the interplay between ATP-dependent remodeling machines and other remodeling machines 
such as the SAGA complex or HAT and HDAC containing complexes is still a matter of dis­
cussion. Furthermore the biological relevance of the ATP-dependent remodeling machines in 
vivo has been only shown in few cases: for instance the isolation of suppressors of swi/snf 
mutants in histone genes as well as the effects of swi/snf mutations on chromatin structure 
(Winston and Carlson, 1992) revealed the biological relevance of the yeast SWI/SNIF 
complex. Finally, the discovery of cellular processes in which chromatin remodeling plays an 
essential role is still at the beginning.
1.7 Cell-type-specific transcription
For differentiation, morphogenesis and proliferation, cell-type-specific expression of genes is 
crucial. An obvious mechanism for specific regulation of transcription is the restricted 
expression of transcription factors. In the last years, several novel hypothesis have been put 
forward that are based on expression and regulation of components of the general 
transcription machinery or cofactor complexes. This research is still in an early phase. As 
described before (Chapter 1.2.3), several cell-type-specific TBP complexes such as TRF 
(Hansen ret al., 1997; Hori and Carey, 1998) and TAC (Mitsiou and Stunnenberg, 2000) 
have been isolated. Although the final prove is missing, it is likely that these complexes are 
necessary for the transcription of cell-type-specific genes. In addition, protein levels of the 
nuclear receptor corepressor N-CoR (Chapter 2.2) are downregulated by a cell-type 
specifically expressed mammalian protein called mSiah2, which targets N-CoR for pro- 
teosomal degradation (Zhang J. et al., 1998). Furthermore, a few cofactors have been isolated 
that seem to be cell-specifically expressed: The cofactor PGC1, a coactivator of the nuclear 
receptors PPARy, TR, ER for example seems to be specifically expressed in muscle and 
brown fat (Puigserver et al., 1998; Tcherepanova et al., 2000; Michael et al., 2001). The 
cofactor OCA-B (also termed OBF1or BOB1) (Luo et al., 1992; Roberts and Green, 1994; 
Gstaiger et al., 1995; Luo and Roeder, 1995, Pfisterer et al., 1995; Strubin et al., 1995) acts as 
a coactivator of the ubiquitously expressed Oct-1 and the B-cell-specific Oct-2 A protein. 
OCA-B expression appears to be specific for B-cells and inducible in T-cells.
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1.8 Sum m ary
This chapter summarized protein complexes participating in the mechanisms of transcription 
control. Presently at least two levels of transcriptional regulation are recognized. In an initial 
step the basal transcription machinery gains access to the promoter region. This can be 
restricted by repressive chromatin structures consisting of hypomethylated histones or 
positioned nucleosomes. Changes in the state of acetylation of histones caused by cofactor 
complexes may modify the local chromatin structure (Chapter 1.5). Remodeling of the 
chromatin structure may also be mediated by ATP-dependent remodeling machines (Chapter 
1.6). In a second step the general transcriptional machinery is recruited by transcription 
factors either directly or via cofactor complexes (such as the Mediator complexes (Chapter
1.4) or HAT-containing complexes (Chapter 1.5.1)). Selectivity and specificity of the cofactor 
complexes appear to depend on the transcription factor and other conditions of the 
transcription reaction such as the promoter region and the cell-type in which the reaction takes 
place. Shared subunits in cofactor complexes and the ubiquitous use of the these complexes 
permit cross-talks between different transcriptional pathways.
The discovery of new transcription complexes during the past ten years resulted in novel 
concepts of transcriptional regulation. Yet, the new models may require further substantiation. 
For example, the precise identification of components of the general transcription machinery 
requires careful evaluation: Which factors and cofactors constitute a general transcription 
machinery and what is their composition on distinct promoters? Which mechanisms control 
reinitiation of transcription? Which genes are controlled by cell-type-specific general 
transcription factors? Furthermore, fine tuning and interplay of different cofactor complexes 
deserve further investigations. Finally, the role of chromatin in transcriptional initiation and 
reinitiation deserves further intensive studies.
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2. NUCLEAR RECEPTORS
2.1 The superfam ily of nuclear receptors
At the beginning of the last century, ligands such as retinoid acids, thyroid hormones, steroid 
hormones and vitamin D3 were described to affect processes such as differentiation and 
metamorphosis. When the corresponding receptors were cloned in the mid-1980s, it became 
obvious that the steroid and retinoid/thyroid hormone receptors belong to one subfamily. All 
of the receptors have a highly conserved over-all structure and domains with striking 
sequence homology. Over the past decade, a large number of nuclear receptor sequences have 
been described with an increasingly complex and baroque nomenclature. In many cases, 
different names were used for the same gene. To simplify this nomenclature, a general 
classification and a nomenclature of nuclear receptors were developed (Nuclear Receptors 
Nomenclature Committee, 1999). This general system is based on the amino-acid similarity 
within the two most conserved domains: the DNA-binding domain (DBD) and the ligand- 
binding domain (LBD), and yields six subfamilies and many subgroups (Figure 1).
In this Section the properties of the superfamily of nuclear receptors are described, in 
particular their highly conserved structure (Chapter 2.1.1), their ligands (Chapter 2.1.2) and 
their DNA-binding and dimerization behavior (Chapter 2.1.3).
2.1.1 The structure of a nuclear receptor 
Structural organization
Structural and functional analysis of the nuclear receptor superfamily revealed that these 
proteins share a highly conserved protein structure consisting of six regions (denoted A/B, C, 
D, E, F) (Figure 2) (Mangelsdorf and Evans, 1995): the N-terminus (region A/B) varies in its 
size and amino acid sequence and is sometimes lacking, the following DNA-binding domain 
(DBD) (region C) is highly conserved in its amino acid sequence, the hinge region D again is 
variable and the ligand-binding domain (LBD) (region E) well conserved. Some, but not all, 
nuclear receptors contain a C-terminal domain of unknown function (region F). The nuclear 
receptor region C and the carboxyterminal extension (CTE) in the D region participate in 
DNA binding; region E contains the main nuclear receptor dimerization interface and the
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ligand-binding function. A ligand-independent activation function AF-1 has been assigned to 
the A/B region of some receptors, a ligand-dependent activation function AF-2 to the C- 
terminal end of the E-region. Transcriptional repression by nuclear receptors is triggered by 
parts of the D- and the E-region.
Figure 1: Phylogenetic tree connecting 65 known NR genes in vertebrates, arthropods and nematodes. The
figure was published in Cell 1999 (The Nuclear Receptors Nomenclature Committee, 1999). Subfamilies are 
indicated by Arabic numerals at the extreme right of the figure, groups by capital letters and brackets, and indi­
vidual genes by Arabic numerals together with a representative name. The scale shows the length of the maxi­
mum possible bootstrap value (100). The bootstrap values defining the subfamilies are boxed.
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Figure 2: S tructural organization of a typical nuclear receptor. A typical nuclear receptor can be subdivided 
into six conserved regions (A-F). DNA-binding has been shown to be triggered by region C and the carboxyter- 
minal extension (CTE) of region D. For some receptors, region A/B is involved as well in DNA-binding. Re­
gions C, D and E trigger nuclear receptor dimerization. Ligand binding and transcriptional activation is mediated 
by regions D and E. An additional ligand-independent activation domain is located in regions A/B. 
Transcriptional silencing by nuclear receptors is mediated by regions D and E.
Crystal structures
The understanding of the secondary and tertiary structure of nuclear receptors increased 
significantly due to nuclear magnetic resonance (NMR) spectroscopy and crystal structure 
analysis. At present, only parts of nuclear receptors have been crystallized and studied, in 
particular the DBD of several nuclear receptors bound to oligonucleotides (Lee M.S. et al., 
1994; Rastinejad et al., 1995; Zhao et al., 1998; Meinke and Sigler, 1999; Rastinejad et al., 
2000; Zhao et al., 2000) and the LBD in an unliganded (apo-form) (Bourguet et al., 1995; 
Uppenberg et al., 1998; Nolte et al., 1998; Watkins et al., 2001), agonist-bound (holo-form) 
(Renaud et al., 1995; Wagner et al., 1995; Shiau et al., 1998; Williams and Sigler, 1998; Xu 
HE et al., 1999; Egea et al., 2000; Rochel et al., 2000) or antagonist-bound configuration 
(Shiau et al., 1998). Very recently, heterodimeric complexes of the RXR-RAR (Bourguet et 
al., 2000) and RXR-PPAR (Gampe et al., 2000) LBDs were crystallized. In addition, several 
co-crystals (Voegel et al., 1998) have been resolved containing peptides of coactivators 
(Chapter 2.2.2) interacting with nuclear-receptors.
The nuclear receptor DNA-binding domain
The crystals of nuclear receptor DBDs bound to DNA display highly conserved structural 
features. In addition, the interaction patterns between residues of the receptors and specific 
nucleotide sequences are highly conserved in the crystals studied up to now. Nuclear receptor
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DBDs contain two Zn-finger modules that form the so called 'core' DBD (Figure 3A) with 
two a-helices, one of which (the recognition helix) engages the major groove of the DNA to 
make specific contact with the bases of one conserved nuclear receptor binding site (also 
called half site) (Figure 3B). In Chapter 2.1.3, DNA-binding of nuclear receptors is reviewed 
in more detail. The minimal target sequence recognized by a nuclear receptor DBD consists of 
a conserved six basepair sequence (Figure 3B) which is contacted by the recognition helix of 
the Zn-finger structure. The sequence AGAACA is preferentially recognized by the 
glucocorticoid, mineralocorticoid, progesterone and androgen receptors. In contrast, the 
sequences AGGTCA or AGTTCA are preferentially recognized by virtually all other known 
members of the nuclear receptor superfamily including the retinoid acid receptors and the 
orphan receptors of the ROR-family.
Mutagenesis experiments identified a number of sequence motifs within the DBD (Meinke 
and Sigler, 1999) (Figure 3A): the D-box (a reverse ß-turn) which is involved in dimerization 
(Zechel et al., 1994) and the P-box which coincides with the recognition helix. The T- and A- 
box, which are located in the CTE, form a third helix and make additional protein-DNA 
contacts to nucleotides 5' of the conserved half site. These contacts are essential for the 
specific recognition of monomeric response elements by nuclear receptors (Terenzi et al., 
1998; Zhao et al., 1998; Meinke and Sigler, 1999).
Figure 3: Nuclear receptor DNA-binding (A) Schematic presentation of the nuclear receptor DNA-binding 
domain. The P-, D-, and the T/A-box are highlighted. (B) The sequence of the conserved nuclear receptor half 
site.
The nuclear receptor ligand-binding domain
The structures of the nuclear receptor ligand binding domains (LBD) analyzed to date (e.g. 
the one of RAR, RXR, TR, ER, PPAR, PXR) are also very similar (Bourguet et al., 1995; 
Renaud et al., 1995; Wagner et al., 1995; Wurtz et al., 1996; Brzozowski et al., 1997; Nolte 
et al., 1998; Uppenberg et al., 1998; Watkins et al., 2001) (Figure 4). The LBDs comprises 
12 a-helices (numbered H1 to H12) which are organized in a three layer structure with the
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helices H4, H5, H8, H9 and the N-terminal part of helix H12 sandwiched between the helices 
H1, H2 and H3 on one side and H6, H7 and H10 on the other. Short ß-strands are located 
between the helices H5 and H6 forming a ß-hairpin structure. This ß-hairpin structure 
together with several helices form a cavity, the ligand-binding pocket. Helix H12 which 
contains the previously identified ligand-dependent activation function AF-2 is of particular 
interest. In the unliganded RXR receptor, helix H12 is not packed onto the core LBD, but 
rather points away (Figure 4A), while in the liganded receptors (holo-form) helix H12 is 
folded back onto the core LBD (Figure 4B), enclosing the ligand in the receptor molecule 
(mouse trap model). Together with the helix H3 and parts of other helices, helix H12 creates 
an interaction surface for nuclear-receptor cofactors (Voegel et al., 1998; Nolte et al., 1998; 
Egea et al., 2000). Furthermore, it has been observed that helix H12 in the antagonist bound 
estrogen receptor folds in a conformation that buries residues within the coactivator 
recognition groove, thereby occluding coactivator binding (Shiau et al., 1998).
Despite the high degree of conservation, nuclear receptor structures display several differ­
ences. Helix H2 for example is missing in RARy (Renaud et al., 1995) (Figure 4B), while 
PPARy has additional structural elements, such as a short helix H2b followed by a ß-structure 
(Uppenberg et al., 1998).
Figure 4 : Schematic presentation of nuclear receptor ligand-binding domains.
A 'typical' nuclear receptor ligand-binding domain consists of 12 helixes (H1-H12) and two short ß-strands (in 
this figure symbolized by an arrow).
Most, but not all nuclear receptors display their functional activity as homo- or heterodimers. 
Astonishingly, the dimerization interface appears to be very similar for most of the homo-
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(Bourguet et al., 1995; Brzozowski et al., 1997; Nolte et al., 1998; Williams and Sigler, 1998) 
and heterodimers (Bourguet et al., 2000; Gampe et al., 2000) studied to date. The major part 
of the dimerization domain is provided by helix H10 with additional charge contacts involv­
ing the helices H9, H7 and the loop connecting helix H7 and helix H8. For the RARa- 
RXRaF318A co-crystal, additional contacts of the helices H10, H11 and the loops L8-9 and 
L9-10 have been described (Bourguet et al., 2000). An interesting feature of the homo- and 
heterodimers observed in the RXR-RXR (Bourguet et al., 1995) and RXR-PPARy (Gampe et 
al., 2000) crystals is the proximity of helix H12 of one receptor molecule to helix H7 in the 
other which could provide the basis for an allosteric cross-talk between the monomers.
Apart from these similarities, each hetero- or homodimer interface displays specific 
characteristics. The homodimer interface in the estrogen receptor , for example, is larger than 
the RXR homo and heterodimer interfaces. This observation might explain the promiscuity of 
RXR, since a smaller interface may lower the stability of the dimer.
In conclusion, nuclear receptors have a highly conserved structure which can adopt different 
conformations.
2.1.2 The ligands of the nuclear receptor family
The remarkable structural similarity amongst the different members of the nuclear receptor 
superfamily is in striking contrast with the diversity in the chemical structure of their ligands, 
which can be steroid hormones, lipophilic vitamins (such as retinoids), hormones (such as 
thyroid hormones) or fatty acids. For several nuclear receptors, a ligand has not been 
identified yet and these are therefore referred to as orphan receptors.
Ligand-binding in the evolutionary process
To find out when ligand-binding was attained during the evolutionary process, Laudet and 
coworkers compared the degree of relationship of nuclear receptors (based on their amino 
acid sequences) from different species present at critical positions in the evolutionary tree 
(Escriva et al., 1997; Laudet 1997) with the chemical nature of their ligands. They found no 
correlation between the position of a given receptor in the evolutionary tree and the chemical 
nature of its ligand. Furthermore, orphan receptors were randomly distributed all over the 
evolutionary tree. These observations suggest that ligand binding was achieved independently 
during evolution starting from an ancestral nuclear orphan receptor.
Chapter 2 47
A good example underlining this hypothesis are the homologues RXR (mammalian) and USP 
(Drosophila). While the mammalian receptor RXR is activated by retinoid acid, no ligand 
could be identified yet for the Drosophila receptor USP.
It seems likely that the ability of ligand-binding developed as a possibility of locking a 
receptor into an active (agonist) or repressive (antagonist) conformation.
Antagonists and inverse agonists
Some receptors, in particular the steroid hormone receptors, can also be locked into an inac­
tive or repressive state by binding to synthetic antagonists. These 'anti-hormones' have a 
number of current and potential applications in the clinical treatment of hormone-dependent 
disorders; for instance the anti-estrogen tamoxifen is used as tumor inhibitor in estrogen- 
receptor expressing breast cells. Here, the binding of tamoxifen to the estrogen receptor 
blocks its function and results in growth inhibition of the breast cancer cells.
An other kind of ligand was found for the orphan receptor CAR-ß. This receptor is constitu­
tively active in its unliganded state and can be switched off by binding to the steroids andros- 
tenol and androstanol (Forman et al., 1998). At presence no known agonist for CAR-ß exists. 
Therefore the steroids androstenol and androstanol cannot be referred to as antagonist, but 
rather as inverse agonists (Forman et al., 1998).
2.1.3 DNA-binding and dimerization
Nuclear receptors trigger their function primarily by binding to specific DNA elements. The 
analysis of the DNA response elements revealed that nuclear receptors can bind to DNA in at 
least three different modes: as homodimers, heterodimers or monomers (Figure 5) but a given 
nuclear receptor might have the potential to bind to DNA in different modes. There is no 
correlation between the DNA-binding and dimerization properties of a given receptor and its 
position in the evolutionary tree (reviewed by Glass, 1994 and Mangelsdorf and Evans, 1995).
The identification, purification and cloning of the first nuclear receptors (nuclear receptors of 
subfamily 3) in the late 1970s and early 1980s led to the characterization of hormone response 
DNA-elements consisting of two half sites (Chapter 2.1.3) in a palindromic configuration 
spaced by three nucleotides (reviewed in Evans, 1988). This finding suggested that these re­
ceptors bind to DNA as homodimers, a hypothesis later confirmed by several protein-DNA 
interaction studies (reviewed in Beato, 1989; Evans, 1988; Gronemeyer 1992).
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Homodimeric DNA-binding was also observed between nuclear receptors belonging to 
subfamily 2 of the nuclear receptor superfamily (for instance RXR, HNF4, COUP-TFII) 
(Zhang et al., 1992b; Jiang et al., 1995; Butler and Parker, 1995), to subfamily 1 (for instance 
RevErb) and to subfamily 6 (GCNF1) (Borgmeyer, 1997). These receptors can dimerize and 
subsequently bind to DNA also in the unliganded state. Some of the homodimers (such as 
RXR) can be activated by a ligand, some (such as HNF4) are constitutive activators and some 
(such as RevErb and COUP-TFII) are constitutive repressors (Mangelsdorf and Evans, 1995). 
Since steroid hormone receptors bind as homodimers, it was assumed that receptors such as 
TR and RAR also function as homodimers. While the TR homodimer can be formed in vitro 
(Forman et al., 1989; Wahlström et al., 1992), several studies demonstrated that receptors 
such as RAR, VDR and TR require an additional factor for high affinity DNA-binding 
(reviewed in Mangelsdorf and Evans, 1995). The accessory factor was identified to be the 
nuclear receptor RXR (or USP, the RXR analogue in Drosophila) (Yu et al., 1991; Kliewer et 
al., 1992a, Kliewer et al., 1992b; Leid et al., 1992; Zhang et al., 1992a; Marks et al., 1992; 
Bugge et al., 1992; Thomas et al., 1993). This finding suggested that RAR, VDR and TR bind 
to DNA and regulate transcription as RXR-heterodim ers. Subsequently, several nuclear 
receptors have been identified that bind to DNA as RXR-heterodimers. These receptors can 
be either ligand-regulated receptors (such as RAR, TR) or orphan receptors (such as NURR1, 
NGFI-B/ also called Nur77) (Perlmann and Jansson, 1995).
The heterodimeric binding of these proteins offers alternative arrangements for the resulting 
complex. In general, RXR occupies the 5' half site, the partner (e.g. RAR, TR, VDR) the 3' 
half site (Kurokawa et al., 1993; Perlmann et al., 1993; Zechel et al., 1994); only on a DR1 (a 
direct repeat with one spacing nucleotide), the polarity of RAR-RXR is reversed (Kurokawa 
et al., 1995; Rastinejad et al., 2000). Typically, RXR is not liganded in the RXR-heterodimers 
and functions as a silent partner. However, in some heterodimers (for instance in the RXR- 
NGFI-B/NURR1 heterodimers) RXR is activated by its ligand 9-cis retinoid acid (RA) 
(Forman et al., 1995; Perlmann and Jansson, 1995), in others (such as the PPAR-RXR 
heterodimer) both partners are independently and synergistically activated by their ligands 
(Kliewer et al., 1992b). Heterodimerization could also be observed between nuclear receptors 
that have a close proximity in the evolutionary tree, e.g. between ER a and ERß (Cowley et 
al., 1997) or between NURR1 and NGFI-B (Maira et al., 1999). Although these heterodimers 
have different DNA-binding and transcriptional properties compared with the corresponding 
homodimers, it is unclear if  they have any relevance in vivo.
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Figure 5: DNA-binding and dimerization properties of the nuclear receptor superfamily
Members of the nuclear receptor superfamily can bind to DNA as homodimers (for instance steroid hormone 
receptors, or nuclear receptors such as TR2, RXR, COUP-TFII, Rev-erb, HNF4, GCNF), as RXR-heterodimers 
(for instance TR, RAR, VDR, NURR1, NGFI-B, PPAR), as heterodimers that consist of two closely related 
members of one subfamily (ERß/ERa, NGFI-B/NURR1) or as monomers (for instance members of the ROR 
and the Rev-erb subfamily, NGFI-B, NURR1, NOR1, SF-1, ERR-1, ERR-2). The binding modes are illustrated 
by pictures in which the nuclear hormone receptor is symbolized by an ellipse, the ligand by a triangle (a striped 
triangle illustrates that ligand binding is not in all cases required), and the half site by an arrow. The amount of 
nucleotides spacing the two half sites is indicated by a number or by n, respectively.
M onomeric DNA binding can be encountered in subfamily 1 (members of the Rev-erb and 
the ROR family), in subfamily 3 (ERR-1, ERR-2), in subfamily 4 (NGFI-B, NURR1, NOR1), 
and in subfamily 5 (SF1). Interestingly, the monomeric DNA-binding receptors isolated so far 
are all orphan receptors. This observation, together with the hypothesis that the ancestor 
receptor was most probably an orphan receptor (Chapter 3.1.1), suggests that monomeric 
DNA binding might be the ancient mode of DNA binding. A study which compared the 
monomeric DNA binding of RORa with the homodimeric DNA binding of RevErba
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(Moraitis and Giguère, 1999) demonstrated that transition from monomeric to homodimeric 
DNA binding can be easily achieved by mutating only few amino acids.
As mentioned in Chapter 2.1.3, the binding site for one receptor molecule (half site) consists 
of a conserved 6 base pair sequence (Figure 3B). The response elements of nuclear receptors 
that bind to DNA as dimers consist of two half sites which can be arranged as direct, inverted 
or everted repeats. The specificity is generated by the spacing between the half sites as well as 
by subtle differences in the sequence of the hexad half site and the 5' extensions of the re­
sponse elements (Mangelsdorf and Evans, 1995 and refs therein). One exception is the re­
sponse element of nuclear receptors of the superfamily 3 that always consist of two half sites 
in a palindromic configuration spaced by three nucleotides. Monomeric DNA-binding sites 
require specific nucleotides 5' of the conserved nuclear receptor half site.
2.2 Transcriptional control mediated by nuclear receptors
As ligand-inducible transcription factors, nuclear receptors regulate many different genes by 
activation as well as by repression. Highly sophisticated protein complexes are involved in the 
transcriptional regulation mechanisms, such as the Mediator complexes (Chapter 1.4), several 
cofactors complexes with histone acetyltransferase and deacetylase activities (Chapter 1.5), 
and chromatin remodeling machines (Chapter 1.6). These protein complexes are thought to 
trigger transcription-factor-dependent gene regulation (activated transcription) in principle in 
two ways: on the one hand they help to recruit the general transcription machinery to the pro­
moter by direct interaction, on the other hand they can remodel chromatin by histone acetyla­
tion or deacetylation and nucleosome rearrangement. Although these mechanisms and most of 
the cofactors are used by all known transcription factors, there are some specific hallmarks of 
nuclear receptor transcription regulation mechanisms.
2.2.1 Principle of activation and repression
An important point is that nuclear receptors can both activate and repress transcription. This 
dual function results from the ability of most nuclear receptors to change their conformation 
by binding of their cognate ligands, a process which in turn leads to the association of 
different cofactor complexes. Based on their transcriptional activation properties, nuclear
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receptors are often divided into three different types: type I is represented by the steroid 
hormone receptors, type II by the RXR-heterodimers, and type III by orphan receptors.
Figure 6: Transcription regulation principle of activation and repression.
Repression and activation is a principle underlying transcription regulation by nuclear receptors of type I, type II 
and type III.
The principle of activation and repression is most pronounced in the group of nuclear recep­
tors that bind to DNA as RXR-heterodimers (type II). These receptors bind to DNA also in 
their unliganded state and actively repress transcription. When a ligand is bound, they 
strongly activate transcription. The ‘classical’ steroid hormone receptors (type I) are, in their 
unliganded state, associated with heat shock factors. After the ligand-induced conformational 
change, the receptor-heat-shock protein interaction is disrupted and the steroid hormone
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receptors bind as homodimers to specific promoter elements and activate transcription. 
Steroid hormone receptors repress transcription if they interact with an antagonist (e.g. trans- 
hydroxytamoxifen (TOT) for the ER). Orphan receptors (type III) do not have a ligand and 
therefore should be either constitutive activators or repressors. However, also orphan 
receptors can regulate a specific promoter via transcriptional activation and repression. For 
example, members of the subgroup of the constitutively active orphan receptors ROR and 
members of the subgroup of constitutively repressive orphan receptors Rev-erb can bind as 
monomers to highly similar binding sites (Laudet and Adelmant, 1995; Forman et al., 1994). 
Members of the ROR subgroup constitutively activate transcription from this binding site, 
members of the Rev-erb subgroup are inactive and have been shown to suppress ROR- 
dependent transactivation in transient transfection assays (Forman et al., 1994). Evidence that 
this binding site competition is an important process in gene regulation has been reported for 
the N-myc proto-oncogene (Dussault and Giguere, 1997) and the far-upstream enhancer of the 
rat a-fetoprotein gene (Bois-Joyeux et al., 2000). Furthermore, several mechanisms (such as 
phosphorylation, protein dimerization) have been discovered for ligand-regulated receptors 
that can activate a receptor in a ligand-independent manner (see Chapter 2.2.3). Similar 
mechanisms might exist for orphan receptors.
2.2.2 Ligand-dependent transcriptional activation
In the late 1980s, transient transfection studies with deletion mutants and chimeric receptors 
led to the identification of two transferable activation domains within nuclear hormone re­
ceptors (Gronemeyer et al., 1987; Webster et al., 1988; Hollenberg et al., 1988; Tora et al., 
1989; Meyer et al., 1990; Barettino et al., 1994), a ligand-independent one (AF-1) at the N- 
terminus of the protein, and a ligand-dependent one (AF-2) at the C-terminus.
Crystallization studies of nuclear receptors, in particular of the RAR and RXR ligand-binding 
domain, revealed that the AF-2 is located within the conserved helix H12 of the nuclear 
receptor superfamily. As described in Chapter 2.1.1, helix H12 is the major player in the 
ligand-induced structural rearrangement that creates new cofactor surfaces.
Many of the Mediator and cofactor complexes described in Chapter 1 have been identified by 
their AF-2 and ligand-dependent interaction with nuclear receptors (reviewed in Rosenfeld 
and Glass, 2001; Lee J.W. et al., 2001; Xu L et al., 1999; Torchia et al., 1998). The Mediator/ 
TRAP/DRIP complexes have been identified by their interaction with liganded VDR and TR, 
respectively. The interaction with liganded nuclear receptors resulted also in the isolation of
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the cointegrator CBP/p300 (Hanstein et al., 1996), the coactivator PCAF and a nuclear 
receptor specific group of cofactors, the p160 family which are related in size (160 kDa) and 
amino acid sequence (e.g. SRC-1/ NCoA-1 (Onate et al., 1995; Torchia et al., 1997), TIF2/ 
NCoA-2 (Voegel et al., 1996), GRIP1 (Hong et al., 1997, Walfish et al., 1997), ACTR (Chen 
et al., 1997), AIB1 (Anzick et al., 1997), pCIP (Torchia et al., 1997) (for review see Leo and 
Chen, 2000)).
The analysis of the interaction domain of cofactors and nuclear receptors revealed a motif - 
the so called LXXLL motif (L = leucine and X = any amino acid) - within the coactivators, 
which is necessary and sufficient for ligand-dependent interactions with nuclear receptors 
(Torchia et al., 1997; Heery et al., 1997; Takeshita et al.,1998; Voegel et al., 1998). Structural 
studies of the PPARy, ER and TR ligand binding domains complexed to fragments of the 
nuclear receptor interaction domain of p160 proteins revealed that these motifs form a short 
alpha helix (Nolte et al., 1998; Shiau et al., 1998; Feng et al., 1998; Darimont et al., 1998). A 
functional LXXLL motif was also found in the nuclear receptor interacting 
TRAP220/DRIP205 component of the mediator TRAP/DRIP complexes (Rachez et al., 1998; 
Yuan et al., 1998, Rachez et al.,1999).
Functional analysis in cells suggest that liganded nuclear receptors activate transcription by 
the mechanisms summarized in Chapter 1.8: (i) Chromatin remodeling by the histone 
acetyltransferase activity of cofactors or ATP-dependent chromatin remodeling machines and 
(ii) preinitiation complex recruitment or stabilization (Dilworth and Chambon, 2001 and refs 
therein). The analysis of ligand-dependent transactivation by nuclear receptors at a molecular 
level turned out to be difficult: Cellular system are too complex for studying single 
mechanistic steps in the transcriptional process. Moreover, cell-free systems with naked 
templates give only little, if  any, ligand-dependent transactivation (Klein-Hitpass et al., 1990, 
Kalff et al., 1990; Elliston et al., 1990; Lee I.J. et al., 1994; Valcárcel et al., 1994; Lemon et 
al., 1997). The problem was solved when in-vitro systems with chromatinized templates were 
developed in which strong ligand-dependent transactivation could be observed (Dilworth et 
al., 1999; Dilworth et al., 2000; Kraus and Kadonaga, 1998; Kraus et al., 1999; Liu Z et al., 
1999; Rachez et al., 1999). Based on studies in these systems, a model has been proposed in 
which nuclear receptors activate transcription by several temporally-ordered steps (Dilworth 
and Chambon, 2001). The important steps are described in the following.
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In a first step, nuclear receptors need to bind tightly to their cognate DNA response elements. 
DNase I footprinting data have demonstrated that the RXR-RAR heterodimers binds only 
weakly to the DNA elements in a chromosomal context (Dilworth et al., 2000). An increase 
of binding stability could be achieved for RXR-RAR heterodimers (Dilworth et al., 2000) as 
well as for PR homodimers (Di Croce et al., 1999) by the activity of ISWI-containing ATP- 
dependent chromatin remodeling complexes. Tight DNA binding of nuclear receptors seems 
to be ligand-independent (Dilworth et al. , 2000; Kraus and Kadonaga, 1998; Minucci et al.,
1998), only under certain cellular conditions DNA binding of nuclear receptors appears to 
depend on a ligand (Bhattacharyya et al., 1997; Dey et al., 1994; Savoldi et al., 1997). The 
protein-DNA binding studies have been performed on nucleosomal templates in a transcrip­
tionally ‘repressed’ state. Whether ATP-dependent remodeling machines are generally neces­
sary for tight nuclear receptor DNA binding in an in vivo situation in which a promoter might 
be in a permissive state is not clear and might depend on the individual situation.
In a second step, the liganded nuclear receptor appears to recruit coactivators from the p160 
and p300/CBP family. In transient transfection and yeast activation assays, overexpression of 
single cofactors such as CBP/p300, SRC-1, GRIP1 enhances the transactivation of several 
nuclear receptors (Dowell et al., 1997; Onate et al., 1995; Hong et al., 1997). Simultaneous 
overexpression of CBP and SRC-1 in mammalian cells results even in synergistic activation 
of ER- or PR-dependent transcription (Smith et al., 1996). In vitro, the p160 proteins TIF2 
and SRC-1 increase the transactivation by RXR-RAR (Dilworth et al., 2000) and PR (Liu Z et 
al., 1999) respectively; while p300 enhances the transativation of RXR-RAR (Dilworth et al.,
1999) and ER (Kraus and Kadonaga, 1998; Kraus et al., 1999). As mentioned above, ligand- 
dependent direct interaction between nuclear receptors and members of the p160 and 
CBP/p300 protein family have been clearly demonstrated. In addition, direct interaction was 
demonstrated between p160 proteins and CBP/p300 proteins. Furthermore, the steroid 
receptor RNA coactivator SRA (Lanz et al., 1999) and other unknown components have been 
described to associate with this complex.
Since the nuclear receptor interaction domain of CBP/p300, in contrast with the nuclear re­
ceptor interaction domain of p160 proteins, is not required for mediating maximal ligand-de­
pendent transactivation for the ER homodimer in vivo (Kraus et al., 1999) and the RXR-TR 
heterodimer in vitro (Li J. et al., 2000a), a scenario seems likely in which the p160 cofactors 
associate first with the DNA-bound nuclear receptor and then recruit the p300/CBP coactiva­
tor. This hypothesis is underscored by chromatin immunoprecipitations (ChIp) experiments, a
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technique which detects endogenous transcription factors and associated cofactors under 
physiological conditions. ChIp experiments revealed that p160 coactivators, CBP, p300 and 
PCAF are recruited in a specific order to the ER complex after estrogen stimulation in MCF-7 
breast cells (Shang et al., 2000). The precise mechanism by which the coactivator complex 
with p160 and CBP/p300 proteins functions is not yet clear. As discussed in Chapter 1.5.1, 
CBP/p300 possesses an intrinsic histone acetyltransferase activity and can interact directly 
with the RNAP holoenzyme. p160 proteins also acetylate histones (Spencer et al., 1997; Chen 
et al., 1997). It has therefore been suggested that the coactivator complex with p160 and 
CBP/p300 proteins functions by increasing the acetylation state of chromatin in the proximate 
promoter region in order to make the promoter more accessible for the general transcription 
machinery. The chromatin remodeling effect of this HAT containing complex might be 
enhanced by additional factors such as arginine methyltransferases (Koh et al., 2001). Cell 
transfection studies suggest that the arginine methyltransferase CARM1 synergise with p160 
and p300 proteins to increase nuclear-receptor-dependent transactivation, possibly by its 
ability to methylate the histone H3 (Chen et al, 2000). Methylation of histone H4 by the 
arginine methyltransferase PRMT1 facilitates subsequent acetylation of histone H4 tails by 
p300 (Wang H et al., 2001).
In a next not yet very well characterized step, the complex with p160 and CBP/p300 proteins 
is exchanged by a Mediator-like complex, most probably followed by recruitment of 
Polymerase II holoenzyme (see also Chapter 1.4) (Dilworth and Chambon, 2001). The Me­
diator complexes strongly increase nuclear-receptor-dependent transcription in highly purified 
cell-free transcription systems in a ligand-and AF-2-dependent manner (Fondell et al., 1996; 
Fondell et al., 1999; Rachez et al., 1999).
Although this model is attractive, it leaves several questions open. First of all, it is unclear 
which mechanism leads to the dissociation of the CBP coactivator complex and the 
association of the TRAP/DRIP complex. Since it has been demonstrated in in-vitro studies 
that CBP/p300 is also involved in preinitiation complex recruitment (Kraus and Kadonaga, 
1998; Kraus et al., 1999), the CBP coactivator complex might not leave the transcription 
factor but rather form one big coactivator complex with the Mediator complex. Alternatively, 
the two complexes might trigger completely different transcription reactions. In addition, 
some nuclear receptors such as VDR can directly contact the general transcription factor
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Figure 7: Model for ligand-dependent transcription regulation. In a first step, ISWI and ATP trigger tight 
DNA-binding of the nuclear receptor, followed by the recruitment of HAT-containing cofactors that can remodel 
the chromatin of the promoter region by acetylating histones. In a next step, the HAT-containing cofactor com­
plexes are replaced by Mediator-like complexes, which help to recruit the preinitation complex.
TFIIB (Masuyama et al., 1997; MacDonald et al., 1995) suggesting that nuclear receptors 
may participate in the recruitment of the general transcription machinery. Furthermore, 
several additional protein complexes (such as the SAGA/PCAF complex) and nuclear- 
receptor-dependent cofactors (for instance ASC-1 and ASC-2) have been isolated that appar­
ently play a role in transcription regulation mediated by nuclear receptors ( Wallberg et al., 
2000b; Wallberg et al., 1999; Kim H.J. et al., 1999; Lee et al., 1999). Moreover, the
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transcriptional activation of some nuclear receptors can be increased by arginine 
methyltransferases (Chen et al., 1999; Koh et al., 2001) or kinases (Kane and Means, 2000), 
indicating a role of methylation and phosphorylation in specific nuclear receptor-mediated 
transcription. Finally, the cold-inducible coactivator PGC1, who is induced in brown fat cells 
by thermal stimulation and acts as a coactivator for PPARy- and TR-mediated transcription 
(Puigserver et al., 1998), provides a good example for promoter-specific coactivator 
requirement.
Hence, nuclear receptors seem to use different highly elaborated transcriptional regulation 
mechanisms dependent on a given nuclear receptor, the promoter and the cellular conditions.
2.2.3 Ligand-independent transcriptional activation
Some, but not all, nuclear receptors contain also a ligand-independent activation function 
(AF-1) at the N-terminus. This activation function can be activated by phosphorylation, as it 
has been reported for the AF-1 of R A R a1 (Rochette-Egly et al., 1997) and RARy (Bastien et 
al., 2000). Several of the nuclear receptor cofactors mentioned above functionally interact 
with the AF-1 in the absence of ligand: Unliganded ER can recruit SRC-1 to its AF-1 as a 
consequence of phosphorylation (Tremblay et al., 1999) or via an adapter protein cyclinD1 
(Zwijsen et al., 1998). CBP and the p160 proteins SRC-1 and pCIP can be recruited to the 
AF-1 domain of unliganded TR (Oberste-Berghaus et al., 2000). Recruitment of SRC-1 to the 
AF-1 of the androgene receptor seems to be crucial for the transcriptional activity of the AR 
(Bevan et al., 1999).
In addition, a ligand-independent transactivation pathway has been described for the orphan 
nuclear receptor OR1 in which the active conformation of the nuclear receptor is achieved by 
heterodimerization with RXR (Wiebel and Gustafsson, 1997). Heterodimerization appears to 
be sufficient for recruiting the coactivator SRC-1 (Wiebel et al., 1999). A conformational 
change of a nuclear receptor by direct protein-protein contact with another transcription factor 
has also been described for the unliganded VDR and the transcription factor Ets-1. On a 
promoter with DNA-binding sites for nuclear receptors and Ets-1, a RXR-VDR heterodimer 
in which both receptors lack the core AF-2 domain can recruit cofactors in the presence, but 
not in the absence of Ets-1 (Tolón et al., 2000).
In conclusion, several ligand-independent activation pathways for nuclear receptors exist. 
Most of these pathways require the activation of the nuclear receptor by ligand-independent 
mechanisms such as phosphorylation or heterodimerization and result in the recruitment of
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coactivators. It is very likely that for some receptors the recruitment of coactivator complexes 
is meditated by an interplay of both activation function AF-1 and AF-2.
2.2.4 Nuclear-receptor-m ediated repression
In the late 80th and early 90th, the importance of repression mechanisms mediated by 
unliganded nuclear receptors became apparent (Sap et al., 1989; Damm et al., 1989; Damm 
and Evans, 1993; Fondell et al., 1993). Few years later, two highly related proteins N-CoR 
(Hörlein et al., 1995) and SMRT (Chen and Evans, 1995) were identified which interacted in 
GST-pull down experiments and EMSAs with unliganded TR and RAR (Chapter 1.5). Both 
proteins contain a highly conserved transferable repression domain which is able to actively 
repress transcription in transient transfection assays (Hörlein et al., 1995). The interaction 
between N-CoR/ SMRT and nuclear receptors is triggered by the hinge region of nuclear 
receptors and two attached conserved domains at the C-terminus of N-CoR/ SMRT (Hu et al., 
2001; Hörlein et al., 1995; Zamir et al., 1996). The conserved consensus sequence 
LXXXIXXXI/L of the corepressor that mediates the interaction with nuclear receptors 
appears to form an extended helix similar to the LXXLL motif of coactivators (Hu and Lazar, 
1999; Perissi et al., 1999b; Nagy et al., 1999).
How do these corepressors work? There are two obvious possibilities for corepressors to 
interfere with transcriptional activation: Firstly by inhibiting preinitiation complex formation 
or similarly locking the preinitiation complex into an inactive conformation and secondly by 
deacetylating the histone tails in order to create a hypo-acetylated closed form of chromatin. 
Both hypotheses have been tested.
The deacetylation hypothesis is supported by the observation that N-CoR as well as SMRT 
are able to recruit the core Sin3-histone-deacetylase complex (Chapter 1.5.2) by interacting 
with the components mSin3A and SAP30 (Laherty et al., 1998; Heinzel et al., 1997; Alland et 
al., 1997). Microinjection experiments revealed a participation of components of the Sin3- 
histone-deacetylase complex (e.g. Sin3, HDAC2 and SAP30) in nuclear-receptor-mediated 
repression (Heinzel et al., 1997; Laherty et al., 1998).
More recently, purification of N-CoR complexes from HeLa cells resulted in the discovery of 
at least three distinct complexes (for review see Rosenfeld and Glass, 2001). Two of the com­
plexes contains HDAC1 and HDAC2 (Underhill et al., 2000; Heinzel et al., 1997). The third 
complex contains HDAC3 (Underhill et al., 2000; Guenther et al., 2000; Li J. et al., 2000b).
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In addition, a specific conserved corepressor domain of N-CoR and SMRT was demonstrated 
to interact with HDAC4 and HDAC5 (Huang et al., 2000). These data demonstrate that 
distinct corepressor complexes exist and suggest that corepressor complexes are assembled in 
a nuclear-receptor- and gene-specific manner. The idea that nuclear receptors assemble 
specific corepressor complexes is also supported by the finding that the subunit SAP30 
appears to trigger repression mediated by antagonist-bound ER, but not by unliganded RAR 
or TR (Laherty et al., 1998).
Sin3 and N-CoR have intrinsic repression domains which are not linked to the recruitment of 
HDAC complexes (Laherty et al., 1997), suggesting additional repression mechanisms apart 
from histone deacetylation. One of such repression mechanisms of the N-CoR corepressor 
complex might be the inhibition of active preinitiation complex formation either by complete 
prevention or by locking central components into an inactive complex. This hypothesis is 
based on the observation that N-CoR and SMRT can directly interact with the preinitiation 
complex components TFIIB, TAFII32 and TAFII70 (Wong and Privalsky, 1998; Muscat et 
al., 1998). Furthermore the unliganded thyroid hormone receptor inhibits transcription at an 
early step during preinitiation complex formation (Fondell et al., 1993; Malik et.al., 1998). 
The interaction between N-CoR/ SMRT and components of the basal transcription machinery 
is not inhibited by association with the Sin3-histone-deacetylase complex, suggesting a 
coexistence of both mechanisms.
Since N-CoR and SMRT are so highly related, it is interesting if these two corepressors have 
specific or redundant functions. The N-CoR protein has more amino acids than SMRT and 
contains an additional second transferable repression domain at its extreme N-terminus. 
Recently, SMRT isoforms, SMRTe (for SMRT extended) with an extended N-terminus were 
isolated (Ordentlich et al., 1999; Park et al., 1999). This SMRTe N-terminus shows striking 
homology to the N-terminus of N-CoR and also includes a second repression domain. Other 
splicing variants of N-CoR (RIP13a, RIP13delta1) and SMRT have been described, some of 
which contain additional nuclear receptor interaction domains (Downes et al., 1996). Since 
the NR box and the Sin3A interaction domain are located on distinct parts of the corepressors, 
splice variants opens many possibilities for regulating the activity of corepressors. For 
instance, a splice variant containing only the NR-box, but no Sin3A interaction domain, 
would have potent antirepressive activity. The discovery of several splice forms with distinct 
activities complicates the comparison between SMRT and N-CoR. However, one study
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reveals some evidence for different specificities of N-CoR and SMRT. Microinjection of 
antibodies against N-CoR abolished unliganded TR and RAR repression, while antibodies 
against SMRT does not (Lavinsky et al., 1998).
2.2.5 Special features of transcription regulation by orphan nuclear receptors
The hallmark of an orphan receptor is its constitutive activity. Because of the lack of ligand 
regulation, orphan receptors are considered to fold in only one conformation that can either 
interact with coactivator complexes (constitutive activator) or with corepressor complexes 
(constitutive repressor).
The crystallization of orphan receptors appears to be very difficult most probably because the 
protein structure is unstable due to the missing ligand. A recent study of the orphan LBD of 
RORß overcame this problem by crystallizing the protein with a peptide of the coactivator 
SRC-1 and a fortuitous pseudo-ligand coming from the expression host (Stehlin et al., 2001). 
According to this study the LBD of a constitutively active orphan receptor resembles the 
liganded form of RAR (see Chapter 2, Fig. 4 and Chapter 6). The crystallization strategy used 
in this study appears to be successful but it is not without problems. Since the structure of the 
ligand influences the protein structure of a receptor molecule, exemplified for example by the 
distinct conformations of agonist- or antagonist-bound steroid hormone receptors (Shiau et 
al., 1998), it is possible that the ligand forces the receptor into an unnatural conformation. An 
example illustrating this problem is the crystal structure of the Drosophila orphan receptor 
USP (Billas et al., 2000). The protein was also crystallized with an unexpected ligand from 
the E.coli expression host, but the ligand seems to force the protein into an unnatural 
repressive conformation. In addition, the isolation of a pseudo-ligand questions whether these 
‘orphan’ receptors are ‘true’ orphans since there might be natural ligands of the receptor 
which have a similar structure as the pseudo-ligand but are presently unknown. To predict the 
structure of an orphan receptor based on its amino acid similarity to ligand-regulated 
receptors is difficult since several studies show that mutating only one amino acid is sufficient 
to turn a ligand-dependent nuclear receptor into a constitutive receptor (e.g. mRXRa (Vivat et 
al., 1997) and ER (White et al., 1997)).
It is important to keep in mind that the terms 'orphan' receptor as well as 'constitutive' activity 
can only be used as an expression with temporary validity and might have to be change
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following future experiments. Several receptors initially regarded as ‘orphans’ were 
subsequently found to be activated by new kinds of ligands: e.g., the peroxisome proliferator- 
activated receptors (PPAR) by fatty acids and eicosanoids (Göttlicher et al., 1992; Yu et al., 
1995; Forman et al., 1997; Kliewer et al., 1997; Krey et al., 1997; Green and Wahli, 1994), or 
the embryonic receptor BXR by a novel class of endogenous benzoate metabolites (Blumberg 
et al. , 1998).
Orphan receptors might be regulated by ligand-independent activation mechanisms. DNA 
binding and dimerization, for example, seem to influence strongly the transcriptional activity 
of orphan receptors. Orphan receptors such as NURR1 or NGFI-B require heterodimerization 
with RXR for efficient transactivation (Perlmann and Jansson, 1995). In addition, the orphan 
repressor Rev-erba which can bind to monomeric response elements, represses transcription 
actively only on the dimeric response element DR2 (Zamir et al., 1997; Adelmant et al., 
1996; Harding and Lazar, 1995). Furthermore, some nuclear receptors such as the ligand- 
dependent heterodimer RXR-PPAR or the orphan receptor RORa can interact with SMRT or 
N-CoR in solution, but not when they are bound to DNA (Zamir et al., 1997; Harding et al.,
1997). These observations suggest that binding to DNA can stabilize an active conformation 
of nuclear receptors.
Orphan receptors may also be regulated by posttranslational modifications. The 
transcriptional activity of the orphan receptor SF-1 appears to be stimulated by 
phosphorylation (Hammer et al., 1999) as well as by acetylation (Jacob et al., 2001). In 
contrast, phosphorylation of NGFI-B decreases its transcriptional activity (Pekarsky et al.,
2001).
An interesting feature of the regulation of orphan nuclear receptors is the finding that the con­
stitutive activity can be switched off. It has been shown that the constitutive activity of 
CAR-ß can be inhibited by the steroids androstanol and androstenol (Forman et al., 1998). 
Biochemical studies identified an inhibitory activity in Xenopus embryos for the orphan 
receptor HNF4 (Peiler et al., 2000). Moreover, a recent study shows that the biological 
function of NGFI-B is inhibited by phosphorylation (Pekarsky et al., 2001, Masuyama et al.,
2001).
Crosstalk between orphan receptors and hormone signalling pathways
Orphan receptors exert at least part of their function by modulating known hormone signal­
ling pathways. Firstly, the binding sites of orphan receptors can overlap with response
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elements for hormone-dependent receptors. For example, the orphan receptor RORa 
competes with RXR-RAR for a binding site within the yF-crystallin promoter (Tini et al., 
1995). Secondly, orphan receptors and ligand-dependent nuclear receptors can bind 
independently to different response elements in a promoter and activate transcription 
synergistically. This behavior has been observed for RORa and RXR-PPARa that can both 
bind to independent elements in the peroxisomal hydratase-dehydrogenase promoter. RORa 
can amplify PPARa-dependent transcription in transient transfection assays (Winrow et al.,
1998). Other orphan receptors (e.g. NGFI-B, NURR1) modulate hormone-dependent 
signalling pathways by dimerization with RXR (Perlmann and Jansson, 1995). Interestingly, 
the RXR component in these heterodimers is responsive to ligand, opening two possibilities 
for the orphan receptors to interfere with hormone-signaling pathways: On the one hand, they 
form ligand-dependent RXR-heterodimers, on the other hand, they might compete with other 
ligand-dependent nuclear receptors for functional RXR.
Orphan receptors might also compete with ligand-dependent nuclear receptors for available 
cofactor complexes. Although not much is known about the interaction between cofactor 
complexes and orphan receptors (with the exception of the interaction between Rev- 
erba,ß and the Sin3A corepressor complex), it seems likely that orphan receptors use the 
same or similar cofactor complexes as those described in Chapter 2.2 to mediate 
transcriptional responses. Several interactions between constitutively active orphan receptors 
and components of the cofactor complexes (e.g. p300/ CBP, p160 proteins, N-CoR/SMRT, 
TRAP220/ DRIP205) have been shown (Atkins et al., 1999; Lau et al., 1999; Burke et al., 
1998; Downes et al., 1996).
Atypical orphan receptors
Although most nuclear receptors are highly conserved in their overall structure, some atypical 
orphan receptors have been isolated that either lack one of the functional domains conserved 
in the classical receptors or contain extra domains normally not present. For example, the 
human receptor DAX-l (Zanaria et al., 1994) and the mouse receptor SHP (Seol et al., 1996) 
contain only the nuclear-receptor LBD but lack a conventional DBD. While SHP does not 
have a known DBD at all, DAX-1 has a novel type of DBD that lacks conventional zinc- 
fingers but possesses a unique region composed of four alanine- and glycine-rich repeats. The 
C.elegans receptor Odr-7 (Sengupta et al., 1994) instead has a DBD that is homologous to 
known nuclear receptors, but it lacks sequences corresponding to a nuclear-receptor LBD. 
These atypical receptors can function as negative regulators of the transcriptional response of
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‘classical' nuclear receptors. SHP, for instance, can heterodimerize with RAR, RXR, TR and 
ER and downregulate the transcription levels mediated by these receptors (Johansson et al., 
2000; Seol et al., 1996). In addition, nuclear receptors with only a DNA-binding or a ligand- 
binding domain might also interfere with 'classical' nuclear-receptor signaling by binding-site 
(Odr-7) or cofactor competition (DAX-l, SHP).
2.3 The nuclear receptor subgroup of retinoid acid related orphan receptors
A very interesting subgroup of nuclear receptors is the subgroup 1F (Nuclear Receptors No­
menclature Committee, 1999) of the retinoid acid related orphan receptors (RORs) consisting 
of RORa (Becker-André et al., 1993; Giguère et al., 1994), RORß (Carlberg et al., 1994), 
RORy (Hirose et al., 1994; Medvedev et al., 1996, He et al., 1998), dDHR3 (Hong et al.,
1999), MHR (Palli et al., 1992) and CHR3 (Carney et al., 1997). All members of this group 
are orphan receptors and have the ability to bind DNA as monomers. They are found in higher 
(human and mouse: RORa-y) and lower (Drosophila: DHR3 and Caenorhabditis elegans: 
CHR3) developed metazoans.
Biological relevance o f RORa and RORß
Members of the ROR subgroup have been described to participate in important biological 
processes. RORa appears to have a key role in the maturation of Pukinje cells which is a 
basic event in cerebellar development. This hypothesis is based on a study that linked a 
deletion in the RORa gene to the staggerer phenotype in mice (Hamilton et al., 1996). 
Staggerer mice have a characteristic severe cerebellar ataxia due to a cell-autonomous defect 
in the development of Purkinje cells. In addition, target disruptions of the RORa gene have 
been shown to cause a phenotype similar to that of the staggerer mutation (Dussault et al., 
1998; Steinmayr et al., 1998). RORa has been proposed to be also involved in the 
inflammatory response (Delerive et al., 2001), the lipid and lipoprotein metabolism (Vu-Dac 
et al., 1997), and in atherosclerosis (Raspe et al., 2001) because of the identification of 
RORa-responsive response elements in promoters such as the promoter of IkappaBa, the 
major inhibitory protein of the N F -kB  signalling pathway (Delerive et al., 2001), the 
promoter of the apolipoprotein A-I (Vu-Dac et al., 1997) and the promoter of the 
apolipoprotein C-III (Raspe et al., 2001). Moreover, expression studies, transient transfection 
studies and the characterization of transgenic mice suggested a role for RORa in bone 
development (Meyer et. al, 2000) and myogenesis (Lau et al., 1999).
64 Nuclear receptors
RORß expression is highly restricted to the nervous system, in particular to the three principal 
anatomical components of the mammalian timing system: the suprachiasmatic nuclei, the 
retina and the pineal gland (Becker-André et al., 1994). In addition, mRNA levels of RORß 
oscillate in retina and pineal gland with true circadian rhythmicity, peaking at night time 
(André et al., 1998). These findings led to the hypothesis that RORß might be part of an 
output pathway of circadian rhythm regulation. An R O R ß'' knockout mouse revealed a close 
relationship to the spontaneous mouse mutation vacillans (André et al., 1998). The circadian 
rhythmicities of RORß- - mice differed from wild type mice in the period of free-running 
rhythmicity. Furthermore, RORß- - mice displayed a duck-like gait, transient male incapability 
to sexually reproduce and a severely disorganized retina that suffered from postnatal 
degeneration. The severe defect in the retina development is interesting because extensive in 
situ hybridization studies revealed high levels of RORß in retinal progenitor cells in the 
embryonic rat retina (Chow et al., 1998). The study showed in addition that RORß colocalize 
with Chx10, a transcription factor that is thought to influence retinal progenitor proliferation. 
The link between Chx10 and RORß is also supported by the observation that RORß 
expression is dramatically reduced in the ocular retardation mutant which has a defect in the 
Chx10 gene. These observations make it likely that RORß might be one of the target genes of 
Chx10 in the process of retinal neurogenesis. In addition, RORß is expressed in other cortical 
areas of the somato-sensory, visual and auditory systems and in the thalamic nuclei for each 
of these sensory pathways (Park et al., 1997; Schaeren-Wiemers et al., 1997) and has been 
proposed to play a role in sensory input integration.
Initial studies suggested that RORß acts as a nuclear melatonin receptor (Becker-André et al., 
1994), but the first author of the original study called his study into question (Becker-André et 
al., 1997). The nuclear receptors of the ROR subgroup are therefore still regarded as orphan 
receptors.
DNA binding and transcriptional activation o f RORa and RORß
The molecular mechanism of how these orphan receptors regulate transcription is still only 
poorly understood. Both receptors bind as monomers to highly related half sites (Becker- 
André et al., 1994; Giguère et al., 1995b), a finding which is in line with the observation that 
especially RORa and RORß have an extremely conserved DBD and T/A-box (Carlberg et al.,
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1994; Medvedev et al., 1996). DNA-binding of these receptors appears to be influenced by an 
additional domain illustrated by the finding that RORa exists in different splice variants 
which share the DBD and the C-terminal rest of the protein but have distinct N-termini. The 
splice variants differ in their DNA-binding properties, e.g. they display a distinct binding site 
recognition behavior on artificial (Giguère et al., 1994) and natural (Vu-Dac et al., 1997) 
response elements. These results suggest that the N-terminus may participate in DNA-binding 
maybe by providing additional direct DNA contact or by changing the overall structure of the 
protein. The different RORa isoforms display distinct spatiotemporal-specific expression 
patterns during postnatal development of rodent brain (Sashihara et al., 1996), suggesting 
distinct physiological functions for the isoforms.
Members of the ROR subgroup have been reported to be constitutive activators. It is very 
likely that they regulate transcription by associating with coactivators and coactivator 
complexes such as HAT containing cofactors (Chapter 1.5.1), Mediator complexes (Chapter
1.4) and chromatin remodeling machines (Chapter 1.6). Association with p300 was shown for 
the RORa LBD (Lau et al., 1999). Whether members of the ROR subgroup activate via the 
Mediator complex has not been investigated yet. Interestingly, RORa can associate in 
solution with the corepressor SMRT and N-CoR. However, upon binding to DNA, the ability 
to bind the corepressors is lost, suggesting a conformational change of the receptor induced by 
DNA-binding (Harding et al., 1997). RORa transactivation is potentated by a 
Ca2+/Calmodulin-independent form of Ca2+/Calmodulin-dependent protein kinases (CaMKs). 
This activation mechanism seems not to be triggered by direct phosphorylation of RORa 
(Kane and Means, 2000). In addition, two-hybrid screens have identified several proteins that 
interact with RORß such as the c-myc regulatory factor PuF, the metastasis suppressor 
candidate nucleotide diphosphate kinase NM23 (Paravicini et al., 1996) and a potential 
cofactor NIX-1 (Greiner et al., 2000). Whether these interactions are functionally relevant in 
vivo needs further careful examination.
The potential o f cell-specific transcription control
Interestingly, the LBD of RORß has been reported to activate transcription in transient trans­
fections in a cell-type-specific manner. A GAL-fusion protein consisting of the GAL DBD 
and the RORß LBD was active in neuronal cells (such as Neuro2A, NGP) and inactive, or 
even repressive, in non-neuronal cells (such as 3T3, CV1, 293 cells) (Greiner et al., 1996). In 
addition, a neuronal-specific cofactor has been isolated by its interaction with RORß (Greiner
66 Nuclear receptors
et al., 2000). NIX-1 binds to RORß and in a ligand-dependent manner to several ligand­
regulated nuclear receptors, including RAR and TR, but not to RXR. However it is 
completely unclear how this cofactor regulates cell-type specific transcription mediated by 
nuclear receptors, in particular since this cofactor, which binds to RAR and TR in a ligand- 
dependent manner, represses transcription.
2.4 Outline of this thesis
Because of their putative function in the central nervous system, the expression pattern of 
RORa and RORß have been studied extensively. Yet, hardly anything is known about the 
molecular mechanism of how these orphan receptors regulate transcription.
The work presented in this thesis attempted to analyze several aspects of transcriptional 
regulation by the orphan receptor RORß. In particular, we were interested in the following 
aspects: i.) the putative role of RORß in circadian signalling pathways; (ii) the transcriptional 
activation mechanism of RORß and iii.) the potential cell-type-specific regulation of RORß- 
mediated transcription.
Since initial studies had shown that mRNA levels of RORß change as a function of time, we 
set out to characterize the expression of RORß mRNA during the day-night cycle 
(C hapter 3) in more detail. These studies resulted in the isolation of a second isoform RORß2 
whose mRNA is expressed in pineal gland and retina and oscillates with a ‘truly’ circadian 
rhythm. RORß1 is strongly expressed in cerebral cortex, thalamus and hypothalamus, while 
little is found in retina and pineal gland. In addition, the two isoforms of RORß differ in their 
DNA-binding and transcriptional behavior, suggesting the regulation of different genes by 
RORß isoforms.
RORß belongs to the subgroup of nuclear receptors that bind to DNA as monomers. While at 
the outset of this work transcription control by nuclear receptor dimers has been extensively 
studied, little was known about transcription regulation mediated by nuclear receptor 
monomers. This and the potential of the RORß ligand binding domain to regulate 
transcription in a cell-type specific manner prompted us to analyze the transcriptional 
mechanism of RORß. Therefore, we established an in-vitro transcription system with 
transcription factors expressed in a vaccinia-virus system and nuclear extracts from Neuro2A 
and HeLa cells. In C hapter 4, the DNA-binding and in-vitro transcription behavior of
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vaccinia-expressed RO Ra4 and RORß1 is compared. We report that vaccina-expressed 
R O Ra4 in contrast to RORß1 binds cooperatively to two palindromically arranged binding 
sites. The studies also suggest that RORß appears to be a good candidate for a nuclear 
receptor that activates transcription as monomer since vaccinia-expressed RORß activates 
transcription strongly through a single DNA-binding site in vitro.
In C hapter 5, we compared the in-vitro functional properties of RORß with the one of the 
nuclear receptor heterodimer RXRa-RARa in nuclear extracts derived from different cell- 
types. We detected a relatively low DNA-binding affinity of RORß. Nevertheless, RORß was 
equally efficient in supporting single round transcription in vitro, suggesting that the low 
DNA-binding affinity might be compensated for example by cooperative binding with the 
PIC.
In addition we found that RORß could activate transcription efficiently only in Neuro2A but 
not in HeLa nuclear extracts. In contrast, RXRa-RARa and the acidic transcriptional 
activator GAL-VP16 activated transcription efficiently in nuclear extracts from both cell 
lines. We analyzed this behavior further and found that RORß was able to support single 
round transcription in vitro with the same kinetics in HeLa and in Neuro2A nuclear extracts. 
However, under multiple round conditions, only the Neuro2A nuclear extract supported 
efficient RORß-dependent transcription, while transcription ceased in HeLa nuclear extracts 
after the first transcription round was completed. This observation demonstrates that the 
transcriptional activation mechanism of RORß differs in Neuro2A and HeLa nuclear extracts 
and suggest a different (co)factor requirement for efficient transactivation by members of the 
NR1 subfamily of nuclear receptors. In C hapter 6, the main conclusions derived from this 
work are presented and discussed.
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Abstract
RORß is a member of the nuclear hormone receptor superfamily whose ligand is unknown. 
Expression of RORß is confined to the central nervous system and its pattern suggests this 
orphan nuclear receptor is implicated in the processing of sensory information and in circadian 
timing. In rats RORß mRNA levels robustly oscillate in pineal gland and retina displaying a 24 
hour rhythm. Here we report the cloning of the cDNA of a novel isoform of RORß from rat 
pineal tissue. Expression of this isoform, called RORß2, is confined to pineal gland and retina 
and strongly increases at night. RORß2 shares common DNA- and putative ligand-binding 
domains with the canonical RORß (referred to as RORß1) but is characterized by a different 
amino-terminal domain. This structural difference renders RORß2 much more selectively 
binding to DNA than RORß1. Moreover, in contrast to RORß1, the novel isoform efficiently 
activates transcription also in non-neuronal cell lines. Thus, the two RORß isoforms are likely 
to regulate different sets of genes in different physiological contexts.
Introduction
RORß is a transcription factor and belongs to the nuclear receptor family the members of 
which share a common modular structure composed of a transactivation domain, a DNA- 
binding domain and a ligand-binding domain (Carlberg et al., 1994; Evans, 1988). Typically, 
their transcriptional transactivation function is regulated by small lipophilic molecules, such as 
steroid hormones, yet a growing number of nuclear receptors have been identified for which no 
ligands are known. These nuclear receptors are referred to as “orphan” nuclear receptors 
(O’Malley and Conneely, 1992; Laudet and Adelmant, 1995). RORß is unique from all other 
known nuclear orphan receptors for its expression restricted to the central nervous system 
localizing to anatomic brain structures serving sensory input integration (e.g., thalamus, cortex) 
and circadian clock functions (e.g., pineal gland, retina) (Schaeren-Wiemers et al., 1997). 
Furthermore, RORß mRNA abundance oscillates in pineal gland and retina (at the level of 
photoreceptor cells) in a diurnal fashion with peak levels during the hours of darkness (Baler et 
al., 1996; Schaeren-Wiemers et al., 1997). Recently, we have shown that these oscillations are 
of truly circadian nature: they persist under constant darkness conditions and they transiently 
disappear when the animal’s circadian rhythmic behavior collapses, e.g. after a phase advance 
shift (André et al., 1998).
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Here we show that most of the nocturnal increase of RORß abundance is due to the expression 
of a novel isoform of RORß exclusively expressed in these two tissues. This isoform, called 
RORß2, differs from RORß1 with respect to DNA binding and transcriptional activity. 
Therefore, RORß1 and RORß2 might serve different physiological functions.
Materials and Methods
Experimental animals. Male Sprague-Dawley rats were maintained under light/dark condi­
tions (12h:12h; LD). Rats were deeply anesthetized using pentobarbital and killed at different 
time points under bright light or dim red light, respectively (Zeitgeber time ZT6, six hours after 
onset of light period; ZT18, six hours after onset of the dark period). Brain tissues, eyes and 
pineal glands were used either fresh or after freezing on dry ice and stored at -80°C. RNA was 
extracted using established methods (Chomczynski and Sacchi, 1987).
Plasmids. The expression vector pRORß2 was constructed as follows: the 5’RACE-generated 
cDNA fragment encoding the amino terminal domain specific for RORß2 and the generic DNA 
and ligand binding domains was cut with EcoRI (restriction site within the ‘anchor’ primer 
sequence) and BamHI (restriction site within the stop codon-containing downstream primer). 
The resulting subfragment was then introduced into the pSG5 expression vector (Stratagene, La 
Jolla, CA). The basic reporter vector p-tk-LUC was constructed in the following way: the 
minimal thymidine kinase (tk) promoter was cut from the chloramphenicol-acetyl-transferase 
(CAT)-based reporter vector pBL-CAT2 (Luckow and Schütz, 1987) using the restriction 
endonuclease HindIII and BglïI. Partial fill-in of the HindIII site of the DNA fragment end 
using Klenow fragment of DNA polymerase allowed insertion into the luciferase reporter 
vector pGL2-Basic (Promega, Madison, WI) via the partial filled-in NheI site and the BgHI site. 
RORß response elements (RORE) were created by annealing synthetic complementary 
oligonucleotides and inserted into the p-tk-LUC vector between the SmaI and KpnI site. Three 
RORE-containing reporter plasmids were constructed differing by their particular RORE 
preceding the minimal tk promoter: pDR8GT-tk-LUC (T A A GT AGGTCACTATAA GT- 
AGGTCAA), pDR8 T4 -tk-LUC (TAAT4AGGTCACTAT-AAT4AGGTCAA), pDR8GC-tk- 
LUC (TAAGCAGGTCACTATAAGCAGGTCAA).
Molecular cDNA cloning. Initially, a partial cDNA encoding the amino terminal part of 
RORß2 was cloned using 5’ RACE following the instructions of the supplier of the respective
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kit (Clontech, Palo Alto, CA). Briefly, total RNA extracted from rat pineal gland was reverse 
transcribed using an oligonucleotide antisense primer derived from the carboxy-terminal end of 
RORß (‘downstream’ primer). Following various enzymatic manipulations according to the 
supplier’s protocol PCR was carried out using an antisense primer derived from the second 
zinc-finger of RORß and the supplier’s ‘anchor’ primer. The amplification product was 
subcloned into pBluescript (Stratagene, La Jolla, CA) for sequence analysis. Full-length 
RORß2 was cloned by RT-PCR employing specific primers derived from the upstream 
untranslated sequence of RORß2 and a common ‘downstream’ primer containing the stop 
codon. The amplification product (1514 bp) was sequenced using a set of sequence-specific 
primers proving the identity of the DNA-binding and putative ligand-binding domains of 
RORß1 and RORß2. To allocate the RORß isoforms to transcript sizes total RNA from pineal 
gland dissected at ZT18 was separated on a formaldehyde-agarose gel. RNA larger than 3 kb 
and RNA in the size range 0.5 kb - 3 kb was recovered from appropriately cut agarose gel 
pieces using the RNAid kit (Bio101 Ltd., La Jolla, CA) following the instructions of the 
supplier. The size-fractionated RNA was reverse transcribed using a generic RORß 
downstream primer containing the stop codon. PCR was performed using a downstream primer 
derived from the ligand binding domain and RORß isoform-specific upstream primers. The 
primers used in this study are: RORß 1-specific upstream primer (CATCAGCAACAGCAT- 
CAA); RORß2-specific upstream primer (GGACCTCAAGTGAAACGGGAG); generic 
upstream primer (GCAGAACAATGCCTC-TTACT); generic downstream primer containing 
the stop codon (TCATTTGCAGACCGC-AGCAC); generic downstream primer derived from 
the ligand binding domain (GTTTAATGGGTTGAAGG).
Electrophoretic mobility shift assay. Oligonucleotides with the sequence 
GGGTCTAGAANNAGGTCATCTAGACCC containing the canonical hexameric reti­
noid/thyroid response element (AGGTCA) preceded by two arbitrary nucleotides (NN) were 
incubated with an antisense oligonucleotide primer (GGGTCTAGATGACC) at room tem­
perature for 10 minutes in 10 .^l 1x universal buffer (Stratagene, La Jolla, CA). The Klenow 
fill-in reaction in the presence of [a-32P]dCTP was performed in 20 ^l for 30 minutes at 37°C. 
The reaction was stopped with 30 ^l 20mM EDTA, the labeled fragments were purified on 
Sephadex G25 columns (Boehringer Mannheim, FRG) and incubated at 65°C for 10 minutes. 
The pSG5 vector-based expression plasmids for RORß1 and RORß2 were used to program 
rabbit reticulocyte lysates (Promega, Madison, WI). Binding was performed by co-incubating 1 
^l programmed lysate and 105 cpm of labeled fragment for 30 min at room temperature in 10 ^l
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20mM Tris pH 6.8, 5mM DTT, 0.2mM EDTA, 50mM NaCl, 1mg/ml poly(dI-dC). The 
electrophoretic mobility was assayed in a 1.5 mm thick 5% polyacrylamide gel in 0.5x TBE 
buffer at 10V/cm. The dried gel was exposed to X-ray film for one hour.
Cell culture and transfection assays. HeLa and Neuro2A cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM, Life Technology, Gaithersburg, MD) containing 
10% fetal calf serum. For each experiment 5 x 104 cells were seeded into 24-well culture plates 
16 hours before transfection. Twenty ^l of DNA solution (0.4 ^g DNA in total) in serum free 
medium (DMEM, Life Technologies) were mixed with 20 ^l of an 8% Lipofectamine (Life 
Technologies) solution in DMEM and incubated at room temperature for 30 minutes. This 
mixture was then added to the cells covered with 160 ^l serum free medium and the cells were 
incubated at 37°C for 3-5 hours. After removing the transfection mixture and adding 
DMEM/10% fetal calf serum the cells were incubated at 37°C for 40 hours. Luciferase activity 
and, as internal control for transfection efficiency, ß-galactosidase activity of 20% of the cell 
lysate were measured in a luminometer (Berthold, FRG) using the Dual-Light assay system 
from Tropix (Bedford, USA).
Immunoblotting. Fifteen ^g of purified protein was loaded on a 4-15% gradient poly­
acrylamide SDS gel (BioRAD) and electrophoresis was performed at 25mA. The protein was 
electrophoretically transferred onto a nitrocellulose filter and the amount was controlled by 
Ponceau staining. The filter was incubated at room temperarure for 1h in blocking solution 
(phosphate-buffered saline, 3% milk powder, 3% fetal calf serum, 0.1% Tween 20) followed by 
two 30 min incubations with, firstly, a rabbit anti-RORß antibody (diluted 1/2,000 in blocking 
buffer) and, secondly, an anti-rabbit goat antibody coupled with horse radish peroxidase 
(diluted 1/3,000 in blocking buffer). Signal detection was performed using the ECL kit from 
Amersham.
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Results and Discussion 
RORß2 is a novel isoform with circadian expression in retina and pineal gland
RORß mRNA levels change as a function of circadian time in pineal gland (Baler et al., 1996; 
Schaeren-Wiemers et al., 1997). To further characterize the upregulation of RORß in pineal 
gland we performed Northern blot extracted from rat pineal glands dissected at different time 
points. The animals were kept under defined light/dark conditions (LD 12:12) and sacrificed 
either during the day (6 hours after the light was switched on: ZT6) or in the night (six hours 
after the light was switched off: ZT18). RNA prepared from pineal glands dissected at night 
(ZT18) showed moderately upregulated levels of RORß-specific transcripts 10 kb in size 
confirming results previously reported (Baler et al., 1996). However, a novel transcript 1.5 kb 
in size was detected to a much higher extent at this nocturnal time point while its abundance 
was greatly reduced at ZT6 (Fig. 1A). A similar rhythmic expression of a 50 kD protein could 
be observed using a RORß-specific polyclonal antiserum in the immuno-blot experiment (Fig. 
1B). These results suggest that the 1.5 kb transcript strongly contributes to the circadian 
rhythmicity of RORß mRNA abundance in pineal gland.
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Figure 1. Nocturnal expression of RORß in pineal gland is upregulated both at the transcript and the 
protein level. (A) Northern hybridization was performed using 5 |ag total RNA extracted from rat pineal gland 
dissected at daytime (“D”; ZT6) and nighttime (“N”; ZT18), respectively. (B) Western blot experiment using 
rabbit antiserum raised against bacterially expressed RORß. Fifteen |ag total protein extracted from pineal gland 
dissected at daytime or nighttime were loaded. The RORß-specific signal migrating at 50 kD is indicated by an 
arrow.
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To further investigate this 1.5 kb RORß transcript we cloned its cDNA using RT-PCR and a 
5’RACE protocol. Sequence analysis of the RT-PCR product revealed that this clone encodes 
RORß. Interestingly, upstream of a splice site separating the N-terminus from the first zinc 
finger the sequence of this RORß clone diverges from the known RORß sequence. The new 
5’end harbors an open reading frame starting with an ATG and encodes a novel N-terminal 
amino acid sequence (Fig. 2A). Therefore we call this alternative gene product RORß2. Both 
isoforms of RORß are otherwise identical in their amino acid sequence, i.e. the DNA binding 
domains and the ligand binding domains display exactly the same sequence.
To allocate the two RORß cDNA isoforms to the two transcript forms expressed in pineal 
gland (10 kb and 1.5 kb) we have separated total RNA extracted from nocturnal pineal gland 
by gel electrophoresis and recovered the RNA for RT-PCR employing isoform-specific up­
stream oligonucleotides and common downstream oligonucleotides. RNA greater than 3 kb 
only gave RORß 1-specific amplification products while RNA smaller than 3 kb only gave 
RORß2-specific amplification products (see Materials and Methods section). Thus, RORß1- 
specific sequence localizes to the 10 kb transcript, while RORß2-specific sequence localizes to 
the 1.5 kb transcript.
To investigate whether the two isoforms of RORß display differential distribution patterns we 
used RT-PCR employing isoform-specific primer sets. RNA extracted from various brain areas, 
from eye and from pineal gland, which were dissected at day or at night, was reverse 
transcribed using a common downstream primer derived from the ligand binding domain. 
Aliquots of the reverse transcription reaction mixtures were PCR-amplified using a nested 
common downstream primer and either a common, a RORß 1-specific, or a RORß2-specific 
upstream primer. Our data show that amplification products derived from the common RORß 
domains can be detected in all tested samples. This experiment served as a control (Fig. 2B). 
However, RORß1 is strongly expressed only in cerebral cortex, thalamus, and hypothalamus 
while comparatively little is found in retina and pineal. Inversely, RORß2 is strongly expressed 
exclusively in retina and pineal gland but is absent from the cerebral areas. Thus, the 
expression of RORß2 is restricted to those organs in which the RORß mRNA levels oscillate. 
RORß1 and RORß2 very likely originate from the same gene by either alternative splicing or, 
more likely, by transcription from an alternative promoter. Therefore, it is tempting to 
speculate that the hypothetical alternative promoter driving the expression of this isoform is 
controlled by the circadian clock.
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Figure 2. RORß2 is a novel isoform specifically expressed in pineal gland and retina. (A) Comparison of the 
nucleotide and amino acid sequences of RORßl and RORß2 at the level of the amino-terminal domain. The 
nucleotide sequence encoding the amino-terminal domain is printed in boldface letters; the 5’ untranslated 
sequence is printed in lower case letters. For orientation, the cysteine residues of the first zinc-finger motif of the 
DNA-binding domain are underlined. (B) Reverse transcription PCR using total RNA extracted from various 
brain areas, pineal gland and retina dissected at mid-day (“Day”; ZT6) and mid-night (“Night”; ZT18), 
respectively. Oligonucleotide primer pairs were used to amplify cDNA fragments encoding part of the putative 
ligand-binding domain (RORß common), or cDNA fragments encoding RORßl- or RORß2-specific amino- 
terminal domains (RORß isoform 1 and RORß isoform 2, respectively). Amplification products were separated on 
agarose gels.
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RORßl and RORß2 display different specificity for DNA binding and transactivation
RORa, a nuclear receptor closely related to RORß, exists in four subtypes defined by different 
N-terminal domains fused to the invariant DNA binding and ligand binding domains (Giguère 
et al., 1994; Matsui et al., 1995; Sashihara et al., 1996; Becker-André et al., 1993). These 
various receptor isoforms display differential response element specificity (Giguère et al., 
1994), based on their respective N-terminal domains. They select their preferred DNA binding 
site by consensus sequences preceding the canonical hexameric retinoid/thyroid response 
elements (a/gGGTCA). In analogy to the RORa isoforms, we hypothesized that the two RORß 
isoforms prefer distinct 5’-flanking nucleotide sequences resulting in a modified response 
element specificity. To address this question we performed DNA binding assays using rabbit 
reticulocyte lysates programmed for in vitro translation of RORß1 and RORß2, respectively, 
and sixteen different double-stranded oligonucleotide probes. These probes contained a single 
hexameric core response element (RE1) and varied at the position of two preceding nucleotides 
(AANNAGGTCA). The data obtained from experiments done with RORß1-programmed lysate 
essentially confirmed the results previously published (Carlberg et al., 1994). RORßl bound 
preferentially to RE1 elements that are preceded by thymidine in the -1 position. However, in 
case the -2 position was occupied by a pyrimidine or an adenine RORß1 also accepted other 
oligonucleotides in this position, although with reduced affinity (Fig. 3A). In contrast, RORß2 
displayed a much more discrete preference for a T-residue at the -1 position than did RORß1 
(Fig. 3B). This requirement was found to be less stringent if thymidine was in the -2 position. 
In comparison to RORß1, therefore, the isoform RORß2 discriminates with a more stringent 
selectivity between the various possible 5’-flanking sequences and efficiently binds to only few 
selected response elements.
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Figure 3. DNA binding specificity of RORß isoforms. Electrophoretic mobility shift assay analysis of in vitro- 
translated RORß1 (A) and RORß2 (B) using 16 different double-stranded [32P]-labeled oligonucleotide probes 
containing the nuclear receptor binding half-site AANNAGGTCA. The two varied nucleotides NN in the -1 and -2 
position flanking the canonical half-site core sequence AGGTCA are indicated above each lane.
To test the functional activity of the novel RORß isoform and to compare it with that of 
RORß1 we performed transient transfection assays. We over-expressed the RORß isoforms in 
a neuronal and a non-neuronal cell line (Neuro2A and HeLa, respectively) using a reporter 
plasmid harboring a minimal thymidine kinase promoter complemented with an ROR response 
element (RORE) driving the expression of luciferase. We chose to use a dimeric response 
element composed of two direct repeats of RORß binding half-sites spaced by eight 
nucleotides (DR8) because RORß does not operate effectively from single binding half-sites 
(Greiner et al., 1996). Based on the DNA binding studies we selected three representative 
RORE’s: (1) an optimal RORE (DR8-GT); (2) a moderate RORE (DR8-TA); (3) a very weak
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RORE (DR8-GC). The data show that in the neuroblastoma cell line the performance of the 
two RORß isoforms on the three representative RORE’s parallels the DNA binding assays 
(Fig. 4). In this cell line both isoforms operate equally well on the optimal response element. 
However, in the non-neuronal HeLa cell line, RORß2 displays a strongly increased activity 
while RORß1 displays a strongly reduced activity (Fig. 5). The preference of RORß2 for non­
neuronal cells corroborates its expression confined to non-neuronal cells in the central nervous 
system: pinealocytes and retinal photoreceptor cells. The amino-terminal domain of RORß2 is 
highly hydrophilic containing two acidic and two basic amino acid residues more than that of 
RORß1 (Glu3, Asp11; Lys7, Lys9). While this difference is probably the basis for the 
pronounced DNA binding specificity of RORß2 it could also be the basis for RORß2’s strong 
performance in non-neuronal cells, e.g. via interactions with putative cell type-specific 
cofactors.
Taken together, RORß1 and RORß2 differ by their N-terminal domain, their spatio-temporal 
expression profile and their functional activity profile. They are likely to regulate different sets 
of target genes serving important functions either in the cerebral processing of sensory 
information (RORß1) or in the circadian timing system (RORß2).
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Figure 4. Transactivation of various RORE-tk-luciferase reporter genes by RORß1 and RORß2 in 
Neuro2A cells. Three different reporter plasmids were used containing upstream of the minimal thymidine kinase 
promoter (tk) a dimeric RORß response element (“DR8”) differing in the two nucleotide positions preceding the 
AGGTCA core sequence of each binding half-site (GT, TA, GC). Reporter plasmid tk.luc serves as control. Each 
column represents the mean value of five experiments. Standard deviations are indicated by error bars.
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Figure 5. Transactivation of the optimal RORE-tk-luciferase reporter gene DR8(GT).luc by RORß1 and 
RORß2 in HeLa cells. The empty expression vector pSG5 served as a control. Each column represents the mean 
value of five experiments. Standard deviations are indicated by error bars.
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Abstract
Nuclear receptors are ligand-inducible transcription factors that can be classified into two 
major groups according to their DNA binding properties. Members of the first group bind to 
DNA as dimers, either homo- or heterodimers; members of the second group are also able to 
bind as monomers. While the first group has been extensively studied biochemically, very 
little is known about nuclear receptors that bind and act as monomers. In this study, we 
compared the binding and transcriptional behaviour of RORa [NR1F1] and RORß [NR1F2], 
two representatives of the subgroup of monomer binding receptors. We show that although 
they are highly related in their amino acid structures, they display remarkably different 
binding behaviours. Furthermore, we provide evidence that RORß can efficiently activate 
transcription in vitro as a monomer.
Introduction
Nuclear receptors are ligand inducible transcription factors that have been reported to bind 
predominantly as dimers - either homo- (such as steroid hormone receptors) or RXR- 
heterodimers (such as the thyroid hormone receptor TR or the retinoid acid receptor RAR) - 
to their cognate DNA response elements. However, other members of the superfamily such as 
the orphan receptors NGF1-B, NURR1 (Wilson et al., 1993) and members of the RevErb and 
ROR subfamily (Carlberg et al., 1994; Giguère et al., 1994; Harding et al., 1993) have been 
shown to bind DNA as monomers. While the 'classical' homo- and heterodimeric binding 
receptors have been studied in great detail (for review see Xu L et al., 1999; Freedman, 1999; 
Mangelsdorf et al., 1995), very little is known about nuclear receptors that bind to DNA as 
monomers. Monomeric compared to dimeric nuclear receptor DNA-binding is typified by two 
features: (i) The monomeric response element has a 5' extension as compared to the 
conserved nuclear receptor half site - AGGTCA - of a 'classical' dimeric response element. 
The 5' extensions define the specificity of the monomeric binding site (Wilson et al., 1993; 
Giguère et al., 1995b). (ii) The protein domains involved in the contact between a receptor 
monomer and DNA are, apart from the conserved nuclear receptor DNA binding domain 
(DBD), the C-terminal flanking T/A box and in some cases the N-terminus of the receptor 
(Wilson et al., 1993; Giguère et al., 1994; Giguère et al., 1995b; Zhao et al., 1998; Glass, 
1994).
Many of the monomeric binding receptors have been demonstrated to also bind to DNA as 
homo- (e.g. RevErb) (Harding and Lazar, 1995) or RXR-heterodimers (e.g. NGF1-B or 
NURR1) (Perlmann and Jansson, 1995), some of which activate or repress transcription better
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or even exclusively as dimers. These findings raise the question whether nuclear receptors 
that apparently bind to DNA as monomers are transcriptionally functional as monomers. In 
this study, we compared the binding behaviour of two members of the ROR subfamily: 
RORa4 [NR1F1] (Giguère et al., 1994; Becker-André et al., 1993; Matysiak-Scholze and 
Nehls, 1997; Nuclear Receptors Nomenclature Committee, 1999) and RORßl [NR1F2] 
(Chapter 4; Carlberg et al., 1994; Nuclear Receptors Nomenclature Committee, 1999). The 
two proteins have highly related amino acid sequences (Fig. 1), in particular the domains 
involved in DNA binding are almost identical (DNA binding domain: 91% identity; T/A box: 
97% identity). While RORa is ubiquitously expressed, RORß has a highly restricted 
expression pattern and is predominately found in neuronal cells (Schaeren-Wiemers et al.,
1997). Both have been demonstrated to bind as monomers to an extended binding site con­
taining a thymine at position -1 and an adenine at position -4 of the nuclear receptor half site 
(Carlberg et al., 1994; Giguère et al., 1994; Giguère et al., 1995b), but whether they can exert 
their presumed transcriptional activation function as monomers is still a matter of discussion. 
Transient transfection studies have been ambiguous: some reports demonstrated the ability of 
RORa and RORß to activate transcription from a single RORE (Carlberg et al., 1994; 
Harding et al., 1997), while other studies could not observe an increase of transcription from 
single binding sites (Greiner et al., 1996).
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Figure 1: A schematic comparison of the protein domains of RORa4  and RORßl. The numbers above the 
schematic domains give the percentage of identical amino acids (% I) within the domains (DBD = DNA binding 
domain, T/A = T/A box, LBD = ligand binding domain, AF-2 = activation function 2).
Here we show that both vaccinia-expressed 6His-RORa and 6His-RORß bind as monomers 
to an extended response element. However, while RORa binds cooperatively to two binding
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sites, DNA-binding of RORß is not cooperative. Consistent with its binding behaviour, RORß 
strongly activates transcription in vitro from monomeric sites, with an additive response from 
dimeric binding sites. Our data demonstrate that, although RORa and RORß are highly 
related in their amino acid sequences, their functional behaviour diverge in vitro.
Material and methods
Recombinant vaccinia viruses. Recombinant vaccinia viruses expressing 6His-RORß and 
6His-RORa were prepared according to the protocol as described (Valcácel et al., 1994). The 
vector, PMS56 (Janknecht et al., 1991), used to generate the recombinant viruses, contains 
either the RORß1 (Chapter 4; Carlberg et al., 1994) or the RORa4 (Carlberg et al., 1994; 
Matysiak-Scholze and Nehls, 1997) cDNAs. The amino acids -MSHHHHHHGEF precede the 
second amino acid of the RORa and -ß sequences.
Receptor purifications. Preparations of nuclear extracts from virus infected HeLa cells
2+followed by Ni -NTA chromatography purification were performed essentially as described 
(Valcácel et al., 1994; Schmitt and Stunnenberg, 1993). The following buffers were used: 
buffer C [50 mM Tris-HCl (pH 8.5), 5 mM MgCl2, 0.1 mM EDTA, 17.4% Glycerol, 420 mM 
NaCl, 3 mM 2-mercaptoethanol, 0.1mM PMSF] and buffer D [50 mM Tris-HCl (pH 8.5), 5 
mM MgCl2, 0.1 mM EDTA, 17% Glycerol, 100 mM NaCl, 3 mM 2-mercaptoethanol, 0.1 
mM PMSF].
Western blotting. The protein extracts were electrophoretically separated on 10 % poly­
acrylamide SDS gels (BioRAD) and transferred onto nitro-cellulose filters. The filters were 
incubated for 30 min in blocking buffer (for the RORß-Western blots: phosphate-buffered 
saline, 5% milk powder, 1 M NaCl, 1% Triton; for the RORa Western blots: Tris-buffered 
saline, 5% milk powder). Next, the filters were incubated for 2 hours either with a polyclonal 
rabbit antibody against the ligand binding domain of RORß (diluted 1/1000 in blocking 
buffer) or with a monoclonal antibody against the T/A box and C-terminal flanking sequences 
of RORa (diluted 1/500) in blocking buffer, followed by an 1 hour incubation with a goat 
anti-rabbit or goat anti-mouse antibody coupled with horseradish peroxidase (diluted 1/5000 
in blocking buffer). Signal detection was performed using the ECL kit (Amersham). 
Oligonucleotides. The oligonucleotides used in this study were composed of the binding sites 
listed in Fig. 3A and SacI flanking sequences.
DNA-binding and transcriptional behaviour of RORa4  and RORß1 87
32Electromobility shift assays. The P-labelled response elements were prepared by using
32double stranded oligos, y-[ P] dATP and T4-polynucleotide kinase (Biolabs). Nuclear 
extracts were incubated with 0.1 ng (around 20 000 cpm) of the labelled oligonucleotide in 
binding buffer (80 mM KCl, 0.1 % Triton X-100, 2 ^g poly(dGdC), 0.1 mg/ml BSA, 10 mM 
Hepes (pH 7.9), 2.5 mM MgCl2, 0.05 mM EDTA, 5% Glycerol, 0.5 mM DTT) for 20 min on 
ice. For antibody supershift assays, nuclear extracts were preincubated with 0.1 or 1 .^l serum 
or pre-immune serum, respectively, for 10 min on ice prior addition of the labelled 
oligonucleotide. Complexes formed during the bandshift reactions were separated on pre­
cooled, pre-run (1h, 200 V) 4% polyacrylamide gels containing 0.25 X TBE at 4°C and 200 
V.
Transcription templates. The annealed ROR-specific response elements were cloned into 
the SacI site of the TK38[380] plasmid (Monaci et al., 1988) containing the tk minimal 
promoter -38 to +1 linked to a 380 bp G-less cassette. In addition, the TI[320] G-less con­
struct (Pugh and Tjian, 1990) was used as an internal control.
In vitro transcription assays. 3 ml packed cell volumes (PCV) of Neuro2A cells were used 
to prepare crude nuclear extracts (Berkenstam et al., 1992) with a final KCl concentration of 
300 mM. A typical nuclear extract preparation had a protein concentration of 5-8 mg/ml. 
Transcription reactions were performed as described (Valcácel et al., 1994). The KCl 
concentration of the transcription reactions was adjusted to 50 mM. 8 ^g of the crude nuclear 
extract preparations were used per reaction. The typical incubation times at 30 °C were 40 
min preincubation in the absence of nucleotides, followed by a 60 min reaction time after 
nucleotide addition.
Results and Discussion 
Expression of RORa and RORß with the vaccinia virus system
To investigate the binding and transcriptional properties of the two orphan receptors RORa 
and RORß, histidine-tagged fusion proteins, 6His-RORa and 6His-RORß, were expressed in
HeLa cells using the vaccinia virus expression system. The nuclear extracts were purified
2+over a Ni -NTA column. A SDS-PAGE polypeptide pattern of a typical 6His-RORß prepa­
ration revealed a polypeptide of approximately 50 kDa which is not present in preparations 
from HeLa cells infected with wild type vaccinia (vwt preparations) (Fig. 2A, left panel and 
data not shown). Western blot analysis using a polyclonal antiserum raised against RORß
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identified the 50 kDa polypeptide as RORß (Fig. 2B). A SDS-PAGE polypeptide pattern of a 
typical 6His-RORa preparation resembled strongly the pattern of vwt preparations (Fig. 2A, 
right panel and data not shown). Western blot analysis using a monoclonal antibody against 
RORa identified a polypeptide at around 55 kDa as RORa (Fig. 2C). Apart from 6His-
RORß and 6His-RORa, other poly-histidine containing polypeptides present in vaccinia
2+infected HeLa cells also bind to Ni -NTA (Fig. 2A and data not shown, Valcácel et al., 
1994).
2+Figure 2. Analysis of the Ni -NTA-purified 6His-RORß and 6His-RORa vaccinia preparation. (A) Silver 
stained Protein gels. The positions at which 6His-RORß and 6His-RORa migrate are indicated. (B, C) 0,3 |ag 
and 0,9 |ag of the RORß preparation (B) or the RORa preparation (C) and 0,9 |ag of the vaccinia wild type 
preparation (vwt) (B,C) were used in Western blot analysis. The Western blots were developed with a 
polyclonal RORß-specific antibody (a-RORß) (B) or a monoclonal RORa-specific antibody (a-RORa) (C).
RORa and RORß bind as monomers to DNA
To gain insight into the binding behaviour of vaccinia-expressed 6His-RORa and 6His- 
RORß, electrophoretic mobility shift assays (EMSAs) were performed using oligonucleotides 
which contained either a single or two palindromically arranged ROR-responsive elements 
(ROREs) (Fig. 3A). Because the DNA binding affinities of RORa and RORß reportedly 
depend on sequences 5' of the consensus half site (Chapter 4, Carlberg et al., 1994; Giguère et 
al., 1994;Harding and Lazar, 1995), the ROREs contained a thymine at position -1 and an 
adenine at position -4 of the nuclear receptor half site. 6His-RORa as well as 6His-RORß 
readily bound as monomers to a single RORE sequence (RE1) (Fig. 3B). The receptor
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monomer-DNA complexes are referred to as Ca 1 and Cß1 for 6His-RORa and 6His-RORß, 
respectively.
RORa, but not RORß bind cooperatively to a dimeric binding site
Next, a binding site termed POP that contained two ROREs in a palindromic configuration 
was tested. On this binding site, 6His-RORa formed a protein-DNA complex (Ca 2) with 
significantly lower mobility as compared to the monomeric complex Ca 1 (Fig. 3C, left 
panel). Ca 1 was hardly detectable even at low 6His-RORa concentrations (Fig. 3C), sug­
gesting strong cooperative DNA binding.
The DNA binding behaviour of 6His-RORß differed markedly from that of 6His-RORa.
At low concentrations, RORß formed only a monomeric complex (Cß1) on the POP element 
(Fig. 3C, lane 9); at higher concentrations, RORß formed an additional complex with lower 
mobility (Cß2). The presence of the monomeric RORß complex (Cß1) even at high 6His- 
RORß concentrations (Fig. 2C, lanes 11-13) indicated that 6His-RORß, in contrast to 6His- 
RORa did not bind cooperatively to the POP element.
To confirm the presence of RORa in the Ca 1,2 and RORß in the Cß1,2 complexes, EMSA 
analysis were performed with RORa- and RORß-specific antibodies. The monoclonal anti­
body raised against RORa could not be used for supershifting the 6His-RORa-DNA com­
plexes since it abolished DNA-binding (data not shown). The antibody raised against the 
highly related RORß ligand binding domain (LBD) also recognised the RORa LBD and 
supershifted the RORa complexes Ca 1 and Ca 2 (Fig. 3D, lanes 2,3) as well as the RORß 
complexes Cß1 and Cß2 (Fig. 3D, lanes 9,10), whereas the pre-immune
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Figure 3: RORa, in contrast to RORß, binds cooperatively to two binding sites. (A) Binding sites used in 
this study. The conserved nuclear receptor half site is symbolised by an arrow, the 5' extension of the half site by 
a box. The nucleotides within the extensions that are critical for RORa and RORß DNA binding are marked 
with an asterisk. (B) EMSA analysis of 6His-RORa and 6His-RORß to one extended binding site (RE1). The 
protein-DNA complexes formed are termed Ca 1 for RORa and Cß1 for RORß. (C) EMSA analysis of RORa 
and RORß to the two binding sites containing POP element. The complexes formed by 6His-RORa or 6His- 
RORß were termed Ca 1,2 or Cß1,2 respectively. (D) 27 ng of the RORa (lanes 1-5) or RORß preparation 
(lanes 6-10) and 0.1 and 1 |al of a RORß-specific polyclonal antibody (lanes 2, 3 and 9,10) or pre-bleed (lanes 
4,5 and 7,8) serum were used in EMSA analysis. The antibody supershifts were named aCa  or aCß, respec­
tively.
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serum had no effect on the migration of the complexes (Fig. 3D, lanes 4,5 and 7,8). When 
2+Ni -NTA purified extracts from vaccinia-wild type or mock infected cells were used in 
EMSA analysis, no protein-DNA complexes could be detected on a RE1 or POP element 
(data not shown). These findings indicate that the complexes Ca 1,2 and Cß1,2 contain the 
overexpressed proteins 6His-RORa or 6His-RORß, respectively.
Taken together, our data demonstrate that the two highly related orphan receptors RORa and 
RORß can both bind as monomers to a single response element. However, the binding of 
RORa and RORß to two palindromically arranged binding sites differs markedly: while 
RORa binds cooperatively, RORß binds not cooperatively.
RORß strongly activates transcription as a monomer
To answer the question if RORa and RORß can activate transcription from a single response 
element, we employed a cell free transcription system. The specific templates contained a 
RORE in front of the TATA box of the tk-promoter and a G-less cassette of 360 basepairs. 
The basal transcription efficiency of the reactions was measured with a template that 
contained the TATA box of the adenovirus major late promoter in front of a G-less cassette of 
320 basepairs (TI-template). Fig. 4A shows that RORß increased the level of transcription 
strongly and in a concentration-dependent manner from a template containing two ROREs in 
a palindromic configuration (lanes1-5). To assess if a single RORE is sufficient for RORß- 
dependent transcription, the distal or proximal half site of the POP element was mutated, 
yielding POPMut1 and POPMut2, respectively. 6His-RORß bound to these oligonucleotides 
only as monomer (data not shown). A single RORE was sufficient to mediate 6His-RORß- 
dependent transactivation (Fig. 4A lanes 6-10 and 11-15). The level of transcription from two 
ROREs arranged as a palindrome yielded approximately three fold higher transcription levels 
as compared to POPMut1 and POPMut2 at every 6His-RORß concentration tested, i.e. 
transcription of 6His-RORß from two binding sites was marginally if at all cooperative. 
These results provide the first evidence that a nuclear hormone receptor, RORß, can indeed 
mediate transcriptional activation from a monomeric binding site in vitro.
In contrast, 6His-RORa boosted the transcription levels only poorly from a POP containing 
template (Fig. 4B). Higher concentrations of the 6His-RORa preparation did not increase but 
rather 'poisoned' the in vitro transcription reactions (data not shown).
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Figure 4: RORß can activate transcription in vitro from a single response element. (A,B) in vitro 
transcription reactions with 6His-RORß (A) or 6His-RORa (B) and templates containing either a POP, or a 
mutated POP element (see also Fig.3A). These specific templates produce transcripts with 380 bases. The 
transcripts with the length of 320 bases derive from the TI-template, a control template containing the 
adenovirus major late TATA box in front of a G-less cassette.
Transcriptional activation in vitro is very sensitive to the relative concentrations of (trans­
cription) factors, cofactors and templates. Since 6His-RORß was more efficiently over­
expressed in HeLa cells than 6His-RORa, the low transcription levels mediated by vaccinia 
expressed 6His-RORa might be due to a disadvantageous ratio between 6His-RORa and 
factors copurified from HeLa cells. An alternative explanation could be that vaccinia-ex­
pressed 6His-RORa is properly folded for its DNA-binding activities, but requires additional 
proteins or modifications for its transcriptional properties. It has been reported that binding of 
RORa to cognate response elements is not per se sufficient for transcriptional activation 
(Harding et al., 1997).
To investigate whether 6His-RORß requires post-translational modifications to acquire
transcriptional competence, histidine tagged RORß was expressed in an E.coli expression
2+system. Using an equal amount of bandshift units (Fig. 5A), bacterially-expressed and Ni - 
NTA purified RORß activated transcription at least as efficiently at low receptor concentra­
tions as the vaccinia preparation (Fig. 5B, lanes 8-12 and lanes 1-5). Higher concentrations of 
the 6His-RORß coli preparation lead to a decrease of the specific transcription levels (Fig. 
5B, lanes 13,14), while the same amount of vaccinia-expressed 6His-RORß resulted in a 
proportional increase of the transcription levels (Fig. 5B, lanes 6,7). Our data suggests that 
RORß does not require a post-translational modification for its transcriptional function. 
However, we can not formally exclude that a modification of 6His-RORß occurred during the
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transcription reaction, as it had been shown for the HNF4 nuclear orphan receptor (Malik and 
Karathanasis, 1996). The reduced transcription levels at high concentrations of coli expressed 
RORß could be the result of (co-)factor squelching, which might be compensated in the 
vaccinia preparation by copurified proteins. This interpretation would imply that RORß 
requires additional (co-)factors for its specific transactivation.
Figure 5: Comparison of the binding and transcriptional properties of vaccinia and E.coli expressed 6His- 
RORß. (A) EMSA titration of vaccinia and E.coli expressed 6His-RORß on a RE1 response element. (B) In 
vitro transcription assays with vaccinia and E.coli expressed RORß on a POP response element.
In conclusion, we have demonstrated that 6His-RORß behaves as expected from a 'true' 
monomeric receptor in DNA-binding and in vitro transcription. In addition, we have shown 
that the two nuclear receptors 6His-RORa and 6His-RORß display different binding be­
haviour on dimeric sites, which is surprising if one takes into account that both receptors are 
highly related and display high homology for the domains previously shown to be important 
for DNA-binding and dimerization. The observation that RORa but not RORß binds with 
high cooperativity to two binding sites suggests that RORa but not RORß contains a 
homodimerization domain. Since receptor-induced DNA bending has been shown for 
RORa (McBroom et al., 1995), the cooperative DNA-binding of RORa might be supported 
by bent DNA. The difference in the dimeric binding behaviour of RORa and RORß yields 
new insight into the highly complex network of transcriptional regulation. In contrast with the 
simplistic view that highly related nuclear receptors use the same or highly similar activation 
mechanisms there is growing evidence that transcription factors use highly specific regulatory 
mechanisms to control gene expression.
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Abstract
An important model system for studying the process leading to productive transcription is 
provided by the superfamily of nuclear receptors, which are for the most part ligand-controled 
transcription factors. Over the past years several 'orphan' nuclear receptors have been isolated 
for which no ligand has been identified yet. Very little is known about how these 'orphan' re­
ceptors regulate transcription. In this study, we have analyzed and compared the biochemical 
and transcriptional properties of the neuronal-expressed orphan nuclear receptor RORß 
[NR1F2] with the retinoid acid receptor heterodimer RXRa-RARa [NR2B1-NR1B1] and 
GAL-VP16 in vitro. Although RORß binds to its DNA-binding sites with comparatively low 
affinity, it efficiently directs transcription in nuclear extracts derived from a neuronal cell 
line, Neuro2A, but not in nuclear extracts from non-neuronal HeLa cells. In contrast, RXRa- 
RARa and the acidic transcription factor GAL-VP16 equally efficiently support transcription 
in Neuro2A and HeLa nuclear extracts. These observations point to a different (co)factor re­
quirement for transactivation by members of the NR1 subfamily of nuclear receptors.
Introduction
The spatio-temporal regulation of gene expression is one of the key issues in differentiation 
and development. A central role in the control of gene expression is played by transcription 
factors that bind to specific enhancer/promoter elements and activate or repress the transcrip­
tion of a specific gene. The complex mechanism of transcriptional activation permits tight 
control at multiple levels, such as binding of the transcription factor to its response element, 
recruitment of coactivator/corepressor complexes and the basal transcription machinery, and 
facilitating reinitiation of transcription.
Among many model systems, the nuclear receptors of the thyroid/steroid superfamily have 
been of particular importance in the continuing dissection of the mechanisms responsible for 
the control of transcription. The nuclear receptor superfamily now comprises more than 50 
distinct members which have been grouped into 6 different subfamilies based on sequence 
similarities in the two well-conserved regions of this family, the DNA-binding and the ligand- 
binding domain (Nuclear Receptors Nomenclature Committee, 1999).
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The 'classical' nuclear receptor acts as a ligand-controlled transcription factor, which responds 
either to steroid hormones, small lipophilic molecules or vitamins. The last few years have 
witnessed major breakthroughs in understanding the molecular mechanisms of transcription 
signal transmission by these receptors (for reviews see Freedman, 1999; Westin et al., 2000 
and ref. therein). In addition to these 'classical' receptors, a rather large number of proteins 
have been identified that share the overall protein structure of nuclear receptor family 
members but for which no ligand has (yet) been found. These receptors are commonly 
referred to as orphan receptors (Enmark and Gustafsson, 1996).
Some orphan receptors have DNA-binding and dimerization properties very similar to those 
of 'classical' receptors, including their ability to bind as homo- or RXR-heterodimers to half 
sites arranged either as a palindrome or direct repeats. However, a subgroup of orphan 
receptors exists that bind as monomers to so-called extended half sites. Nucleotides 5' of the 
conserved receptor half site (AGGTCA) are contacted by these orphan receptors increasing 
DNA-binding affinity and providing specificity in the recognition of monomeric response 
elements (Giguère et al., 1995b). An intriguing question is how the transcriptional activity of 
orphan receptors is regulated in the absence of a ligand and of a heterodimerization partner. It 
is possible that the transcriptional activity of orphan receptors is controlled by protein 
modifications. Alternatively, these receptors may display a constitutive ability to bind either 
corepressor or coactivator complexes.
A good model system for studying transcriptional control by orphan receptors that bind to 
DNA as monomers is the subgroup of the ROR [NR1F] (also referred to as RZR) and the 
RevErb receptors [NR1D]. In transient transfections, members of the ROR subgroup appear 
to act as constitutive activators, whereas members of the RevErb subgroup act as constitutive 
repressors.
Two members of the ROR subgroup, RORa [NR1F1] (Becker-André et al., 1993; Giguère et 
al., 1994) and RORß [NR1F2] (Carlberg et al., 1994), are highly related but display very dif­
ferent expression patterns. While RORa is ubiquitously expressed, RORß expression is re­
stricted to neuronal cells, in particular to areas in the central nervous system that are involved 
in the processing of sensory information (spinal cord, thalamus, sensory cerebellar cortices)
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and the major areas of circadian rhythm regulation (retina, pineal gland and suprachiasmatic 
nuclei) (Schaeren-Wiemers et al., 1997). Despite the high degree of amino acid similarities, 
we could recently demonstrate that these two receptors display a different DNA-binding 
behavior (Chapter 4) suggesting that specific transcriptional regulation mechanisms may be in 
place for these transcription factors.
To unravel the mechanism underlying regulation of transcription by monomeric binding 
orphan receptors, we expressed RORß using the vaccinia virus system and compared its 
DNA-binding and transcriptional properties with those of the RXRa-RARa [NR2B1-NR1B1] 
heterodimer and the synthetic acidic activator GAL-VP16 in vitro. In this report we show that 
although RORß has a weak affinity for its response elements compared with the RXRa- 
RARa heterodimer, it potently drives transcription in Neuro2A but not in HeLa nuclear 
extracts. RXRa-RARa and GAL-VP16 are able to efficiently activate transcription in 
Neuro2A and HeLa nuclear extracts.
Material and Methods
Recombinant vaccinia viruses. Recombinant vaccinia viruses expressing 6His-RORß and 
RXRa-6His-RARa were prepared according to the protocol as described (Chapter 4, 
Valcácel et al., 1994). The expression vector of RORß contained the RORß1 cDNA (Carlberg 
et al., 1994) in pMS56 (Janknecht et al., 1991). The amino acids -MSHHHHHHGEF precede 
the second amino acid of the RORß sequence.
Receptor purifications and Western blotting. Preparations of nuclear extracts from virus-
2+infected cells followed by Ni -NTA chromatography purification were performed 
essentially as described (Chapter 4, Schmitt and Stunnenberg, 1993; Valcácel et al., 1994). 
Western blotting was performed as previously described (Chapter 4). Signal detection was 
performed using the AP kit (Promega).
Oligonucleotides. The synthetic oligonucleotides used in this study comprised nuclear recep­
tor binding sites (listed in Fig. 2A) and SacI flanking sequences.
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32Electromobility shift assays. For the preparation of the P-labelled oligonucleotides, two
32complementary single stranded oligos were annealed and incubated with y- [ P] dATP and 
T4-polynucleotide kinase (Biolabs). The electromobility shift assays were performed as pre­
viously described (Chapter 4). Off-rate experiments were performed by adding a 500-fold 
molar excess of specific oligonucleotides to the preformed protein-DNA complexes. 
Complexes formed during the bandshift reactions were separated on pre-cooled, pre-run (1h, 
200 V) 4% polyacrylamide gels containing 0.25 X TBE at 4°C and 200 V.
Transcription templates. The annealed RORß-specific response elements were cloned into 
the SacI site of the TK38[380] plasmid (Monaci et al., 1988) containing the tk minimal pro­
moter -38 to +1 linked to a 380 bp G-less cassette. The template 4RE1 contains four copies of 
the annealed RE1 element cloned into the SacI site of TK38[380]. The 5' located RE1 element 
is in antisense orientation, three 3' located elements in sense orientation. In addition, the fol­
lowing templates were used: the RARß[380] G-less construct (Valcácel et al., 1994), the 
TI[320] G-less construct (Pugh and Tjian, 1990) and the HIV-1 core promoter carrying five 
GAL4 recognition sites (Halle et al., 1995).
In vitro transcription assays. 10 ml packed cell volumes (PCV) of HeLa cells and 3 ml PCV 
of Neuro2A cells were used to prepare crude nuclear extracts (Berkenstam et al., 1992). The 
nuclear extracts had a final KCl concentration of 400 mM. A typical nuclear extract prepara­
tion had a protein concentration of 5-8 mg/ml. Transcription reactions were performed as de­
scribed (Chapter 4). The final KCl concentration in the transcription buffer for RXRa-6His- 
RARa and GAL-VP16 transcription were set to 80 mM, for RORß transcription to 50 mM. 4­
8 .^g of the crude nuclear extract preparations were used per reaction. A typical transcription 
reaction was performed by preincubating the samples for 40 min at 30 °C in the absence of 
nucleotides. After the addition of nucleotides the procedure was followed up by a 60 min 
reaction time. Single round transcription experiments were performed by adding Sarkosyl to a 
final concentration of 0.05% 30 sec after nucleotide addition.
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Results
Expression of RORß using the vaccinia virus system
To assess the transcriptional properties of RORß, a histidine-tagged fusion protein, 6His-
RORß, was expressed in HeLa cells using the vaccinia virus expression system and purified
2+over a Ni -NTA column. A SDS-PAGE polypeptide pattern of a typical 6His-RORß prepa­
ration revealed a polypeptide of approximately 50 kDa which is not present in preparations 
from HeLa cells infected with wild type vaccinia (Fig. 1A and data not shown). Western blot 
analysis using a polyclonal antiserum raised against RORß identified the 50 kDa polypeptide
as RORß (Fig. 1B). Apart from RORß, other poly-histidine containing polypeptides present
2+in vaccinia infected as well as in non-infected HeLa cells bind to Ni -NTA (Fig. 1A, 
Chapter 4, Valcácel et al., 1994 and data not shown). The purity of 6His-RORß was estimated 
to be 5-10 %.
2+Figure 1. Analysis of the Ni -NTA-purified 6His-RORß preparation. (A) Protein gel stained with
2+Coomassie Brilliant blue R-250. (B) Western blot analysis o f the Ni -NTA purified receptor preparation. M, 
molecular mass marker. The position at which 6His-RORß migrates is indicated.
RORß has a weak affinity for its DNA site
Since DNA-binding of a transcription factor is the prerequisite for transcriptional activation, 
the DNA-binding properties of 6His-RORß were analysed in electrophoretic mobility shift as­
says. Several oligonucleotides were used containing either a single or two consensus half sites
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-AGGTCA- in a direct or palindromic configuration (Fig. 2A). Because DNA-binding of 
RORa and -ß reportedly depends on sequences 5' of the consensus half site (Chapter 3; 
Carlberg et al., 1994; Giguère et al., 1994), the ROR-responsive element (RORE) used 
throughout the experiments contained a thymine at position -1 and an adenine at position -4 
preceeding the nuclear receptor halfsite. 6His-RORß readily bound as a monomer to a single 
half site (RE1) (Fig. 2B, left panel). Two complexes were obtained on POP, a binding site 
containing two half sites in a palindromic configuration (Fig. 2B, middle panel). In agreement 
with published results (Carlberg et al., 1994; Greiner et al., 1996) two distinct complexes 
were also detected using response elements consisting of two half sites arranged as direct 
repeats with 7 or 8 spacing nucleotides (DR+7, DR+8) (data not shown). Both protein-DNA 
complexes were supershifted with a RORß-specific antiserum, whereas the pre-immune 
serum did not alter the mobility of the complexes (Fig. 2C). Binding of 6His-RORß to 
TREpal containing two palindromically arranged consensus binding sites without appropriate 
5' extensions was very inefficient; a weak protein-DNA complex migrating at the position of 
a monomer was obtained only at high receptor concentrations (Fig. 2B, right panel).
Next, the relative affinity of 6His-RORß for the RORE was assessed. For this purpose, off­
rate experiments were performed and compared with those of the related RXRa-6His-RARa 
heterodimer (Fig. 2D). In these assays, vaccinia-expressed receptors were pre-incubated with 
labelled oligonucleotide probes to allow formation of protein-DNA complexes. Dissociation 
of the pre-formed protein-DNA complexes was measured as a function of time by loading ali­
quots onto a continuously running acrylamide gel at 0, 1, 4, 16 min after addition of a 500­
fold molar excess of specific cold competitor. While the RXRa-6His-RARa heterodimer 
complex bound to the RAREß2 element was not or only marginally affected by addition of an 
excess competitor (Fig. 2D, right panel and Bugge et al., 1992), 6His-RORß-DNA complexes 
formed on the POP-element dissociated rapidly after addition of competitor (Fig. 2D, left 
panel). Similar results were obtained using other ROREs (RE1, DR+8, DR+7) (data not 
shown).
Taken together, these data show that 6His-RORß can bind to elements that contain either one 
or two extended binding sites. However, 6His-RORß has a low affinity for the response ele-
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ments tested compared with the affinity of the related nuclear receptor heterodimer RXRa- 
6His-RARa for a RAREß2.
Figure 2. DNA-binding behavior of RORß. (A) Binding sites used in this study. The conserved nuclear 
receptor half site is symbolized by an arrow, the 5' extension of the half site by a box. The nucleotides within the 
extensions that are critical for RORß DNA-binding are marked with an asterisk. (B, C) EMSA analysis of 
RORß DNA-binding to distinct binding sites, which are indicated below the experiments. (C) 27 ng of the 
RORß preparation (lanes 2-6) and 0.1 and 1 |al of a RORß-specific polyclonal antibody (lanes 3, 4) or prebleed 
(lanes 5, 6) serum were used. (D) Off-rate analysis o f RORß binding to a POP element and RXRa- 
RARa binding to a RAREß2 element.
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Transcriptional activation in Neuro2A and HeLa nuclear extracts
To assess the transcriptional activity of 6His-RORß, we established an in vitro transcription 
system similar to that described for the RXRa-6His-RARa heterodimer (Chapter 4, Valcácel 
et al., 1994). The reporter construct contained a RORE in front of the TATA-box of the tk 
promoter fused to a G-less cassette of 380 nucleotides (Fig. 3A). A template with the adenovi­
rus major late TATA-box initiator fused to a G-less cassette of 320 nucleotides (TI) served as 
an internal control, monitoring the basal transcriptional activity of the extracts. Since RORß 
is expressed predominantly in neuronal tissues, nuclear extracts from the neuroblastoma cell 
line Neuro2A were used in inititial experiments as a source of basal transcription factors and 
putative cofactors. For quantitative analysis, transcription levels were measured using a 
Phosphoimager.
Figure 3. RORß is a strong transcriptional activator in Neuro2A nuclear extracts in vitro. (A) In vitro
transcription templates used in this study. RORE, RORß-specific response element. RARß2, fragment of the 
RARß2 promoter containing two DR5 elements. (B, C, D) In vitro transcription assays using Neuro2A (B, C, D) 
or HeLa (D) nuclear extracts. The vaccinia-expressed proteins used in the experiments are indicated above, the 
response elements of the in vitro transcription templates below the experiments. vwt, vaccinia wild type nuclear 
extract. (C) 0.2 |ag of vaccinia-expressed 6His-RORß and vaccinia-expressed RXRa-6His-RARa were added to 
the in vitro transcription templates when indicated.
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6His-RORß preparations boosted the level of transcription up to 30-fold from the palindromic 
POP element-containing template in a concentration-dependent manner, whereas the levels of 
transcription from the internal control were not or only marginally affected (Fig. 3B, lanes 1­
4; Fig. 3C, lanes 1,2; Fig 3D, lanes 1-4). The increase in the levels of transcription is specific 
for 6His-RORß because control extracts derived from wild-type vaccinia virus-infected cells 
did not boost the level of transcription from the specific reporters (Fig. 3B, lanes 5-7). 
Furthermore, 6His-RORß-dependent transcription was very low to undetectable when a 
reporter was used containing the TREpal element that did not support binding of RORß (Fig. 
2B right panel and Fig. 3B, lanes 8-10). Maximal transactivation by 6His-RORß was 
observed with a template containing four extended binding sites (4RE1) (Fig. 3C and data not 
shown). Taken together, the ability of 6His-RORß to bind to the ROREs correlates with its 
ability to mediate transcription through these elements.
Next, we wanted to compare the transcriptional activities of RORß and RXRa-RARa. We 
previously showed that RXRa-6His-RARa was a transcriptional activator in HeLa nuclear 
extracts when a transcription template was used that contained a fragment of the RARß2 pro­
moter with two natural DR5 elements (RAREß2) (Valcácel et al., 1994). Therefore, in vitro 
transcription reactions were performed with 6His-RORß and RXRa-6His-RARa in Neuro2A 
and HeLa nuclear extracts.
RXRa-6His-RARa strongly boosted transcription from the RARß2 promoter containing tem­
plate in the neuronal extracts (Fig. 3C, lanes 7, 8). In addition, RXRa-6His-RARa activated 
transcription very efficiently from a template containing a TREpal binding site in front of the 
minimal tk promoter, which is identical to the POP-tk reporter except for the 4 bp flanking the 
palindromic element, the so-called 5' extensions (Fig. 3C, lane 9, 10). Loading the 
heterodimer with all-trans retinoic acid did not further enhance the level of transcription 
under the conditions used in these experiments (data not shown). The experiments revealed 
that RORß and RXR-RAR are comparably efficient in transcriptional activation in Neuro2A 
nuclear extracts in vitro.
When the transcriptional activities of 6His-RORß and RXRa-6His-RARa were compared in 
HeLa nuclear extracts, only few transcripts instigated by 6His-RORß could be detected using
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templates containing the POP binding site (Fig 3D, lanes 5-8). RORß was also unable to acti­
vate transcription efficiently from templates containing two extended binding sites arranged 
as direct repeats (DR+7, DR+8) or four extended binding sits (4RE1) (data not shown). In 
contrast, RXRa-6His-RARa activated transcription very efficiently from the RARß2 (Fig. 
3D, lanes 9, 10) as well as from the TREpal template (Fig. 3D, lanes 11, 12) indicating that 
the HeLa nuclear extracts were capable of supporting activated transcription.
Taken together, RORß is in vitro a strong transcriptional activator in Neuro2A but not in 
HeLa nuclear extracts.
RORß supports formation of functional preinitiation complexes
The insufficiency of RORß to activate transcription in HeLa nuclear extracts prompted us to 
investigate whether RORß is able to support the formation of an active preinitiation complex 
(PIC) in Neuro2A and HeLa nuclear extracts.
The formation of functional PICs can be measured by single round transcription assays 
(Hahn, 1998). One commonly used method to restrict transcription to a single round in vitro is 
the addition of the anionic detergent Sarkosyl shortly after the transcription reactions have 
been started by the addition of nucleotides. Addition of a defined concentration of Sarkosyl 
prevents PIC assembly as well as formation of the first phosphodiester bonds but not 
elongation of an initiated transcript (Hawley and Roeder, 1985). To define the optimal 
conditions in our experimental setup (schematic presentation in Fig. 4A), the transcriptional 
activity of RORß was analyzed at different Sarkosyl concentrations. Addition of Sarkosyl to a 
final concentration of up to 0.025 % during PIC assembly (a) or to a final concentration of up 
to 0.05% prior to the formation of the first phosphodiester bonds (b) prevented transcription 
(Fig. 4B, lanes 1-2, 7-8, 13-14 and lanes 3-4, 9-10, 15-16), indicating that these processes 
cannot take place under these conditions. Addition of 0.05% (final concentration) Sarkosyl 30 
sec after addition of nucleotides (c), i.e. after the formation of the first phosphodiester bonds, 
resulted in a low but appreciable level of transcription, in fact consistent with only one round 
of transcription (Fig. 4B, lanes 17-18 and Fig. 4D). Addition of higher concentrations of 
Sarkosyl (0.08%) prevented transcription altogether (Fig 4 B, lanes 19-24). These results
108 Chapter 5
suggest that adding Sarkosyl to a final concentration of 0.05% immediately following the 
addition of nucleotides limits transcription to a single round (single round condition). The 
underlying assumption of this interpretation is that formation of preinitiation complexes is 
saturated after 40 min.
To test this hypothesis, in vitro transcription reactions with RORß were preincubated under 
single round conditions for different time periods. (Figure 4C). In our experimental system 
10-15 min preincubation time was necessary to detect the first RORß-dependent transcripts. 
The level of transcription did not further increase after 40 min. indicating that saturation of 
preinitiation complex formation was reached.
Figure 4. RORß can efficiently support single round transcription in vitro. (A) Scheme of the in vitro
transcription reaction. After a pre-incubation time of 40 min, the transcription reactions were started by addition 
of nucleotide triphosphates (NTPs), followed by a 60 min reaction time. Sarkosyl was added at different time 
points either before pre-incubation (a), 30 seconds before (b) or after (c) addition of nucleotides. (B) In vitro 
transcription reactions in which Sarkosyl was added according the scheme of (A) to different final 
concentrations. (C) In vitro transcription reactions under single round conditions with different preincubation 
times. (D) In vitro transcription reactions under multiple round and single round conditions. The levels of 
transcription obtained when Sarkosyl was added 30 sec after addition of nucleotides (single round conditions) 
were normalized to 1 for each RORß concentration. The quotient between the amount of transcripts o f the 
specific experiment and the amount of transcripts under single round condition (ratio (mr)/(sr)) is indicated 
below the experiments.
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To assess the ability of RORß to support single round transcription in HeLa and Neuro2A nu­
clear extracts, in vitro transcription experiments under single and multiple round conditions 
were performed with RORß and RXRa-6His-RARa. Experiments with the unrelated trans­
cription factor GAL-VP16 served as additional controls. In vitro transcription experiments 
with 6His-RORß were performed with templates containing either the 4RE1 or the POP 
binding site. 6His-RORß behaved on both templates in a similar fashion. In the experiments 
presented, templates with the 4RE1 binding site were used. The transcriptional activity of 
RXRa-6His-RARa were analyzed on templates containing a fragment of the RARß2 
promoter. In single round assays, only transcription from the specific template was examined 
to avoid competition between the templates. To ensure the reproducibility of the experiments, 
every experiment was repeated several times; the experiments presented are typical examples. 
Figure 5 demonstrates that 6His-RORß, RXRa-6His-RARa and GAL-VP16 were able to 
support low but consistent single round transcription in Neuro2A (Fig.5A) and HeLa (Fig.5B) 
nuclear extracts (lanes 4, 8, 12 respectively). Thus all three proteins, including RORß, pro­
moted preinitiation complex formation in Neuro2A and HeLa nuclear extracts.
Next, we determined the ratio of transcripts under multiple and single round conditions (indi­
cated in Fig. 4, 5 and 6 as ratio (mr)/(sr)) for 6His-RORß, RXRa-6His-RARa and GAL- 
VP16 in Neuro2A and HeLa nuclear extracts. In Neuro2A nuclear extracts, 6His-RORß, 
RXRa-6His-RARa and GAL-VP16 (Fig. 5A, lanes 1-4, 5-8 and 9-12, respectively) 
efficiently instigated transcription under multiple round conditions. In HeLa nuclear extracts 
however, efficient transactivation under multiple round conditions could be observed for 
RXRa-6His-RARa (Fig. 5B, lanes 5-8) and GAL-VP16 (Fig. 5B, lanes 9-12), but not for 
6His-RORß (Fig. 5B, lanes 1-4). The number of transcripts instigated by RORß in HeLa 
nuclear extracts under multiple to single round conditions was approximately equal.
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Figure 5. In vitro transcription reactions with RORß, RXRa-RARa and GAL-VP16 under single and multiple 
round conditions using Neuro2A (A) and HeLa (B) nuclear extracts. (C) In vitro transcription reaction in 
Neuro2A and HeLa nuclear extracts with RXRa-RARa using an artificial template with a TREpal binding site. 
0.2 |ag RORß or RXRa-RARa and 80 ng GAL-VP16, were added when noted. The levels of transcription 
obtained when Sarkosyl was added 30 sec after addition of nucleotides (single round conditions) were 
normalized to 1 for each experimental set. The quotient between the amount of transcripts of the specific 
experiment and the amount of transcripts under single round condition (ratio (mr)/(sr)) is indicated below the 
experiments.
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The observed difference in the transcriptional behavior of 6His-RORß and RXRa-6His- 
RARa may have been caused by the differential requirements of the basal promoter used in 
these experiments, i.e. the minimal tk versus RARß2 promoter. To rule this out, the 
experiments were repeated for RXRa-6His-RARa using an artificial template that contained 
a TREpal binding site in front of the minimal tk-promoter. RXRa-6His-RARa activated 
transcription efficiently from this template in Neuro2A as well as in HeLa nuclear extracts, 
indicating that the basal promoter composition of the templates did not influence the 
transcriptional behavior of the proteins (Fig. 5C). Taken together, these experiments suggest a 
different transcriptional behavior of the two nuclear receptors RORß and RXRa-RARa in 
HeLa nuclear extracts in vitro.
The observation that 6His-RORß instigated significantly more transcripts in Neuro2A as 
compared with HeLa nuclear extracts, prompted us to assess the rate at which 6His-RORß 
boosts formation of functional preinitiation complexes in Neuro2A and HeLa nuclear 
extracts. As already demonstrated in Figure 4C, the rate of PIC assembly can be measured by 
performing experiments under single round conditions at different preincubation times. In 
Neuro2A as well as HeLa nuclear extracts, transcripts were synthesized in the presence of 
RORß proportional to the time of preincubation (Fig. 6A). These experiments suggest that 
6His-RORß recruits PICs with equal efficiency in Neuro2A and in HeLa nuclear extracts. 
Thus, the low amount of transcripts instigated by RORß in HeLa nuclear extracts is not due to 
an extract-dependent insufficiency in the formation of functional PICs.
Figure 6. RORß-dependent transcription is insufficient in HeLa nuclear extracts. (A) In vitro transcription 
assays under single round conditions in Neuro2A and HeLa nuclear extracts with different preincubation times. 
(B) In vitro transcription reactions were pre-incubated for 40 min, started with nucleotides and then incubated 
under multiple round conditions for the indicated times. Transcription reaction in lanes 1, 2, 9, 10 were 
performed under single round condition with a reaction time of 60 min. (C) Same experimental setting as in (B), 
but with longer reaction times. The ratios (mr)/(sr) are plotted against the time. In all experiments 0.2 |ag RORß 
or RXRa-RARa were added when noted.
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Next,we investigated the time required by 6His-RORß, RXRa-6His-RARa and GAL-VP16 
to synthesize the equivalent of a single round of transcription to assess the rate at which tran­
scripts are synthesized in HeLa and Neuro2A nuclear extracts. In vitro transcription experi­
ments were performed under multiple round conditions and stopped at different times after 
addition of nucleotides (reaction times). RORß-induced transcripts reached the equivalent of 
a single round transcription within five minutes after the addition of nucleotides in Neuro2A 
(Fig. 6B, left panel) as well as in HeLa (Fig. 6B, right panel) nuclear extracts. This suggests 
that the rate of the synthesis of transcripts instigated by RORß does not differ significantly in 
Neuro2A and HeLa nuclear extracts. Similar results were obtained for RXRa-6His- 
RARa and GAL-VP16 (data not shown).
Similar experiments were performed with longer reaction times to assess the transcriptional 
efficiency of the proteins in the extracts. In Neuro2A nuclear extracts, 6His-RORß instigated 
transcription resulted in doubling of the amount of transcripts approximately every ten to thir­
teen minutes, whereas no further increase in the number of transcripts could be observed in 
HeLa nuclear extracts (Fig. 6C). In contrast, RXRa-6His-RARa and GAL-VP16 
continuously produced transcripts in Neuro2A as well as in HeLa nuclear extracts.
Taken together, these experiments demonstrate that 6His-RORß is equally efficient in sup­
porting single round transcription in Neuro2A and HeLa nuclear extracts. However, in vitro 
the ability of RORß to instigate transcripts is impaired in HeLa nuclear extracts.
DISCUSSION
RORß is an orphan member of the nuclear receptor superfamily that belongs to the subfamily 
1 with TR and RAR as the most prominent members (Nuclear Receptor Nomenclature 
Committee, 1999). Notwithstanding the extensive amino acid similarity between these 
receptors, our study suggests that the mechanism of transcriptional activation mediated by 
RORß may differ from those of RAR and TR. Firstly, RORß binds DNA as a monomer 
(Chapter 4; Carlberg et al., 1994; Greiner et al., 1996 and this study), whereas TR and RAR 
require heterodimerization with RXR (Bugge et al., 1992, Yu et al., 1991). In agreement with 
these results, RAR is transcriptionaly active in vivo and in vitro only as RXR-heterodimer, 
RORß instead activates transcription as a monomer (Chapter 4).
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In off-rate experiments, the heterodimer RXRa-RARa or RXRa-TRa have a high affinity for 
their cognate DNA-binding sites (Bugge et al., 1992), whereas the affinity of RORß (this 
study) and RORa (Harding et al., 1997) for a single as well as double, extended half site is 
comparatively weak. Although the artificial binding sites used in this study have been shown 
to be optimal for RORß DNA-binding in vitro and for transcriptional activation in vivo 
(Carlberg et al., 1994; Greiner et al., 1996), the existence of natural ROREs with high(er) 
affinities cannot be ruled out. Despite the different affinities for their cognate binding sites, 
RORß and RXRa-RARa are equally efficient in the recruitment of functional PICs to DNA. 
It is important to note that PIC formation is a rather slow process. Several studies have 
determined the half time of complex recruitment, (i.e. the pre-incubation time required to 
obtain 50 % of the final amount of transcripts generated under single round conditions) to be 
between 8 and 20 min (Hawley and Roeder, 1985; Wang et al., 1992; White et al., 1992). 
Saturation of PIC formation has been shown to require as in our study up to approximately 40 
min. (White et al., 1992).
Comparing the number of transcripts instigated by RORß and RXRa-RARa under single ver­
sus multiple round transcription conditions (Fig.5), we observed an insufficiency of HeLa nu­
clear extracts to support RORß-dependent in vitro transcription. Whereas in Neuro2A nuclear 
extracts, transactivation by RORß resulted in the continuous production of transcripts, in 
HeLa nuclear extracts, the accumulation of transcripts ceased after 5 minutes. In contrast, 
RXRa-RARa and the unrelated transcription factor GAL-VP16 supported transcription in 
Neuro2A and HeLa nuclear extracts beyond the initial five minutes of incubation. This 
observation shows that HeLa nuclear extracts were in principle able to support efficient 
transactivation.
There are several explanations why transcription mediated by RORß ceased after an initial 
short period of transcription in HeLa nuclear extracts. RORß, in comparison with RXRa- 
RARa and GAL-VP16, might depend more strongly on general factor(s) that are required for 
subsequent rounds of transcription and limited in HeLa nuclear extracts. Putative candidates 
could be factors required for promoter clearance such as the general transcription factor 
TFIIH (Dvir et al., 1997, Yudkovsky et al., 2000), or for elongation of subsequent 
transcription rounds such as the elongation factor SII (Szentirmay and Sawadogo, 1993). 
Another intriguing possibility is that RORß facilitates cofactor-dependent reinitiation in 
Neuro2A, but not in HeLa nuclear extracts. Several in vitro studies have shown that reinitia­
tion of transcription is fast as compared to the slow first round of transcription. In the first
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round of transcription, a preinitiation complex has to be recruited to the promoter which ap­
pears to be a very slow process in vitro. At some promoters, a committed complex consisting 
of TFIID and other factors such as TFIIA, TFIIB, TFIIH, TFIIE and Mediator, has been de­
tected after the initial polymerase escape (Roberts et al., 1995; Zawel et al., 1995; Yean and 
Gralla, 1997; Sandaltzopoulos and Becker, 1998; Yudkovsky et al., 2000). Such a committed 
complex might act as a scaffold for the rapid formation of subsequent reinitiation complexes. 
Whether the continued presence of an activator is required to stabilize such a complex is un­
clear (White et al., 1992; Sandaltzopooulos and Becker, 1998; Ho et al., 1996) and may de­
pend on the transcription factor and the template (Yudkovsky et al., 2000). Several activators, 
such as the heat shock factor or the estrogen receptor, have been shown to enhance not only 
PIC assembly but also the rate of reinitiation in cell-free systems (Kraus and Kadonaga, 1997; 
Sandaltzopoulos and Becker, 1998). RORß might instigate transcription efficiently in 
Neuro2A but not in HeLa nuclear extracts due to the presence of extract-specific factor(s) in 
Neuro2A nuclear extracts that facilitate RORß-dependent reinitiation of transcription. Such 
factors might be a cell type-specific homologue of TBP, such as TRF (Hansen et al., 1997), or 
a cell type-specific cofactor involved in reinitiation. Alternatively, the impaired ability of 
RORß to reinitiate transcription in HeLa nuclear extracts could also be caused by the 
presence of an inhibitory factor in HeLa nuclear extracts that specifically blocks RORß- 
dependent reinitiation.
The analysis of reinitiation mechanisms is difficult since it requires proof that the initiation of 
the second and later rounds derive from the promoter already used in the first round of tran­
scription i.e. it has to be excluded that the transcripts synthesized at a later stage of incubation 
originate from previously untranscribed promoters. This is of particular importance since sev­
eral studies have demonstrated that in cell-free transcription assays, only a few percent of the 
promoters are transcribed (Hahn, 1998). The experiments shown in this study do not address 
the reinitiation mechanism and further experiments are necessary to analyze if the transcripts 
produced in the first round and subsequent rounds of transcription derived from the same pro­
moters.
The presence of a cell-type specific transcription mechanism seems likely in light of other 
studies. Transient transfection studies have shown that the ligand-binding domains of 
RORa (Harding et al., 1997) and RORß (Greiner et al., 1996) display a neuronal-specific 
transcriptional activity when they are fused to a GAL4 DNA-binding domain. In addition, a 
neuronal-specific cofactor for RORß has been identified recently (Greiner et al., 2000). This
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cofactor, called NIX-1 does not activate but inhibits RORß-dependent transactivation when 
overexpressed in transient transfection assays.
In summary, we have demonstrated that the orphan nuclear receptor RORß is a comperatively 
strong transcriptional activator in vitro when considering its low affinity for the ROREs. 
RORß is equally efficient as strong DNA-binding factors such as RXRa-RARa and GAL- 
VP16 in PIC stabilization and continuous transcriptional activation in Neuro2A nuclear 
extracts. We further showed that RORß, in contrast with RXRa-RARa or GAL-VP16, cannot 
instigate continuous transcription in HeLa nuclear extracts. This observation suggests a 
different (co)factor requirement for transactivation by members of the NR1 subfamily of 
nuclear receptors. Fractionation and further characterization of the nuclear extracts needs to 
be pursued to gain insight into the mechanism of transactivation by the orphan receptor 
RORß.
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6. General Discussion
During the past decade the superfamily of ligand-dependent nuclear receptors has been 
studied extensively. Most of the receptors play a key role in hormone and vitamin signalling 
pathways. Besides ligand-dependent nuclear receptors, a growing number of nuclear receptors 
has been identified that do not seem to be activated by a ligand (for review see Enmark and 
Gustafsson, 1996). These so-called 'orphan receptors' are randomly distributed in the 
evolutionary tree and present in all metazoan organisms encoding nuclear receptors (Escriva 
et al., 1997).
A subgroup of nuclear orphan receptors, the ROR subgroup, seems to be of evolutionary old 
ancestry, since members of this subgroup have been isolated also from nematodes and 
arthropods, e.g. CHR3 from Caenorhabditis elegans (Kostrouch et al., 1995), DHR3 from 
Drosophila (Koelle et al., 1992) and MHR from Manduca sexta (Palli et al., 1992) as well as 
from vertebrates (RORa, RORß, RORy). Two members isolated from vertebrates (RORa and 
RORß) have been shown to play important roles in brain. RORa has been reported to be 
intimately involved in the pathway controlling the development of Purkinje cells in the 
cerebellum (Hamilton et al., 1996). RORß seems to be engaged in many different sensory 
input pathways and in signalling cascades controlled by the circadian clock. Because of a 
putative function in the central nervous system, the expression patterns of RORa and RORß 
have been studied extensively. Yet, hardly anything is known about the molecular mechanism 
of their regulation of transcription.
Therefore this thesis attempted to analyze several aspects of transcriptional regulation by 
orphan receptors, with special emphasis on RORß. Three main questions were addressed in 
these studies: (i) the putative role of RORß in circadian signalling pathways (ii) the 
transcriptional activation mechanism of RORß, and (iii) the potential cell-type-specific 
regulation of RORß-mediated transcription.
The results are discussed in the subsequent sections. Some evidence has been obtained 
supporting differential regulation by theses receptors at distinct steps of the transcription 
process. Yet, a number of questions remain open.
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6.1 Circadian-dependent expression of an RORß isoform
RORß has been suggested to be involved in the circadian signalling pathway because of its 
strong expression in the three principal anatomical components of the mammalian timing 
system, the suprachiasmatic nucleus, the pineal gland and the retina, (Chow et al., 1998; Park 
et al., 1997; Schaeren-Wiemers et al., 1997; Becker-André et al., 1994). This hypothesis was 
strengthened by the analyses of RORß knock-out mice which exhibit significant defects in 
their circadian behavior (André et al., 1998). Furthermore, initial studies demonstrated that 
RORß mRNA levels change as a function of time in pineal gland (Baler et al., 1996; 
Schaeren-Wiemers et al., 1997). We analyzed this behavior further and isolated a second 
isoform of RORß, RORß2, that differs from RORß1 in its expression pattern and its functional 
properties. RORß2 is predominantly expressed in retina and pineal gland and its expression 
oscillates with the circadian rhythm. RORß1 instead is strongly expressed only in areas of the 
central nervous system that are involved in the processing of sensory information and shows 
little differences in its expression during the day-night cycle. Thus, it seems likely that the 
RORß2 isoform functions in circadian signalling pathways, while RORß1 might be involved 
in cerebral processing of sensory information.
The existence of several isoforms derived from one and the same receptor gene that are the 
products of alternate splicing, promoter usage, or both, is a common feature in the nuclear 
receptor family. In the nuclear receptor subgroup 1F, RORa has been isolated in four 
isoforms (RORa1-4) (Giguère et al., 1994), RORß and RORy in two isoforms (RORß1; 2 
(Chapter 4) and RORy, RORyt (Hirose et al., 1994; He et al., 1998)), respectively. Similar to 
RORß, the distinct isoforms of the ROR subgroup show isoform-specific expression patterns 
(Sashihara et al., 1996, He et al., 1998, Medvedev et al., 1996; Hirose et al., 1994).
The function of RORß in the network of circadian signalling pathways is still unclear. It was 
proposed that RORß might be involved in regulation of melatonin synthesis (André et al., 
1998), similar to the inducible camp early repressor ICER (Foulkes et al., 1997). This 
hypothesis was based mainly on two arguments: (i) the rhythmic expression of RORß is 
restricted to the two principal melatonin-producing tissues within the central nervous system, 
the pineal gland and the photoreceptors, and parallels the circadian-dependent melatonin 
biosynthesis and (ii) the onset of rhythmic expression of RORß in retina and pineal gland 
coincides with the start of melatonin production in these tissues. However, no direct
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experiments could link RORß to the melatonin biosynthesis. Several studies connected RORß 
and melatonin at a distinct level by suggesting that the RORß and RORa transcriptional 
activity might be influenced by melatonin. The first study proposed RORß and RORa as 
nuclear receptors for melatonin (Becker-André et al., 1994). However, the direct binding of 
melatonin to these receptors could not be reproduced and the original report has now been 
retracted (Becker-André et al., 1997). As yet, no convincing data have been published 
supporting the idea that melatonin modulates RORß transcriptional activity. A recent study 
reported a decrease in RORa DNA-binding activities in human breast cancer cells treated 
with melatonin (Dai et al., 2001). Since RORa activity has been shown to be modulated by 
the Ca2+/CaM signalling pathway (Kane and Means, 2000) and melatonin has been reported 
to bind CaM and antagonize CaM-dependent enzymes, the authors propose that RORa 
activity might be regulated by melatonin via the Ca2+/CaM signalling pathway (Dai et al., 
2001). It is not yet clear whether the transcriptional activity of RORß might be regulated 
similarly. Conclusions on the biological role of RORß2 in the circadian timing system will 
have to await a more detailed analysis of the influence of signalling pathways on its 
expression and its transcriptional activity and require the identification of target genes.
6.2 Transcriptional activation mechanism of RORß
To investigate the molecular mechanisms governing transcription by the orphan receptor 
RORß, we established a cell-free transcription system with purified transcription factors and 
nuclear extracts from Neuro2A and HeLa cells.
Expression system
Most experiments were performed with histidine-tagged nuclear receptors expressed with the 
vaccinia virus expression system. This expression system has the advantage that the proteins 
are expressed in eukaryotic HeLa cells and thus all putative posttranslational modifications 
should be present. Nuclear receptors expressed in similar expression systems have been 
demonstrated to be functionally active in cell-free transcription reactions (Valcácel et al., 
1994; De Vos et al., 1994; Schmitt and Stunnenberg, 1993). On the other hand, the vaccinia 
virus expression system has the disadvantage that several proteins copurify with the protein of 
interest (Valcarcel et al., 1994; Chapter 4, Figure 1; Chapter 5, Figure 1).
They bind to the column material most probably due to internal histidine-rich sequences. 
Several controls were performed to rule out that these proteins influenced our transcription
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experiments. Since it was known from previous experiments that the RXR-RAR preparation 
contained general transcription factors (GTFs), all protein preparations were checked for the 
presence of copurified general transcription factors. The concentrations of general 
transcription factors were low and comparable in all protein preparation (data not shown). 
Since the HeLa and Neuro2A nuclear extracts contained GTFs in high concentration, it is 
unlikely that the copurified GTFs in the protein preparations influenced the in-vitro 
transcription reactions. Furthermore, nuclear extracts derived from vaccinia wild type infected 
cells which showed in an SDS gel a similar pattern of copurified proteins compared with the 
RORß, RORa and RXR-RAR preparation, did not affect transcriptional activation in our 
system.
In addition to proteins which were non-specifically purified, some proteins of HeLa nuclear 
extracts might be copurified by direct interaction with RORß. The interaction between nuclear 
receptors and cofactors can survive the experimental conditions during a biochemical 
purification procedure. This has been demonstrated for instance by Roeder’s group which 
isolated the eukaryotic Mediator complexes from HeLa protein extracts by their direct 
interaction with flag-tagged nuclear receptors in a Ni2+ column system. (Fondell et al., 1996, 
Gu et al. , 1999).
DNA-binding and dimerization o f RORß
To analyze the DNA-binding behavior of RORß, we compared the DNA-binding properties 
of (i) the isoforms RORß1 and RORß2 (Chapter 3), and of (ii) the subtypes RORa and RORß 
which are both known to bind DNA as monomers (Chapter 4). (iii) In addition we compared 
the DNA-binding behavior of RORß with the related nuclear receptors RAR, which binds to 
DNA as RXR heterodimer (Chapter 5).
RORa and RORß have been reported to bind to a DNA-response element (RORE) that is 
characterized by thymines and adenines, in particular a thymine at position -1 (Carlberg et al., 
1994; Giguère et al., 1994; Giguère et al., 1995b). In Chapter 3, it is reported that the different 
isoforms of RORß have preferences for slightly different ROREs. Different DNA-binding 
specificities were also detected for the four RORa isoforms (Vu-Dac et al., 1997; Giguère et 
al., 1994). Since the isoforms of RORß or RORa, respectively, differ only in their N-terminal 
domain (Chapter 3, Figure 2; Giguère et al., 1994), this finding demonstrates that the N- 
terminus of RORa and RORß influences the recognition of the specific DNA-response 
element.
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Comparison of the DNA-binding behavior of RORa4 and RORß1 (Chapter 4) revealed that 
although the two orphan receptors bound to a monomeric response element in a similar 
fashion, RORa4, in contrast with RORßl5 appears to be able to form homodimers on a dimeric 
palindromically arranged response element. The fact that nuclear receptors that can bind to 
DNA as monomers are also highly functional as dimers has also been shown for other 
receptors. Members of the NGFI-B subgroup for instance bind DNA very efficiently as 
monomers, homodimers (Philips et al., 1997) and heterodimers (Perlmann and Jansson, 1995; 
Maira et al., 1999). Members of the monomeric binding RevErb subgroup actively repress 
transcription only on dimeric response elements (Harding and Lazar, 1995). In fact, it is still 
questionable whether nuclear receptors exist that bind to DNA exclusively as monomers. 
RORß appears to be a good candidate for a ‘true’ monomeric DNA-binder. Modeling of an 
RORß homodimer on the basis of the recent published X-ray study of the RORß ligand 
binding domain (Stehlin et al., 2001) revealed two important clashes which should be 
sufficient to destabilize a putative homodimer. A homology model of RORa demonstrated 
that the ligand binding domain of RORa differs from the one of RORß resulting in a smaller 
ligand binding pocket as compared with RORß (Stehlin et al., 2001). In addition, the amino 
acids generating one of the clashes detected for the putative RORß homodimer are not 
conserved in the RORa ligand binding domain. The structure and in turn the function of 
RORa appear therefore to vary from the one of RORß.
The high amino acid similarity within the functional domains of RORa and RORß does not 
imply that both proteins are folded the same way and expose the same functional domains to 
other proteins such as dimerization partners and cofactors. Subtle changes in the amino acid 
sequence can influence the structural and, in turn, the functional properties of nuclear 
receptors. This is illustrated by the finding that the ligand-regulated nuclear receptor RXR can 
be switched into a constitutive activator by a single amino acid change (Vivat et al., 1997). 
Furthermore, a study that compared the DNA-binding of RORa and RevErb on a DR2 
element revealed that mutating four amino-acids was sufficient for transferring the DNA- 
binding properties of one protein to the other (Moraitis and Giguère, 1999). Moreover, the 
structures of nuclear receptors are influenced significantly by events such as phosphorylation, 
ligand binding, DNA-binding element (Ribeiro et al., 2001; Shen and Subauste, 2000) and 
dimerization. A prediction of the protein structure of RORa is therefore not possible and 
requires NMR or crystal structural analysis.
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A difference in the dimerization behavior of closely related orphan receptors has been 
reported also for the NGFI-B subgroup: NGFI-B and NURR1, but not NOR1, can 
heterodimerize with RXR (Zetterstrom et al., 1996).
Comparison of the DNA-binding behavior of RORß1 with the one of the RXR-RAR 
heterodimer showed that in off-rate experiments the DNA affinity of the monomeric DNA- 
binding receptor RORß1 is weak compared with the nuclear receptor heterodimer RXRa- 
RARa (Chapter 5). Nevertheless, RORß is as efficient as RXRa-RARa in inducing one 
round of transcription in cell-free transcription systems (Chapter 5). The transcription level of 
the first round of transcription is indicative of the ability of a transcription factor to recruit a 
preinitiation complex to the promoter. Thus, the low DNA affinity of the monomeric DNA­
binder RORß might be compensated for by other events, for instance by cooperative binding 
with factors of the preinitiation complex.
Transcriptional activation mechanism o f RORß
Whether RORß activates transcription as a monomer has been disputed. Transient 
transfection studies revealed the ability (Carlberg et al., 1994) as well as the inability (Greiner 
et al., 1996) of RORß to activate transcription as a monomer. The in-vitro study presented in 
Chapter 4 clearly demonstrated the ability of RORß to activate transcription from monomeric 
DNA-binding sites. Furthermore, we were unable to detect synergistic transcriptional activity 
on dimeric DNA-binding elements. These experiments support the hypothesis that 
RORß might activate transcription exclusively as a monomer.
As modifying a constitutive activity appears to be a common feature in the regulation of 
orphan nuclear receptors (Hammer et al., 1999; Pekarsky et al., 2001; Jacob et al., 2001), it is 
possible that the intrinsic constitutive activity of RORa or RORß might be up- or down- 
regulated by an as yet unknown ligand or by a modification. Several observations argue for 
the existence of a ligand for RORa or RORß. The crystallization study of the RORß LBD 
identified a pseudo-ligand coming from the expression host (Stehlin et al., 2001). In this study 
they also investigated how amino acid mutations within the ligand binding pocket influence 
the protein structure. According to these studies RORß proteins, containing amino acid 
mutations which should not influence the structure but should hinder the binding of a ligand, 
were inactive in transient transfection studies. Because of this observation the authors suggest
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the existence of a ligand for RORß. However, up to now no natural ligand for RORß has been 
identified. Thus, RORß is still regarded as a orphan receptor. It is also yet unclear whether 
RORa or RORß are regulated by posttranslational modifications. In Chapter 4, it is reported 
that bacterially-expressed RORß^ a protein which has no posttranslational modification, can 
activate transcription equally strong as the vaccinia-expressed protein. This finding suggests 
that for RORß1 posttranslational modification is not required for its constitutive 
transcriptional activity. However, we cannot exclude the possibility that RORß1 is modified 
during the in-vitro transcription reaction. In addition, bacterially-expressed RORß might be in 
an active conformation because it binds a pseudo-ligand from the E.coli expression host. Also 
for RORa, no requirement for phosphorylation has yet been detected. The transcriptional 
activity of RORa has been shown to be augmented by a Ca2+-independent Calmodulin kinase 
(Kane and Means, 2000). The molecular basis of this observation has not been understood. 
Clearly, however, no phosphorylation of RORa is involved.
6.3 Neuronal-specific transcription regulation by the orphan receptor RORß
While analyzing the transcriptional mechanism of RORß1; we found that RORß1, in contrast 
with RXR-RAR and GAL-VP16, appears to activate transcription efficiently in nuclear 
extracts derived from the neuronal cell line Neuro2A, but not from non-neuronal HeLa cells, 
suggestive of a neuronal-specific transcriptional activity for RORß.
A neuronal-specific transcriptional activity of the RORß ligand-binding domain was first 
observed in transient transfection assays. In these assays, a fusion protein consisting of the 
DNA-binding domain of GAL4 and the ligand-binding domain of RORß was shown to be 
transcriptionally active in neuronal cells and inactive in non-neuronal cells (Greiner et al., 
1996). This neuronal-specific behavior of the ligand binding domain of ROR is less evident 
for the full length RORß protein and seems to depend on the N-terminus of the 
isoforms. While in transient transfections RORß1 and RORß2 activated transcription equally 
efficiently in neuronal Neuro2A cells, RORß1 displayed a strongly decreased and RORß2 a 
strongly increased activity in the non-neuronal HeLa cells (Chapter 3, Figure 4,5).
A further argument in favor of the hypothesis that RORß dependent transcription is 
differentially regulated in neuronal and non-neuronal cells came from a study that described 
the isolation of a neuronal-specific cofactor, NIX-1, that interacted with several nuclear 
receptors including RORß1 (Greiner et al., 2000). NIX-1 does not increase, but decreases
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RORß1-dependent transcription in transient transfection assays (Greiner et al., 2000). In 
addition, NIX-1 interacts also with the RXR-RAR heterodimer, which does not activate 
transcription in a cell-type-specific manner in our in-vitro system (Greiner et al., 2000). 
Therefore, the cofactor NIX-1 seems not to be involved in the mechanism underlying the 
effect observed in our in vitro system.
Cell-type- and receptor-specific transcription mechanisms are rather unusual. Only few cell- 
type-specific cofactors of nuclear receptors have been described: for instance, the tissue- 
specific cofactor of the peroxisome proliferator-activated receptor PGC1, which regulates the 
activity of several nuclear receptors and other transcription factors (Puigserver et al., 1998; 
Zanaria et al., 1994, Knutti and Kralli, 2001) or the androgen-receptor-specific coactivator 
ARA70 (Yeh and Chang, 1996).
RORß regulation o f transcription may involve a transcription factor- and cell-specific 
reinitiation mechanism
Further analysis of the putative cell-specific transcriptional behavior led us to the finding that 
although RORß supported single round transcription in vitro with the same kinetics in HeLa 
and in Neuro2A nuclear extracts, it activated transcription efficiently under multiple round 
conditions only in Neuro2A, but not in HeLa nuclear extracts (Chapter 5). The nuclear 
receptor heterodimer RXR-RAR and the transcription factor GAL-VP16 activated 
transcription strongly in HeLa nuclear extracts. These results demonstrate a clear difference in 
the transcriptional activity of RORß in nuclear extracts derived from Neuro2A and HeLa cells 
and suggest a different pathway for the first and subsequent rounds of transcription for RORß. 
A different pathway for the first and subsequent rounds of transcription had been proposed in 
previous studies based on two observations: Promoters used in the first cycle of transcription 
are preferentially transcribed in subsequent rounds (Hawley and Roeder, 1987; Hahn, 1997). 
Secondly, multiple cycles of initiation occur much more rapidly than formation of the first 
preinitiation complex (Hawley and Roeder 1987; White et al., 1992; Yean and Gralla, 1997). 
Several models have been discussed to explain the facilitated reinitiation of subsequent 
transcription rounds: Several studies demonstrated that transcription factors, or TFIID and 
other factors including TFIIA, TFIIB, TFIIH, TFIIE and Mediator remain bound to DNA after 
the promoter has been cleared, yielding a committed complex (Hahn, 1998; Yudkovsky et al., 
2000). Consequently, the slow step of DNA-binding of the transcription factor and TFIID 
may be bypassed. Secondly, subsequent rounds might also be increased by facilitated 
elongation of transcription. It has been shown that the elongation factor SII (also known as
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RTF) is required for the elongation of the second and subsequent rounds but not for the first 
round of transcription (Szentirmay and Sawadogo, 1991; Szentirmay and Sawadogo, 1993). 
Moreover, a factor has been identified that increases the rate of reinitiation in cell-free 
transcription assays most probably by increasing the number of transcription complexes 
associated with the template at all times after the addition of NTPs (Woodard et al., 2001).
A chromatin environment seems to increase the reinitiation rate in vitro, as demonstrated for 
the estrogen receptor (Kraus and Kadonaga, 1998) and the heat shock factor (Sandaltzopulos 
and Becker, 1998). The mechanism of this observation is not yet understood.
As discussed in Chapter 5, there may be several explanations for the inability of RORß to 
instigate transcripts in HeLa nuclear extracts after the first round of transcription. It may be 
possible that the HeLa nuclear extract is limited in a factor required for promoter clearance or 
elongation of the second round of transcription. Alternatively the Neuro2A nuclear extracts 
may contain a cell-specific ligand or cofactors required for RORß-dependent reinitiation. 
Although our system is not suitable for investigating reinitiation mechanisms (Discussion, 
Chapter 5), it is tempting to speculate about a RORß-specific cofactor involved in reinitiation 
mainly for two reasons. The process of transcriptional reinitiation is most probably 
responsible for high expression of genes since it is often much faster than the first round of 
transcription (for review see Hahn, 1998). Secondly, none of the reinitiation studies so far 
have revealed a mechanism that is specific for the transcription factor and the cell type.
6.4 Perspectives
This thesis covers aspects of transcription regulation by the orphan nuclear receptors sub­
group 1F that appear to regulate transcription in an isoform- (Chapter 3), a subform- (Chapter 
4), and cell-type-specific manner (Chapter 5).
Although we could answer several questions about the role of RORß in the circadian timing 
system and the DNA- and transcriptional regulation mechanism of RORß, many remain open. 
An important point will be to analyze further the potential cell-type-specific transcriptional 
phenomenon described in Chapter 5. For this purpose, the Neuro2A and HeLa nuclear 
extracts need to be fractionated and analyzed in cell-free transcription systems in order to 
isolate a responsible activity. Considering the finding that nuclear-receptor-dependent 
reinitiation of transcription is increased on chromatinized templates (Kraus and Kadonaga,
1998), it will be required to study the influence of chromatinized templates on the putative
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cell-type-specific transcriptional effect in vitro. Moreover, it will be interesting to study the 
difference in DNA-binding and transcriptional behavior of the RORa and RORß isoforms, in 
particular with respect to cell-type-specific transcription. All our studies have been carried out 
in artificial in vitro systems. To understand the role of the isotypes of RORa and RORß in 
brain, it will be necessary to find and study target genes.
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Summary
Nuclear receptors are ligand-regulated transcription factors that have been used for years to 
study transcription regulation. For a subpopulation of nuclear receptors no ligand has been 
identified yet. These receptors are therefore called ‘orphan’ nuclear receptors. In general, 
orphan nuclear receptors use similar transcriptional mechanisms as ‘conventional’ nuclear 
receptors. However, a subgroup of orphan receptors differs from ‘conventional’ nuclear 
receptors in its DNA-binding behavior: DNA-binding of ‘conventional’ nuclear receptors 
requires in general homo or heterodimerisation, whereas some of the orphan receptors are 
able to bind as monomers. The objective of this thesis was to investigate the transcriptional 
activation mechanism of orphan receptors that bind to DNA as monomers. To study this 
question, we chose the orphan nuclear receptor RORß[NR1F2] as a model system.
RORß [NR1F2] forms together with RORa [NR1F1], RORy [NR1F3], dDHR3 [NR1F4], 
CHR3 [NR1F4] a subfamily of nuclear receptors. They are related in their amino acid 
sequence and bind to DNA as monomers. The receptors RORß and RORa are highly related 
to each other. While RORa is ubiquitously expressed, expression of RORß is defined to the 
central nervous system, in particular to areas that are involved in the circadian timing system 
or in processing of sensory information. Furthermore, the mRNA and protein levels of RORß 
oscillate in retina and pineal gland with a 24 hour rhythm and reach peak levels during the 
night.
When we set out to analyze the oscillating expression of RORß mRNA further, we isolated a 
second isoform RORß2 (Chapter 3), that differs from RORß1 in its N-terminal domain. 
RORß2 mRNA is expressed in pineal gland and retina and oscillates with a ‘truly’ circadian 
nature. In fact, the increase of RORß mRNA during the night is almost entirely due to the 
expression of the second isoform RORß2. RORß1 in contrast is strongly expressed in cerebral 
cortex, thalamus and hypothalamus while little was found in retina and pineal gland. 
Furthermore, RORß1 and RORß2 differed in their DNA-binding and transcriptional behavior, 
suggesting that the N-terminal domains of these orphan receptors are involved in DNA- 
binding and transcriptional activation. Our results suggest that the two isoforms of RORß 
regulate different sets of genes in different physiological contexts.
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In order to investigate the molecular transcriptional mechanism of the orphan nuclear receptor 
RORß we established an in vitro transcription system using recombinant transcription factors 
expressed in a vaccinia-virus system and nuclear extracts from Neuro2A and HeLa cells. We 
compared the DNA-binding and transcriptional activation properties of RORß1 with the ones 
of the closely related monomeric DNA-binder RORa4 (Chapter 4) and in addition with the 
ones of RARa [NR1B1] (Chapter 5). We chose RARa, since it belongs to the same subfamily 
of nuclear receptors as RORß (viz NR1) but binds to DNA as RXR-heterodimer.
Interestingly, we detected that vaccinia-expressed RORa4 in contrast to RORß1 bound 
cooperatively to a DNA-element with two palindromically arranged binding sites (Chapter 4). 
This finding was surprising mainly for two reasons: Given that the amino acid sequence of 
RORa and RORß is highly conserved one would not expect a difference in the DNA-binding 
and dimerization behavior. Secondly, members of the ROR subfamily are regarded as typical 
examples for nuclear receptors that bind to DNA as monomers. Our results suggest that at 
least RORa can act under certain conditions as dimer. RORß in contrast displays no 
cooperativity in DNA-binding or transcriptional activation. Furthermore RORß activates 
transcription strongly through a single DNA-binding site in vitro (Chapter 4). Thus, RORß1 in 
contrast to RORa4 is a good example for a nuclear receptor that binds and activates as 
monomer.
When we compared the functional properties of RORß with those of the nuclear receptors 
heterodimer RARa-RXRa (Chapter 5) we found that RORß binds to DNA with a relatively 
low affinity. Nevertheless, RORß turned out to be equally efficient as RARa-RXRa in 
supporting single round transcription in vitro, suggesting that the low DNA-binding affinity 
might be compensated in the transcriptional mechanism.
In addition, we found that RORß activated transcription efficiently in Neuro2A but not in 
HeLa nuclear extracts. In contrast, RARa-RXRa and the artificial acidic transcriptional 
activator GAL-VP16 activated transcription efficiently in nuclear extracts from both cell 
lines. We analyzed this apparent cell-type specific transcription phenomenon further and 
uncoverred that RORß supported single round transcription in vitro with the same kinetics in 
HeLa and in Neuro2A nuclear extracts. However, under multiple round conditions, only 
Neuro2A nuclear extracts supported efficient RORß-dependent transcription, while 
transcription ceased in HeLa nuclear extracts after the first transcription round was completed.
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These observations demonstrate that the mechanism of transcriptional activation of RORß 
differs in Neuro2A and HeLa nuclear extracts and suggest a different (co)factor requirement 
for efficient transactivation by members of the NR1 subfamily of nuclear receptors.
Taken together, we have demonstrated that RORß regulates transcription in an isoform, a 
subform and cell-type-specific manner. Further analysis, in particular the search for target 
genes will be required to understand the biological significance of the differences in the 
transcriptional regulation mechanisms.
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Nucleaire receptoren zijn transcriptiefactoren die worden gereguleerd door ligand. Deze 
factoren worden al jaren gebruikt worden om transcripti onele regulatie te bestuderen. Voor 
een subpopulatie van nucleaire receptoren is nog geen ligand geïdentificeerd. Deze receptoren 
worden daarom ‘orphan’ nucleaire receptoren genoemd. In het algemeen gebruiken deze 
orphan receptoren soortgelijke transcriptionele mechanismen als ‘conventionele’ nucleaire 
receptoren. Een subgroep van orphan receptoren verschilt van conventionele nucleaire 
receptoren in zijn DNA bindingsgedrag: DNA binding door conventionele nucleaire 
receptoren gebeurt in het algemeen door homo- of heterodimerisatie, terwijl sommige orphan 
receptoren als monomeer kunnen binden. Het doel van dit proefschrift was om de 
transcriptionele activatie mechanismen van orphan receptoren die DNA als monomeer binden 
te onderzoeken. Om deze vraag te bestuderen kozen we de orphan nucleaire receptor RORß 
[NR1F2] als een model systeem.
RORß [NR1F2] vormt samen met RORa [NR1F1], RORy [NR1F3], dDHR3 [NR1F4], 
CHR3 [NR1F4] een subfamilie van nucleaire receptoren. Ze zijn gerelateerd in hun 
aminozuursequentie en binden DNA als monomeer. De receptoren RORß en RORa zijn sterk 
gerelateerd aan elkaar. Terwijl RORa overal tot expressie komt is expressie van 
RORß beperkt tot het centraal zenuwstelsel, met name in gebieden die betrokken zijn bij het 
‘’circadian timing system’’ of in het processen van zintuig informatie. Daarnaast oscilleren 
mRNA en eiwit niveaus van RORß in de retina en pijnappelklier met een 24-uurs ritme en ze 
bereiken hun piekniveaus ‘s nachts.
Toen we begonnen met de analyse van de oscillerende expressie van RORß mRNA, 
isoleerden we een tweede isovorm RORß2 (Hoofdstuk 3), die verschilt van RORß1 in zijn N- 
terminale domein. RORß2 mRNA komt tot expressie in de pijnappelklier en retina en 
oscilleert met een echt ‘’circadian’’ ritme. De toename in RORß mRNA gedurende de nacht 
is zelfs bijna geheel toe te schrijven aan de expressie van de tweede isovorm RORß2. RORß1 
daarentegen, komt hoog tot expressie in de cerebrale cortex, thalamus and hypothalamus 
terwijl weinig gevonden wordt in de retina en pijnappelklier. Verder verschillen RORß1 en 
RORß2 in hun DNA bindings- en transcriptionele gedrag, wat suggereert dat de N-terminale 
domeinen van deze orphan receptoren betrokken zijn bij DNA binding en transcriptionele
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activatie. Onze resultaten suggereren dat de twee isovormen van RORß verschillende sets van 
genen in een verschillende fysiologische achtergrond reguleren.
Om de moleculaire transcriptionele mechanismen van de orphan nucleaire receptor RORß te 
bestuderen optimaliseerden we een in vitro transcriptie systeem met recombinante 
transcriptiefactoren die we in een vaccinia-virus systeem tot expressie brachten en nucleaire 
extracten van Neuro2A en HeLa cellen. We vergeleken de DNA bindings- en transcriptionele 
activatie eigenschappen van RORß1 met die van de sterk gerelateerde monomere DNA binder 
RORa4 (Hoofdstuk 4) en ook met degene van RARa [NR1B1] (Hoofdstuk 5). Wij kozen 
RARa, omdat deze behoort tot dezelfde subfamilie van nukleaire receptoren zoals RORß 
(NR1) maar DNA bindt als RXR-heterodimeer.
We detecteerden dat vaccinia-geëxpresseerd RORa4 in tegenstelling tot RORß1 coöperatief 
bindt aan een DNA element met twee bindingsplaatsen die als palindroom gearrangeerd zijn 
(Hoofdstuk 4). Deze bevinding verbaasde ons met name om twee redenen: vanwege het feit 
dat de aminozuurvolgordes van RORa en RORß hoog geconserveerd zijn zou men geen 
verschil in DNA bindings- en dimerisatie gedrag verwachten. Ten tweede, leden van de ROR 
subfamilie worden gezien als typische voorbeelden van nucleaire receptoren die binden aan 
DNA als monomeer. Onze resultaten suggereren dat RORa ten minste onder bepaalde 
condities als dimeer kan binden. RORß daarentegen vertoont geen coöperativiteit in DNA 
binding of transcriptionele activatie. Verder activeert RORß transcriptie sterk door een enkele 
DNA bindingsplaats in vitro (Hoofdstuk 4). Dus is RORß1 in tegenstelling tot RORa4 een 
goed voorbeeld van een nucleaire receptor die bindt en activeert als monomeer.
Toen we de functionele eigenschappen van RORß vergeleken met die van de nucleaire 
receptor heterodimeer RARa-RXRa (Hoofdstuk 5) vonden we dat RORß DNA bindt met een 
relatief lage affiniteit. Niettegenstaande dit feit bleek RORß even efficiënt als RARa-RXRa 
in het stimuleren van ‘’single round’’ transcriptie in vitro, wat suggereert dat de lage DNA 
bindingsaffiniteit gecompenseerd wordt door het transcriptie mechanisme.
Daarnaast vonden we dat RORß transcriptie efficiënt stimuleert in Neuro2A maar niet in 
HeLa nucleaire extracten. Daarentegen activeerden RARa-RXRa en de artificiële zure 
activator GalVP16 de transcriptie efficiënt in nucleaire extracten van beide cellijnen. We 
analyseerden dit celtype specifieke transcriptie fenomeen verder en ontdekten dat RORß 
‘’single round’’ transcriptie in vitro stimuleert met dezelfde kinetiek in HeLa als in Neuro2A
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nucleaire extracten. Hoewel, gedurende ‘’multiple round’’ condities, stimuleerde alleen 
Neuro2A nucleaire extracten efficiënt RORß-afhankelijke transcriptie, terwijl transcriptie 
stopte in HeLa nucleaire extracten nadat de eerste transcriptieronde beëindigd was. Deze 
observaties demonstreren dat het mechanisme van transcriptionele activatie van RORß 
verschilt in Neuro2A and HeLa nucleaire extracten en suggereren een verschil in (co)factor 
gebruik voor efficiënte transactivatie door leden van de NR1 subfamilie van nucleaire 
receptoren.
Alles tezamen hebben we aangetoond dat RORß transcriptie reguleert in een isovorm-, een 
subvorm- en celtypespecifieke manier. Verdere analyse, met name het zoeken naar target 
genen, zal nodig zijn om de biologische significantie van de verschillen in het transcriptionele 
regulatie mechanismen te verklaren.
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Zusammenfassung
Kernrezeptoren sind seit Jahren ein beliebtes Modellsystem, mit dessen Hilfe Mechanismen 
der Transkription untersucht werden. Klassische Kernrezeptoren sind Transkriptionsfaktoren, 
die durch einen Liganden, wie zum Beispiel Vitamine oder Hormone, reguliert werden. Es 
gibt einige Proteine, die zwar die Proteinstruktur von klassischen Rezeptoren aufweisen, für 
die aber noch kein Ligand gefunden werden konnte. Diese Rezeptoren werden deshalb 
,Orphan’-(Waisen)-Rezeptoren genannt. Normalerweise benutzen ,Orphan’-Rezeptoren 
ähnliche Transkriptionsmechanismen wie ,konventionelle’ Kernrezeptoren; aber einige der 
, Orphan’-Rezeptoren unterscheiden sich von ,konventionellen’ Rezeptoren in ihrem DNA­
Bindungsverhalten: Damit ,konventionelle’ Rezeptoren DNA binden können, müssen diese 
normalerweise Homo- oder Heterodimere bilden, einige der , Orphan’-Rezeptoren hingegen 
sind auch als Monomere in der Lage, DNA zu binden. Ziel dieser Arbeit war es, den 
Transkriptionsmechanismus von solchen ,Orphan’-Rezeptoren zu untersuchen. Als 
Modellsystem wurde der ,Orphan’-Rezeptor RORß [NR1F2] gewählt.
RORß [NR1F2] bildet zusammen mit RORa [NR1F1], RORy [NR1F3], dDHR3 [NR1F4] 
und CHR3 [NR1F4] eine Untergruppe der Kernrezeptoren. Alle diese Proteine bestehen aus 
einer ähnlichen Aminosäuresequenz und binden DNA als Monomere. Die Rezeptoren RORß 
und RORa sind nahe verwandt. Während RORa in allen Geweben hergestellt wird, kommt 
RORß nur im Zentralnervensystems vor, vor allem in Zellen, die sensorische Informationen 
verarbeiten bzw. den Tag/Nacht-Rhythmus (circadian rhythm) bestimmen. Außerdem 
oszillieren mRNA und Proteinlevels in der Netzhaut (Retina) und der Zirbeldrüse (pineal 
gland) mit einem 24-Stunden-Rhythmus, der in der Nacht seinen Höhepunkt erreicht.
Bei einer genaueren Untersuchung der oszillierenden Herstellung von RORß mRNA fanden 
wir eine zweite Isoform von RORß, RORß2 (Kapitel 3), die sich von RORß1 in ihrem 
N-terminalen Ende unterscheidet. RORß2 mRNA wird in der Zirbeldrüse und der Netzhaut in 
Abhängigkeit vom Tagesrhythmus hergestellt. Der Zuwachs der RORß mRNA während der 
Nacht kann fast vollständig auf die Herstellung dieser zweiten Isoform RORß2 zurückgeführt 
werden. RORß1 hingegen wird vor allem in der Großhirnrinde (cerebral cortex), dem 
Thalamus und dem Hypothalamus hergestellt. Nur wenig RORß1 mRNA kann in der 
Netzhaut und der Zirbeldrüse nachgewiesen werden. RORß1 und RORß2 unterscheiden sich
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außerdem in ihrem DNA-Bindungs- und transkriptionellem Verhalten. Der N-Terminus dieser 
, Orphan’-Rezeptoren scheint also das DNA-Bindungsverhalten und das 
Transkriptionsverhalten zu beeinflussen. Unsere Ergebnisse deuten darauf hin, dass die 
Isoformen von RORß verschiedene Sets von Genen in unterschiedlichen physiologischen 
Zusammenhängen regulieren.
Um den molekularen Transkriptionsmechanismus des ,Orphan’-Rezeptors RORß zu 
untersuchen, etablierten wir ein /n-vitro-Transkriptionssystem mit rekombinanten 
Transkriptionsfaktoren, die mit einem Vaccinia-Virus- Sy stem hergestellt wurden, und 
Kernextrakten von Neuro2A- und HeLa-Zellen. Wir verglichen die DNA-Bindungs- und 
Transkriptionseigenschaften von RORß1 mit denen des eng verwandten Rezeptors RORa4 
(Kapitel 4), einem Rezeptor der ebenfalls als Monomer DNA bindet, und mit denen des 
Kernrezeptors RARa [NR1B1] (Kapitel 5). Wir wählten RARa, da dieser Kernrezeptor der 
gleichen Unterfamilie angehört wie RORß (NR1), aber als RXR-Heterodimer an DNA bindet.
Interessanterweise bindet RORa4 im Gegensatz zu RORß1 kooperativ an ein DNA-Element, 
das aus zwei palindromisch angeordneten Bindungsstellen bestand (Kapitel 4). Diese 
Beobachtung war aus zwei Gründen überraschend: Auf Grund der hohen Ähnlichkeit der 
Aminosäuresequenzen von RORa und RORß würde man keinen Unterschied in dem DNA- 
Bindungs- und Dimerisierungsverhalten erwarten. Außerdem werden Mitglieder der ROR- 
Untergruppe seit Jahren als ein Modellsystem für monomerisch bindende Kernrezeptoren 
betrachtet. Unsere Ergebnisse legen nahe, dass zumindest RORa unter bestimmten 
Umständen auch als Dimer binden kann. RORß hingegen zeigt keine Kooperativität in seinem 
DNA-Bindungs- oder auch seinem Transkriptionsverhalten. Außerdem aktiviert RORß sehr 
effektiv Transkription durch eine einzelne DNA-Bindungsstelle in vitro (Kapitel 4). Demnach 
ist RORß1 im Gegensatz zu RORa4 ein gutes Beispiel für einen Kernrezeptor, dessen 
funktionelle Einheit das monomere Molekül ist, und zwar sowohl bezüglich seines DNA- 
Bindungsverhaltens als auch seines Transkriptionsverhaltens.
Bei dem Vergleich der funktionellen Eigenschaften von RORß mit denen des Kernrezeptor­
Heterodimers RARa-RXRa (Kapitel 5) stellten wir fest, dass RORß mit relativ geringerer 
Affinität an DNA bindet. Nichtsdestotrotz initiiert RORß eine Transkriptionsrunde in vitro
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genauso effizient wie RARa-RXRa. Diese Beobachtung legt nahe, dass die geringe DNA- 
Affinität während des Transkriptionsmechanismus kompensiert wird.
Wir konnten des weiteren feststellen, dass RORß Transkription effizient nur in Neuro2A-, 
aber nicht in HeLa-Zellen aktiviert. RARa-RXRa und der künstliche saure 
Transkriptionsfaktor GAL-VP16 aktivierten Transkription effizient in Proteinextrakten von 
beiden Zelllinien. Wir untersuchten dieses Zelltyp-spezifische Verhalten weiter und 
entdeckten, dass RORß in vitro eine Transkriptionsrunde mit der gleichen Kinetik in 
Neuro2A- und HeLa-Kernextrakten unterstützt. Hingegen unter Bedingungen, die mehrere 
Runden zulassen, fand eine effiziente Aktivierung der Transkription durch RORß nur in 
Neuro2A-Kernextrakten statt. In HeLa-Kernextrakten konnten nach der ersten Runde kein 
Zuwachs der Transkription festgestellt werden. Diese Beobachtungen zeigen, dass der 
Aktivierungsmechanismus von RORß sich in Neuro2A- und HeLa-Zellen unterscheidet, und 
weist darauf hin, dass Kernrezeptoren der NR1-Unterfamilie unterschiedliche Kofaktoren 
verwenden.
Unsere Ergebnisse zeigen demnach, dass RORß Transkription in einer Isoform-, einer 
Subform- und Zelltyp-spezifischen Weise reguliert. Weitere Untersuchungen, insbesondere 
die Suche nach Zielgenen, sind notwendig, um die biologische Bedeutung dieser 
Beobachtungen zu verstehen.
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Abbreviations:
AcF activating cofactor
ACF ATP-utilizing chromatin assembly 
and remodeling factor
ACTR activator of the thyroid and retinoic 
acid receptor
AD activation domain
Ada alteration/deficiency in activation 
(proteins/complex)
AF-1 or -2 activation function -1 or -2
AIB1 amplifies in breast cancer (protein)
AP1 activator protein-1
AR androgen receptor
ARA70 androgen receptor associated 
protein 70
ARC activator-recruited cofactor
ASC-1 or -2 activating signal cointegrator-1or -2
ATP adenosine triphosphate
BOB1 B cell Oct-binding protein 1
BRM Brahma (chromatin remodeling 
complex)
BSA bovine serum albumine
BXR benzoate X receptor
b-zip basic region leucine zipper
C/EBPa CCAAT/Enhancer Binding Protein
CAF-1 chromatin assembly factor-1
CaM Ca2+/calmodulin
CaMKs Calmodulin-dependent protein 
kinases
CARM1 coactivator-associated arginine 
methyltransferase 1
CAR-ß constitutive active receptor-ß
CBP CREB-binding protein
CDK cyclin-dependent protein kinase
CHD chromodomain-helicase-DNA- 
binding domain
ChIp Chromatin immunoprecipitation
CHR3 Caenorhabditis elegans orphan 
nuclear hormone receptor
CHRAC chromatin-accessibility complex 
Chx10 C. elegans ceh-10 homeo domain- 
containing homolog 
CofA cofactor A
COUP-TFII chicken ovalbumin upstream
promoter-transcription factor II 
CoREST corepressor to the REST 
CREB cyclic AMP element binding protein 
CRSP cofactor required for SP1 activation 
CTD carboxy-terminal heptapeptide repeat
domain of the largest subunit of 
RNAP
CTE Carboxyterminal extension of the
nuclear receptor DBD 
d drosophila
dATP desoxy adenosine triphosphate 
DAX-1 DSS-AHC critical region on the X, 
gene-1 (protein)
DBD DNA-binding domain
DHR3 drosophila orphan nuclear hormone 
receptor 3 
DNA deoxyribonucleic acid
DRIP VDR-interacting protein
DRw direct repeat with n spacing
nucleotides 
DTT dithiothreitol
EC embryonal carcinoma
EDTA ethylenediaminetetraacetic acid 
EKLF erythroid krüppel-like factor 
EMSA electrophoretic mobility shift assay 
ER estrogen receptor
ERR-1 or -2 estrogen receptor related nuclear 
receptor-1 or -2 
GATA GATA-sequence interacting proteins 
GCNF germ cell nuclear factor 
GR glucocorticoid receptor
GRIP1 GR interacting protein-1 
GST glutathione S-transferase
GTF general transcription factor
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h human NURF nucleosome remodelling factor
HAT histone acetyltransferase NURR1/77 Nur related factor 1/77
HDAC histone deacetylase OBF1 Oct-binding factor1
HIV human immunodeficiency virus Oct-1 or -2A  Octamer-binding protein -1 or -2A
HMG high mobility group (proteins) OR1 orphan receptor 1
HNF4 hepatocyte nuclear factor 4 PAF PCAF-associated factor
ISWI Imitation SWI PC positive cofactors
kb kilo bases PCAF p300/ CBP-associating factor
kD kilo Dalton pCIP p300/ CBP interacting protein
LBD ligand-binding domain PCR polymerase chain reaction
LD light/dark (conditions) PCV packed cell volumes
LUC luciferase PGC1 PPAR gamma coactivator
Mad PHD Plant homeodomain
MeCP2 methyl cytosine binding protein 2 PIC preinitiation complex
MED Mediator polypeptides Pit-1 pituitary-specific POU homeodomain
MHR Manduca sexta orphan nuclear factor
hormone receptor PMSF phenylmethylsulfonyl fluoride
NAT negative regulator of activated POU domain (Pit, Oct, Unc) domain
transcription PPAR peroxisome proliferator-activated
NC negative cofactors receptor
NCoA nuclear receptor coactivator(s) PR progesterone receptor
N-CoR nuclear receptor corepressor PRMT protein-arginine N-methyltransferase
NFATp nuclear factor of activated t cells PXR pregnane X receptor
preexisting component Q Glutamine
NF-kB nuclear factor kappa-B RACE rapid amplification of cDNA ends
NGFI-B nerve growth factor I-B RAP74 RNAP-associating protein 74
NIX-1 neuronal interacting factor X 1 RAR retinoic acid receptor
Ni2+-NTA Nickel chelated Nitrolo-tri-acetic acid RbAp retinoblastoma-associated protein 1
NM23 Nonmetastatic protein 23 REST RE1 silencing transcription
NMR nuclear magnetic resonance factor/neural restrictive silencing
(spectroscopy) factor
NOR1 neuron-derived orphan receptor 1 RIP receptor- interacting proteins
NR nuclear receptor RNA ribonucleic acid
NRD nucleosomal remodelling and RNAP RNA polymerase II
deacetylation complex ROR retinoid-related orphan receptor
NTP nucleotide triphosphate RORE ROR response elements
NuRD nucleosomal remodelling and RSF remodeling and spacing factor
deacetylation complex RT reverse transcription
RXR retinoid X receptor
SAGA Spt-Ada-Gcn5 acetyltransferase
SAP mSin3-associated polypeptide
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SDS sodium dodecyl sulphate
SF1 steroidogenic factor 1
SHP short heterodimer partner
SMCC SRB/MED-containing cofactor 
complex
SMRT silencing mediator for RXR and TR
SP1 Selective Promoter Factor 1
SRA steroid receptor RNA activator
SRB suppressor of RNA poymerase B
proteins
SRC-1 steroid receptor coactivator-1
SREBP-1a sterol-responsive element-binding
protein-1a
SRF serum response factor
ss single strand
STAGA SPT3-TAFII31-GCN5-
acetyltransferase (complex)
TAC TBP-TFIIA-containing complex
TAF TBP-associated factor
TBP TATA box binding protein
TCF T-cell Factor
TFIIA-H transcription factor for RNAP- 
dependent transcription A-H
TFTC TBP-free TAFII-containing complex
TIF2 transcriptional intermediary factor-2
TOT trans-hydroxytamoxifen
TR thyroid receptor
TRACs thyroid hormone and retinoic acid 
associated co-repressors
TRAP thyroid receptor associating proteins
TRF TBP related factor
TRRAP transactivation/transformation- 
domain associated protein
USA upstream stimulatory activity
USP Ultrspiracle protein
VDR vitamin D3 receptor
VP16 herpes simplex virion protein 16
vwt vaccinia wild type
y yeast
YY1 Yin Yang (factor)1
ZT Zeitgeber time
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